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The success of our first-line antimalarial treatments is threatened by increased drug resistance 
in Plasmodium parasites. This makes the development of novel drugs critical to combat 
malaria. Historically, natural products have been an excellent source of novel antimalarial 
compounds and thus are an ideal place to search for potential drugs. Filamentous members of 
the bacterial phylum, Actinobacteria, are well-known antibiotic producers, but their 
antimalarial potential has not been well investigated. This makes these actinobacteria a 
potentially valuable source of novel antimalarial compounds. 
To evaluate the antimalarial potential of the filamentous actinobacteria, uncharacterized 
environmental actinobacterial strains from the Meyers laboratory culture collection, as well as 
the type strains of new actinobacterial species identified and characterized in the Meyers 
laboratory, were screened for antiplasmodial activity against drug-sensitive Plasmodium 
falciparum, NF54. Liquid cultures were extracted using the mid-polar solvent, ethyl acetate, 
with the aim of discovering drug-like molecules that can be administered orally. Thirty-one 
strains of actinobacteria belonging to eight genera (Actinomadura, Amycolatopsis, Gordonia, 
Kribbella, Micromonospora, Nocardia, Nonomuraea, and Streptomyces) were screened 
revealing fourteen active strains. Eight strains were identified for further study as the displayed 
antiplasmodial efficacy matching predefined criteria. Of these eight candidates, Streptomyces 
strain PR3 was selected, as it showed excellent antiplasmodial efficacy, no cytotoxicity against 
Chinese Hamster Ovary (CHO) or liver HepG2 cell lines, no haemotoxicity, and was easy to 
culture. 
Bioassay-guided fractionation of the crude extracts of strain PR3, supported by high-resolution 
mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) analysis, was conducted 
to isolate and identify the compounds responsible for the antiplasmodial activity. During 
purification by solid phase extraction (SPE), a novel class of compounds was isolated. The 
structure of these compounds was elucidated by HRMS and NMR analysis and determined to 
be a series of crown ethers with a methylated backbone. These methylated crown ethers (MCE) 
were not produced by strain PR3, but by the cyclization of polypropylene glycol (PPG) 
oligomers from Amberlite® XAD-16N 20–60 mesh resin under aqueous conditions. The MCEs 
displayed weak antiplasmodial activity against P. falciparum NF54, without cytotoxicity 
against the Chinese Hamster Ovary, HepG2 cell lines, nor human erythrocytes. To the author’s 
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knowledge, the MCEs are novel compounds, and this is the first time the cyclization of PPG 
oligomers into crown ethers has been reported. 
As the MCEs were not responsible for strain PR3’s potent antiplasmodial activity, further study 
was conducted. Using the Global Natural Product Social molecular networking (GNPS) 
workflow, genome mining, and NMR analysis, it was revealed that the cyclodepsipeptides, 
valinomycin, montanastatin, and nine other novel analogues were responsible for the high 
antiplasmodial activity detected. A review of the literature revealed that the structure of four 
of these analogues had been predicted, based on MS/MS and the biosynthesis of valinomycin. 
Using the same described biosynthetic logic and MS/MS analysis, two new cyclodepsipeptides, 
compounds 1054 and 1068, were elucidated. Unfortunately, chromatographic systems 
developed were unable to purify the cyclodepsipeptides, and individual evaluation of their 
antiplasmodial efficacy and host selectivity was not possible.  
The fraction containing the cyclodepsipeptides exhibited strong antiplasmodial activity against 
the drug-sensitive, NF54 and multidrug-resistant K1, strains of P. falciparum. No cytotoxicity 
was displayed against the CHO cell line and no haemotoxicity was seen against human 
erythrocytes. Moderate toxicity was exhibited against the liver HepG2 cell line; however, the 
selectivity index  of the cyclodepsipeptides suggested that they are selectively targeting the 
Plasmodium parasites. Overall, these results are positive, and further study of the individual 
cyclodepsipeptides is warranted.  
During the investigation, discrepancies were noticed between different fractions in terms of 
antiplasmodial activity. These fractions contained both the MCEs and, cyclodepsipeptides 
along with a range of impurities, yet they displayed potent antiplasmodial activity. Further 
study suggested that combination of the MCEs and cyclodepsipeptides elicits a synergistic 
response and improves antiplasmodial efficacy. This was determined independently using two 
models, the fixed-ratio isobologram method and the CompuSyn programme based on the mass-
action law principle. The workflow developed during this investigation demonstrates how new 
technologies can be used to dereplicate and elucidate bioactive natural products. This workflow 
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Malaria is a life-threatening, infectious disease that threatens 50% of the world’s population 
(Vinet and Zhedanov, 2010). In 2018, malaria was estimated to be responsible for 228 million 
new infections and 405 000 deaths (World Health Organization, 2019). The vast majority of 
these deaths, 93% (404 550), occurred in African countries. Tragically, children are the most 
vulnerable, with 61% (266 000) of fatalities attributed to children below the age of 5. Malaria 
occurs in tropical and subtropical locations (Figure 1.1) and is localised to regions of high 
temperatures, heavy rainfall, high humidity, and the presence of the Anopheles mosquito vector 
(Centers for Disease Control and Prevention, 2015). Malaria in humans can be caused by five 
parasites of the Plasmodium genus (World Health Organization, 2018). These are Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, and Plasmodium 
knowlesi. Of these five species, P. falciparum causes most infections and deaths and is thus the 
main target of drug therapies. P. falciparum infection is the most prevalent in Africa and South 
East Asia, while P. vivax infection is the most prevalent in Central and South America (World 
Health Organization, 2018).  
P. vivax can replicate and spread at lower temperatures and thus is more widespread than P. 
falciparum (UNICEF/WHO, 2015). Despite this, P. vivax infects fewer people, especially in 
Africa where most of the population do not produce the protein required by P. vivax to enter 
the erythrocyte. This protein is coded for by the Duffy gene, which is absent in many African 








The Plasmodium parasites have a complex, multistage lifecycle as illustrated in Figure 1.2. 
This lifecycle involves two hosts: humans and the female Anopheles mosquito. There are more 
than 400 species belonging to the Anopheles genus, but only 30 of these are capable of 
transmitting malaria (UNICEF/WHO, 2015). During a blood meal, an infected mosquito 
infects the human host with sporozoites clustered in its salivary glands (Cowman et al., 2016). 
These travel through the bloodstream to the liver and infect hepatocytes by a method known as 
traversal.  Once inside the hepatocyte, the sporozoites develop into merozoites over 3–12 days, 
depending on the Plasmodium species (Sturm, 2006). Merozoites leave the hepatocytes by 
budding off in vesicles known as merosomes and travel into the bloodstream via the hepatic 
circulation. Merozoites infect erythrocytes and form immature trophozoites, known as the ring 
stage, as their developing genome is ring shaped (Boddey and Cowman, 2013). Over a 48-hour 
period, immature trophozoites mature and undergo cell division in a process known as 
schizogony. During schizogony, multinucleated schizonts replicate into dozens of merozoites 
which lyse the erythrocyte and are released into the bloodstream. These merozoites then infect 
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erythrocytes, and the process is repeated. The lysis of erythrocytes by merozoites leads to the 
release of toxins and wastes (Kayser et al., 2002).  This leads to the activation of macrophages 
and the release of cytokines and chemokines, which generate an immune response. This process 
induces the three classic symptoms of malaria; fever, chills, and sweating. The lysis of 
erythrocytes decreases red blood cell count, which contributes to lethargy, headaches, and 
anaemia - among other symptoms.  
During infection, large scale molecular remodelling of the erythrocyte occurs to allow 
continued development of the parasite (Boddey and Cowman, 2013). During this process, the 
highly-differentiated erythrocyte is converted into a system that allows the parasite to develop, 
scavenge host nutrients, and evade host immune responses. A massive array of proteins are 
produced and exported through the parasite, into the erythrocyte and onto the erythrocytic 
membrane. Remodelling creates an extra-parasitic transport network that can transport 
resources, wastes, and protein complexes to specific locations. Remodelling increases the 
permeability of the infected erythrocytes’ membranes, improving the transport network. 
During remodelling in P. falciparum-infected erythrocytes, P. falciparum erythrocyte 
membrane protein 1 (PfEMP1) is expressed (Smith et al., 1995). PfEMP1 is responsible for 
cytoadherence between infected erythrocytes and other cells. The PfEMP1 protein family is 
expressed by approximately 60 variable (var) genes per haploid parasite genome, and each 
displays monoallelic expression (Scherf et al., 1998). This generates a highly-variable array of 
surface antigens, enabling the parasite to evade the host immune response. 
Cytoadherence allows sequestration of the parasite-infected cells, which avoids passage 
through the spleen and thus, destruction by splenic macrophages (Boddey and Cowman, 2013). 
Cytoadherence also leads to reduced blood flow in infected areas, reducing the parasite’s 
exposure to immune cells. This sequestration is an important part of P. falciparum pathology. 
Mass clotting can occur in vital areas which can lead to respiratory and renal failure, and to a 
major symptom of P. falciparum infection, cerebral malaria.  
In cerebral malaria, cytoadherence in the capillaries, in and surrounding the brain, can reduce 
blood flow and lead to strokes. If the capillaries rupture, brain oedema and neurological 
impairment can ensue.  
P. falciparum-infected cells can also preferentially adhere to the placenta making pregnant 
women extremely vulnerable to the disease (Greenwood, 2010). Malaria infection in pregnant 
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women can lead to maternal anaemia, child growth retardation, placental infections, low birth 
weights, and, in the worst cases, maternal and neonatal mortalities (Mosha et al., 2014).  
During the next stage of infection, a proportion of merozoites develop into sexual gametocytes 
instead of schizonts, in the erythrocyte. These immature gametocytes do not lyse the 
erythrocyte, but instead mature before the next stage (Cowman et al., 2016). In the case of P. 
falciparum, gametocytes take 11 days to mature and sequester in the bone marrow to avoid 
clearance and immune responses (Joice et al., 2014). The exact cause of this developmental 
switch to gametocyte formation is still uncertain, however, it has been linked to high 
parasitaemia and exposure to certain drugs, such a chloroquine (Cowman et al., 2016). After 
the gametocytes mature, they return to the bloodstream and are taken up when a mosquito feeds 
on the infected human host.  
When in the midgut lumen of the mosquito, female gametocytes are fertilised by male 
gametocytes to form an ookinete (Aly et al., 2009). The ookinete moves to the basal lumina in 
the midgut and develops into an oocyst. Finally, the oocyst develops into sporozoites, which 















1.1.3 Economic Burden 
 
Malaria has a very clear social impact due to the high global mortalities, but the disease also 
causes a great economic burden. A long-term study found that between 1960 and 1995, 
countries with malaria had a mean growth in income per capita of 0.4%, while countries 
without malaria had a mean growth in income per capita of 2.3% (Gallup and Sachs, 2001). A 
decrease in the malaria incidence of 10% was seen to lead to an increase of 0.3% in economic 
growth. Over 25 years, this was predicted to be equal to half the per capita gross domestic 
product (GDP) of a less economically developed country (LEDC). Malaria not only slows 
economic growth, but poverty potentiates the disease itself. As discussed previously, malaria 
occurs in tropical and subtropical regions, which are also the poorest areas in the world.  At the 
household level, poorer-quality housing can make families more vulnerable to infection by 
mosquitoes (Teklehaimanot and Paola Mejia, 2008). Peak malaria incidence times often 
overlap with harvest periods, leading to food insecurity and loss of income if working family 
members are infected. Poorer families often lack access to medical facilities or are unable to 
afford preventive measures such as mosquito nets. Lack of education can slow the uptake of 
prevention schemes and recognition of malaria symptoms. At the national scale, this burden 
becomes even greater. Infected patients drain resources and are unable to work, leading to a 
loss of capital. International investors are discouraged from investing in malaria-afflicted 
countries due to increased labour costs and health risks. Government funding is prioritized to 
combat malaria instead of being invested in developing infrastructure. The poorest suffer the 
most, and it is very difficult to escape the cycle of disease and poverty that is created. This is 
one of the reasons why Africa, the poorest continent, carries the bulk of the global malaria 
burden. 
 
1.2 Prevention and Treatment of Malaria 
1.2.1 History 
 
Malaria causes a severe socio-economic burden, although there has been much success in 
reducing this burden over the past decades. Current incidence and mortality figures represent 
a decrease in the impact of malaria (World Health Organization, 2018). For example, in 2000, 
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malaria caused approximately 262 million new infections and 839 000 deaths, compared to the 
219 million new infections and 435 000 deaths in 2017. This success can be attributed to the 
development of healthcare infrastructures, the use of insecticides to control the Anopheles 
vector, prophylaxis to prevent infection, and first-line antimalarial drugs to treat infections.  
This success has been hard-earned and the result of many failures and tough lessons. The 
greatest example of this was the Global Malaria Eradication Programme (GMEP) launched in 
1955 (Nájera et al., 2011). This was the first large scale programme that focused on combating 
malaria long term and on a global scale. The GMEP focused on eradication techniques over 
control methods. The main methods used were intensive spraying of the pesticide, dichloro-
diphenyl-trichloroethane (DDT), indoors and outdoors to kill mosquitoes and the mass drug 
administration (MDA) of chloroquine to infected patients. The GMEP closed 14 years later, 
after much criticism and a list of failures, but overall it should be seen as a success. It 
successfully eradicated malaria in various regions, such as the United States of America and 
Eastern Europe and reduced the burden of the disease in many others.  
The GMEP was, however, unable to eradicate malaria in the areas that carried the highest 
burden, particularly in Africa. The single-minded focus on using DDT for the eradication of 
mosquitoes and the MDA of chloroquine ended up being the downfall of the GMEP 
(D’Alessandro and Buttiens, 2001; Nájera et al., 2011). Chloroquine resistance was propagated 
due to its extensive use in monotherapy. Furthermore, early signs of chloroquine resistance in 
Southeast Asia were ignored, as it was believed that DDT use would halt the transmission of 
the Plasmodium parasites. DDT resistance in mosquitoes accelerated, health care infrastructure 
was not developed, malaria research stalled, and traditional control measures - such as draining 
marshes, were no longer implemented (Nájera et al., 2011). This allowed these high-burden 
areas to persist.  When eradication programmes were removed, a resurgence of malaria was 
seen, including in areas, such as Sri-Lanka and Madagascar, which were believed to have been 
cleared of the disease (Greenwood et al., 2008). The GMEP proved that, in order to combat 
malaria, a diverse set of methods are required, at a large scale, over a very long time period. It 
also showed the risks of using drugs in monotherapy on such a large scale.  
Today, malaria is combatted with three techniques. These are: halting transmission with control 
measures, preventing infection with prophylaxis and treating infections with a combination of 
antimalarial drugs. To better facilitate these methods, health service infrastructure needs to be 
developed, malaria research encouraged, and surveillance systems put in place. Much was 
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learned from the GMEP and the goals remained the same, despite its failures and setbacks. This 
has contributed to the subsequent success in combatting the disease. However, there is still 
much work to be done and major problems to be faced. 
 
1.2.2 Vector Control 
 
Vector control refers to reducing or eliminating Anopheles vector populations and protecting 
human populations from mosquito bites (UNICEF/WHO, 2015). The bulk of the success 
against malaria can be attributed to vector control (Raghavendra et al., 2011). One of the most 
effective methods of vector control is the use of insecticide-treated nets (ITNs).  ITNs protect 
people while they sleep, which is when they are the most vulnerable, and the Anopheles 
mosquito is the most active. ITNs are also useful in protecting sedentary people, such as 
pregnant women, the elderly, the sick, and young children, who are all extremely vulnerable to 
malaria. ITNs have been shown to reduce malaria incidence by 50% and mortality of under 5 
year olds by 17% (Lengeler, 2004). The insecticides used on ITNs all belong to the pyrethroid 
family, as they have low mammalian toxicity, long lasting residual effects and are highly 
effective against mosquitoes (Raghavendra et al., 2011). 
Indoor residual spraying (IRS) is another effective vector control measure. Insecticides are 
sprayed in residential and working areas to kill mosquitoes and provide residual protection 
(Raghavendra et al., 2011).  It is estimated that ITNs and IRS prevented 517 million cases of 
malaria between 2000 and 2015 (Sherrard-Smith et al., 2018). Carbamates and 
organophosphates, as well as pyrethroids, are used in IRS (Ranson and Lissenden, 2016).  
New biological controls are being investigated, such as the use of members of Wolbachia, a 
genus of intracellular pathogenic symbiotic bacteria, to sterilize mosquito populations. 
Infection of mosquitoes by Wolbachia can cause cytoplasmic instability and sterilization (Bian 
et al., 2013). However, Wolbachia was only recently shown to be able to infect Anopheles 
species, and its use has only been implemented on a limited scale. Biological impact, resistance, 
and effectiveness across the relevant malaria-carrying Anopheles species still need to be 
investigated. 
While vector control is very effective, it does still face several challenges. Distribution, 
implementation and education around ITNs and IRS is lacking, which is slowing progress 
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(World Health Organization, 2018). Of greater concern is insecticide resistance development 
in mosquitoes. Decades of use has led to resistance in Anopheles mosquitoes to all the major 
insecticides (Ranson and Lissenden, 2016).  
In Africa, there is complete pyrethroid resistance in malaria vectors, which threatens to 
neutralize the use of ITNs. Resistance to DDT, carbamates, and organophosphates is also 
emerging and spreading. Areas that rely heavily on ITNs are especially vulnerable, as there is 
such a limited number of insecticides available with similar properties. For example, 
carbamates and organophosphates share the same mechanism of action, which make them 
susceptible to cross resistance. The current strategy implemented by the WHO is to continue 
using ITNs, as the nets create an effective physical barrier (Ranson and Lissenden, 2016; World 
Health Organization, 2018). Rotating the use of insecticides every season is one way to slow 
the development of insecticide resistance, however, novel insecticides are required to continue 
vector-control programmes. Signs are appearing that insecticide resistance is impacting control 




Chemoprevention or prophylaxis involves maintaining levels of antimalarial drugs in the host’s 
blood to suppress malaria infection (UNICEF/WHO, 2015). This is particularly useful in 
protecting vulnerable populations and is recommended by the WHO for children under the age 
of five and pregnant women (World Health Organization, 2018). These treatments can either 
involve intermittent preventative treatment (IPT), which is the periodic administration of an 
antimalarial compound, or seasonal malaria chemoprevention (SMC), where treatment is only 
administered during high-risk periods (i.e. during the rainy season). These treatments have been 
shown to reduce low birth weight cases, maternal anaemia, and neonatal mortalities. The 
WHO-recommended antimalarial drugs for IPT are the folate synthesis inhibiting sulfadoxine-
pyrimethamine (SP) combination  (section 1.2.5.2). For SMC, amodiaquine is recommended, 







Despite decades of research, there are currently no commercial vaccines available for malaria 
(Ajua et al., 2015). An effective vaccine would be the ultimate control measure, as it would 
provide long term and complete protection. Due to the multistage lifecycle and diverse biology 
of the Plasmodium parasites, developing a vaccine is a complex challenge. The most successful 
candidate is the RTS,S/AS01 vaccine, which is comprised of hepatitis B surface antigens fused 
to a fragment of the circumsporozoite protein (CSP) of P. falciparum (Mahmoudi and 
Keshavarz, 2017). The RTS,S/AS01 vaccine stimulates antibody generation specific to CSP, 
an antigen found on sporozoites and liver schizonts.  After successful Phase II clinical trials, 
the vaccine moved into Phase III trials involving 15 000 African children, aged 5–17 months 
(Greenwood and Doumbo, 2016). The trial revealed that the RTS,S/AS01 vaccine provided a 
vaccine efficacy of only approximately 30%. While most vaccines provide at least 70–80% 
vaccine efficacy, considering the complex nature of malaria this is a positive result (Greenwood 
and Doumbo, 2016; Mahmoudi and Keshavarz, 2017). Even partial coverage could help the 
control of the disease, and further work is being done to develop an improved version of the 
RTS,S/AS01 vaccine (Cowman et al., 2016). 
 
1.2.5 Antimalarial Drugs: Past and Present 
1.2.5.1 Quinolines 
 
One of the oldest antimalarials used is quinine, a quinoline isolated from the bark of the 
Cinchona calisaya tree in South America in the 1600s (Hobbs and Duffy, 2011). Although 
quinine is an effective antimalarial in its own right, its adverse side effects (hearing loss, 
vomiting, hypotension, abdominal pain to name a few) and the difficulty of producing large 
quantities hindered its use (Achan et al., 2011).  
Quinine was later synthesised and derivatised into the class of compounds known as the 4-
aminoquinolines. This drug class includes chloroquine, lumefantrine, mefloquine, and 
amodiaquine. Of these, chloroquine is the most widely used (Figure 1.3). Chloroquine was the 
first drug to be administered on a global scale when it was administered in the GMEP (section 
1.2.1). (D’Alessandro and Buttiens, 2001).  
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Chloroquine was considered the gold standard of antimalarials due to its high efficacy, low 
cost, and low toxicity (Fidock et al., 2000). During infection of the erythrocyte, the 
Plasmodium parasites degrade haemoglobin into haem and globin. Haem is toxic and is 
converted into non-toxic hemozoin, inside the digestive vacuole. The globin is metabolized 
into peptides which provide nutrients and are used in biosynthesis (Combrinck et al., 2013). 
Chloroquine has been shown to exert its cytotoxicity by interfering with the conversion of haem 
to hemozoin in the digestive vacuole. This leads to the accumulation of toxic haem and the 
death of the parasite.  
Chloroquine is no longer effective due to the emergence of wide-spread resistance (Greenwood 
et al., 2008). The proposed mechanism of resistance states that a mutation in the P. falciparum 
chloroquine resistance transporter (PfCRT), a proton pump in the membrane of the digestive 
vacuole, effluxes charged chloroquine out of the digestive vacuole (Fidock et al., 2000). By 
removing chloroquine from its site of action, it is unable to exert its cytotoxic mode of action.  
Chloroquine resistance emerged almost simultaneously in Brazil, Venezuela, and Colombia in 
1960 and independently in Myanmar, Cambodia, and Vietnam in 1961 (D’Alessandro and 
Buttiens, 2001). The exact causes are still unknown but, as discussed previously, the GMEP 
exacerbated resistance development. Soon afterwards, chloroquine resistance spread globally 
and is now seen in almost all malaria-endemic countries. Due to this, alternative antimalarials 
have been employed. 
 
Figure 1.3:  Molecular structure of chloroquine (Chemicalize). 
 
   
 
   










The combination of drugs sulfadoxine-pyrimethamine (SP) saw increased use as chloroquine 
resistance became more prominent in the 1960s and is still used in chemoprevention 
programmes today (Figures 1.4 and 1.5) (D’Alessandro and Buttiens, 2001; World Health 
Organization, 2018). SP has a long elimination half-life and good efficacy against the 
Plasmodium parasites, which is why it provides successful chemoprevention treatment (Nzila 
et al., 2000).  
Sulfadoxine inhibits para-amino benzoic acid conversion to folic acid by binding to 
dihydropteroate synthetase (DHPS) (Sarmah et al., 2017). Folic acid is essential for parasite 
replication. Pyrimethamine inhibits the dihydrofolate reductase (DHFR) enzyme complex, 
which is responsible for the production of purines and pyrimidines required for DNA synthesis 
before cell division. Both act as competitive inhibitors of the enzyme substrates (Muller and 
Hyde, 2010). The two drugs are extremely effective in combination, as Plasmodium parasites 
can scavenge dihydrofolate, which reduces the inhibitory effect of pyrimethamine. DHPS is 
only found in the parasite, whereas DHFR is present in both human erythrocytes and 
Plasmodium cells.  
Pyrimethamine is safe for human use, as it binds to parasite DHFR with a much higher affinity 
than to human DHFR. SP treatment is, however, especially vulnerable to resistance 
development. SP has been observed to have a short useful therapeutic life, meaning there is a 
high risk of drug resistance developing (Nzila et al., 2000). One of the main reasons for this, is 
that the long elimination half-lives of the SP drugs can lead to long term exposure of the 
Plasmodium parasites to the drugs at sub-therapeutic doses. This increases selective pressures 
on the Plasmodium parasites, accelerating the development of drug resistance. Noncompliance 
and inadequate dosing are thought to contribute to this effect. Point mutations in the dhfr and 
dhps genes, which convey resistance, have appeared in Plasmodium strains in East Africa, 
South America, and South East Asia (Gatton et al., 2004). While SP is still effective in many 













Figure 1.4: Molecular structure of sulfadoxine (Chemicalize). 
 
 




Artemisinin was isolated from ancient Chinese traditional medicines and first derived from the 
Chinese plant, Artemisia annua, in 1973 (Cragg and Newman, 2013; Haynes et al., 2013). 
Since then, other compounds have been derived from artemisinin, including, 
dihydroartemisinin (DHA), artesunate, artemether, and arteether (Anthony et al., 2012). The 
molecular structure of artesunate is displayed in Figure 1.6. These compounds are collectively 
referred to as the artemisinins or artemisinin derivatives. Artemisinins are structurally unique, 
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as they contain a peroxide bridge between two oxygen atoms linked in a 6 membered ring, 
referred to as a 1,2,4-trioxane (Haynes et al., 2013). Despite the low bioavailability, low 
solubility, poor metabolic stability, and short half-lives that are characteristically displayed by 
the artemisinins, they are still considered the most effective antimalarial compounds available 
(Haynes et al., 2006; World Health Organization, 2018). They demonstrate a high level of 
efficacy, target all the blood stages of the parasite’s lifecycle, and are selectively taken up into 
parasitized erythrocytes, allowing them to reduce the parasitaemia in a patient to a greater 
extent than any other antimalarial drug.  
The mode of action of the artemisinins is still under debate (Haynes et al., 2013). What is 
agreed upon is that the peroxide bridge is the active pharmacophore and is essential for the 
artemisinins’ mode of action. Compounds derived from artemisinins that lack the peroxide 
bridge are not cytotoxic towards Plasmodium parasites (Krishna et al., 2004).  
The artemisinins present low metabolic stability as they are rapidly metabolized by the liver 
cytochrome P450 enzyme CYP3A4 (Haynes et al., 2006). This means monotherapies involving 
artemisinins promote the development of resistance in the Plasmodium parasite (Phan Trong 
Giao et al., 2001). Any parasites that survive the short and potent artemisinin treatment may 
be able to replicate, which increases the likelihood of resistance-mediating genes becoming 
established within a population.  
Recrudescence is another concern that arises when artemisinins are used in monotherapies 
(Chen et al., 2014). Artemisinins have been shown to induce dormancy in ring-stage parasites, 
removing symptoms of the disease and making it appear that the patient has been cured. The 
short half-lives of these compounds can allow the dormant parasites to survive and become 
active again, leading to the re-appearance of symptoms. To evade recrudescence and resistance 
development, artemisinins are partnered with drugs that have a longer half-life in order to 
eliminate any parasites that survive exposure to the artemisinins. Artemisinin-based 
combination therapies (ACT) are the current first-line treatment in most malaria-endemic 
countries and are favoured over other antimalarial therapies, such as SP (Muller and Hyde, 
2010; World Health Organization, 2018). There are many types of ACTs in development or 
use, but the major ones used are: artemether partnered with lumefantrine, artesunate partnered 
with amodiaquine, or DHA partnered with piperaquine (Anthony et al., 2012). ACTs are 
effective, as they require short-term treatments of three days, which reduces the chance of 
patient noncompliance, inhibits gametocyte transmission, reduces the chance of resistance 
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development to the partner drug, and seem to be well tolerated by patients with few side effects 
(Xie et al., 2009).  
Despite the use of drug combinations, the ACTs are currently threatened by the development 
of drug resistance. P. falciparum resistance to artemisinins was first reported along the border 
separating Cambodia and Thailand in 2008 and has now spread to five countries in the Greater 
Mekong region (Noedl et al., 2008; World Health Organization, 2018). Artemisinin resistance 
is clinically defined as reduced parasite clearance and is expressed as a prolonged parasite 
clearance half-life or detection of persistent parasites after three days of treatment with an ACT 
(Ariey et al., 2013). Currently, the ACTs are still effective, however, as a consequence of 
delayed clearance, the dose of the artemisinins used in ACTs has been increased by at least 
twofold (Harmse et al., 2015). The failure rate of ACTs has also increased in the areas with the 
highest burden of malaria. In Cambodia, failure rates have reached 90%, and in Vietnam, 30% 
(Roberts, 2017). It is important to note that, in the case of failures to standard ACT treatments, 
patients are dosed with tailored combinations of clinical antimalarials, which so far are capable 
of treating malaria infection. However, this practice is becoming increasingly frequent, which 
emphasizes the extent of drug resistance.  There are many unknown factors, and much research 
is being done to assess the situation. The exact cause of artemisinin resistance is unknown, but 
it has been linked to mutations in the Kelch 13 (K13) propeller domain in P. falciparum (Ariey 
et al., 2013). One hypothesis is that the resistant mutants are able to down-regulate their 
metabolism during the early stages of erythrocyte infection when the artemisinins are most 
effective (Mok et al., 2011). They then upregulate their metabolic activity later in the blood 
stage when the artemisinins are less effective as a result of their chemical instability.  
The rise of chloroquine resistance was a serious loss in the war against malaria and, if the 
resistance to the artemisinins is not contained, history could repeat itself. If ACT-resistant 
Plasmodium strains spread across the globe, the consequences would be devastating, and the 




Figure 1.6: Molecular structures of artesunate (Chemicalize). 
 
1.2.6 The Future 
 
The fight against malaria has currently stalled. The WHO reported a decrease in the rate of 
reduction of malaria mortalities in the past few years (World Health Organization, 2018). For 
example, an increase in global mortalities was seen from 2015 to 2016 where the global 
incidences increased from 219 million to 231 million cases respectively and since then the 
number of incidences have plateaued (World Health Organization, 2019). The global incidence 
rate (number of cases per 1000 people)  has overall decreased since the start of the decade when 
it was 71 per 1000 people and is currently at 57 per 1000 people. However, the bulk of this 
reduction occurred during the beginning of the decade when the incidence rate dropped from 
60 per 100 people in 2013 to 57 per 1000 people in 2014 (World Health Organization, 2019). 
The incidence rate has unfortunately  remained almost the same for the past 4 year. One of the 
reasons for this stalled progress is a decrease in funding, which hinders control and treatment 
programmes and reduces the availability of funds for new measures. The other major reasons 
are the rise in insecticide resistance and the decrease in efficacy of the ACTs. With insecticides 
being less effective, more pressure is placed on drug treatment schemes to combat malaria. 
However, with the growing threat and impact of ACT resistance, these treatment programs are 
   










vulnerable and may be unable to sustain their success. To avoid this, and continue to combat 
malaria, new antimalarial drugs, with novel mechanisms of action, need to be developed.  
There are several approaches that can be taken to develop new antimalarials. A short-term 
approach is altering the drug combinations used in the ACTs. Mefloquine, piperaquine, and 
lumefantrine are all currently used as partner drugs with the artemisinins (World Health 
Organization, 2018). There is controversy over the cause for ACT failure, as resistance to 
partner drugs has also been detected. Therefore, altering the drug combinations may reverse 
failing treatments and contain the resistant strains (Pink et al., 2005; Roberts, 2017). However, 
this approach may only prolong the time it takes for artemisinin resistance to develop further 
and is unlikely to lead to the eradication of malaria.   
Another short-term approach is testing known antimicrobial agents for antimalarial activity, 
reducing the time and cost required to develop new drugs (Pink et al., 2005). An example is 
DB289, which was originally developed to treat Pneumocystis pneumonia caused by the fungus 
Pneumocystis jirovecii, and has proven to be an excellent antimalarial (Yeates, 2003). This 
approach is not always viable as most drugs are owned by pharmaceutical companies, that may 
not want their drugs being tested for non-commercial or alternative commercial  purposes (Pink 
et al., 2005). 
A medium-term approach is to create analogues of current antimalarials. For example, a drug 
called ferroquine contains the chloroquine nucleus with a ferrocenic group attached (Biot et 
al., 2011). Ferroquine is non-toxic and effective against chloroquine-resistant Plasmodium 
strains. This is a medium-term approach as it shortens the drug discovery leg of the drug 
pipeline, but not the development stage. A series of analogues needs to be synthesized and 
screened, which takes time. This approach is only successful if the drug presents a novel 
mechanism of action that provides efficacy against drug-resistant strains (Pink et al., 2005). 
Short- and medium-term approaches may be effective but, to ensure malaria is halted and 
reversed, long term approaches where novel antimalarials are developed, are required. 
Novel antimalarials need to abide by a strict set of criteria to be effective. These criteria are 
known as Single Exposure Radical Cure and Prophylaxis (SERCaP) treatment (Burrows et al., 
2013). Firstly, new drugs need to have a novel mechanism of action to avoid existing drug 
resistance and be more effective in combination with current drugs. New antimalarials need to 
possess novel mechanisms of action because all known drugs are unable to fulfil the SERCaP 
criteria (Flannery et al., 2013). Novel drugs also need to be active against multiple stages in 
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the parasite lifecycle, to prevent transmission and to clear infection. These drugs  need to be 
cheap to manufacture, ideally at $0.15 per dose, as malaria is a disease of poverty (Burrows et 
al., 2013).  
New drugs also need to be stable at high temperatures, so that they do not require refrigeration. 
Refrigeration is not available in the poorest regions of the world. Drugs need to be able to be 
taken orally so that patients do not need to go to a clinic every day, a requirement which leads 
to noncompliance, which accelerates the development of drug resistance. Ideally, new drugs 
should be able to be administered as a single dose to reduce costs and the likelihood of 
noncompliance.  
The use of novel antimalarials in combination with the current drugs or analogues of the current 
drugs may be enough to avoid drug resistance and eradicate the disease (Flannery et al., 2013). 
Novel antimalarials can be synthesized with the use of combinatorial chemistry or isolated 
from natural products. Historically, the most effective antimalarials have been isolated from 
nature and, therefore, natural products are the ideal source to begin the search for novel 
antimalarial compounds. 
 
1.3 Natural Products in Drug Discovery and Development 
1.3.1 Introduction 
 
Natural products can be defined as pharmacologically active chemical compounds isolated 
from living, biological systems (Mathur and Hoskins, 2017). Natural products have been a 
dominant source of antimicrobial agents in the past. The first example of natural products used 
as medicine is from 2600 BC in ancient Mesopotamia, where cypress, myrrh, and poppy were 
used to treat fevers and other maladies (Borchardt, 2002). Ancient Egyptian and Chinese 
traditional medicines provide a vast collection of treatments and remedies for a spectrum of 
diseases (Chan, 1994; Borchardt, 2002). Most traditional medicines were sourced from plants 
and developed by experimentation over hundreds of years (Kinghorn et al., 2011; Dias et al., 
2012). Traditional medicines were also developed by observing which plants animals eat or 
avoid, a process known as zoopharmacognosy (Rodriguez and Wrangham, 1993). 
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There are many examples of clinically-used drugs developed from natural products from plants 
(Der Marderosian and Beutler, 2014). A well-known example is the analgesic and antipyretic 
drug, acetylsalicylic acid, also known as aspirin. Salicylic acid was originally isolated from the 
bark of the willow tree (Salix alba) and improved by derivatization into acetylsalicylic acid. 
Foxglove (Digitalis purperea) has been used in European medicine for centuries, but the active 
constituent, digitoxin, was only isolated in the 1700s (Der Marderosian and Beutler, 2014). 
Digitoxin is a cardiotonic glycoside used to treat cardiac conditions by enhancing cardiac 
conduction (Dias, Urban and Roessner, 2012). 
Plants are not the only source of natural products, as microorganisms such as fungi and bacteria 
are well-known producers of bioactive compounds. Paclitaxel, sold under the brand name 
Taxol®, is a potent anticancer drug isolated from the bark of the Pacific yew tree (Taxus 
brevifolia). It is actually produced by an endophytic fungus, Taxomyces andrenae, located in 
the phloem of the Pacific yew (Rowinsky and Donehower, 1995). 
The antibiotic, penicillin, is the most well-known example of a fungal natural product, isolated 
from Penicillium notatum in 1929 by Sir Alexander Fleming (Fleming, 1929; Abraham et al., 
1941). Members of the bacterial phylum, Actinobacteria, are another famous source of natural 
products and produce a wide range of antibiotics that have been used in medicine. Streptomycin 
was isolated from Streptomyces griseus and was used to treat tuberculosis (Mycobacterium 
tuberculosis) and the black plague (Yersinia pestis) (Waksman et al., 1946). The discovery of 
penicillin in 1929 and, streptothricin, streptomycin and actinomycin in the 1940s, initiated the 
Golden Age of Antibiotics from the 1940s to the 1960s (Fleming, 1929; Waksman and 
Woodruff, 1942; Bérdy, 2005). During this time, hundreds of fungi and bacteria were screened 
for antibiotics (Davies, 2006). It is estimated that half the number of drugs currently known 
were isolated during this period. The term antibiotic was coined by Selman A. Waksman in 
1942, who defined it as, “any microbial product that is antagonistic to the growth of another 
microorganism”(Waksman and Woodruff, 1942). The Golden Age of Antibiotics initiated 
many natural product drug discovery and development projects run by pharmaceutical 
companies, not just for antibacterial and antifungal antibiotics, but also other classes of drugs, 






1.3.2 The Drug Discovery and Development Pipeline 
 
The process by which new molecules are identified, tested, and improved to produce new drugs 
is known as the drug discovery and development pipeline. First, a new molecule is identified, 
then evaluated for efficacy and safety in vitro, before moving on to preclinical testing (Katzung 
et al., 2012). In preclinical testing, the in vivo pharmacokinetics, efficacy and toxicity are 
evaluated in animal models. If the compound passes these tests, it is moved forward into 
clinical trials in humans where it is tested in three different phases before reaching the public 
market. A fourth and final phase of safety monitoring and data gathering occurs before the drug 
is officially declared safe (Figure 1.7) (Katzung  et al., 2012). 
 
Figure 1.7: Summary of the drug discovery and development pipeline (Michigan State 
University). 
 
The drug discovery and development pipeline is an expensive and time-consuming procedure 
with a low success rate. Only approximately 1 out of every 5000 candidate molecules is 
developed into a commercial drug (Gibson, 2009). It is estimated that it costs $800 million–$1 
billion and requires 10–15 years of dedicated study to develop a new drug for clinical use 
(Katzung et al., 2012). Most drugs fail at some point during testing and either need to be 
derivatised into improved analogues or abandoned, and the process has to be restarted. 
Dedicated researchers across multiple disciplines using expensive instruments are required to 
develop a new drug. This is why the process is so expensive and time-consuming. However, 
the investment in time, effort and money is worth it, as the pharmaceutical market is worth 
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billions of dollars. For example, in 2001 the global profit from prescription pharmaceuticals 
was estimated to be $364 billion dollars (Katzung et al., 2012). 
This investigation will focus on the first part of the pipeline, drug discovery, where molecules 
are screened for activity against a specific disease or disorder (Hughes et al., 2011). Drug 
screening involves a series of experiments that test a large number of samples in quantitative 
assays in vitro or sometimes in vivo (Katzung et al., 2012). Drug screens produce a list of 
compounds that display reproducible and desired activity, known as hit candidates (Hughes et 
al., 2011). The list of hit candidates is evaluated to identify the best or lead candidate to evaluate 
in preclinical tests. This involves in vitro testing against drug-resistant strains, cytotoxicity 
testing against host cell lines to determine selectivity, mechanism of action and ADME 
(absorption, distribution, metabolism and excretion) studies. ADME studies includes a range 
of assays which predict the pharmacokinetics and pharmacodynamics of hit candidates. Some 
examples of ADME assays include kinetic solubility, lipophilicity, metabolic stability, and 
plasma stability. 
 
1.3.3 Advantages of Natural Products in Drug Discovery 
 
The main sources of compounds for drug screens in drug discovery are synthesized molecules 
and natural products (Hughes et al., 2011). Focusing on natural products for drug discovery 
and development has a number of advantages. Natural products exhibit extremely diverse 
chemical structures and represent a vast source of new chemical compounds (Clardy and 
Walsh, 2004). Diverse chemical structures lead to diverse biological functions, which is why 
these structures are sought after (Bérdy, 2005). For example, natural products have more 
stereogenic centres and chemical complexity than most synthetic molecules. 
The chemical diversity exhibited by natural products is a function of their biosynthesis. Natural 
products are produced by secondary and, to a lesser extent, primary metabolism. Primary 
metabolism refers to the breakdown and biosynthesis of carbohydrates, lipids, proteins, and 
nucleic acids. Primary metabolism is generally very conserved, as it is required for growth and 
replication (Dewick, 2002).  
Secondary metabolism is not required for growth and generates molecules that may be unique 
to specific groups or individual organisms (Bérdy, 2005). Secondary metabolites are produced 
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to allow an organism to adapt to its environment and can function as defence mechanisms, 
forms of communication, transporters and metabolic regulators (Demain and Fang, 2000). 
Secondary metabolites are biosynthesised from the intermediates produced by primary 
metabolism, such as amino acids and acetyl CoA. With just a few intermediates, a wide range 
of diverse molecules can be produced by using different tailoring enzymes or incomplete 
processing in some cases (Sarker et al., 2006). For example, it has been theorized that amino 
acids are partially processed by the acetate and shikimate pathways to generate shunt, or 
intermediate metabolites, to create unique secondary metabolites (Clardy and Walsh, 2004; 
Sarker et al., 2006). 
Natural products often provide excellent efficacy and selectivity for drug targets (Cragg and 
Newman, 2013). This could be due to unique and diverse structures, which allow very specific 
binding and, thus, strong responses and reduced toxicity. Another hypothesis is that natural 
products are already biologically validated (Brohm et al., 2002). Because the precursors of 
primary and secondary metabolites are limited and existed in primitive life forms, they have 
co-evolved over thousands of years to interact (Ginsburg and Deharo, 2011). 
Natural products can also act as excellent scaffolds for further study and improvement. Many 
natural product drugs do not function as drugs in their original biological form and are instead 
derivatized to produce improved compounds. Examples include aspirin and the artemisinin 
derivatives used in the ACTs (Krishna et al., 2004; Der Marderosian and Beutler, 2014). Since 
natural products have not evolved as drug compounds, they often need chemical modification 
to improve their efficacy or pharmacokinetic parameters (Ginsburg and Deharo, 2011). 
The final advantage is the untapped potential of natural products. There are many natural 
sources that have never been screened for bioactive compounds. It is estimated that only 6% 
of terrestrial plant species have been screened pharmacologically (Farnsworth et al., 1985; 
Basso et al., 2005). The oceans cover most of the Earth’s surface and contain the bulk of the 
planet’s biodiversity, but improvements in technology have only recently allowed exploration 
of marine products (Faulkner, 2000). Despite, only recent exploration, drugs based on marine 
natural products have already been developed, emphasising their potential. One of the first 
marine-based natural products was a non-narcotic analgesic drug Ziconotide®, isolated from 




However, while natural products have many advantages, there are also a number of 
disadvantages, which led to the end of the Golden Age of Antibiotics (Dias et al., 2012). Issues 
caused by rediscovery of known compounds, high cost of productions and the long duration of 
natural products screening led to pharmaceutical companies favouring semi-synthetic and 
synthetic methods instead. 
 
1.3.4 Disadvantages of Natural Products in Drug Discovery 
 
There are many reasons why natural products were abandoned as a source of drug-like 
compounds. Natural product research is a time-consuming process which increases the cost 
and labour required for screening and development projects (Wagenaar, 2008). While the 
complexity and diversity of natural products can create interesting molecules and effective drug 
compounds, these characteristics can make it more difficult to isolate and purify them (Li and 
Vederas, 2009). Thus, more resources and time are required to determine how to successfully 
isolate these molecules. Molecules may also be unstable, making it nearly impossible to isolate 
them. Once isolated, elucidating the structure of a complex molecule can be very difficult and 
require extremely sensitive instruments (Dias et al., 2012). 
In some cases, the isolated natural product cannot be synthesized due to its unique structure 
(Clardy and Walsh, 2004; Basso et al., 2005). Only an estimated 40% of microbial natural 
products can be synthesized (Bérdy, 2005). This can prevent large scale production and, 
therefore, sale as a therapeutic agent. Therefore, the labour and financial investment into these 
projects cannot always be justified. 
Once isolated, scaled-up production of natural products may not be achievable (Dias et al., 
2012). Many natural products are produced in very small quantities and sourcing the material 
can be difficult (Basso et al., 2005; Guantai and Chibale, 2011). For example, it is difficult to 
cultivate the Pacific yew as a source of paclitaxel (Nikolic et al., 2011). The Pacific yew grows 
slowly and is an endangered species making it an inefficient source for large scale production. 
Sources, such as sea sponges, may produce highly active compounds, but only occur in certain 
reef systems and may not be viable to farm (Faulkner, 2000). 
Other sources, like plants or animals, may be endangered or protected by traditional laws. 
While an advantage of natural products is the untapped biodiversity they represent, there are 
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often reasons these sources have not been explored. For example, most bacteria are 
unculturable in a laboratory environment, depriving us of access to an enormous number of 
diverse molecules (Bérdy, 2005; Davies, 2006). 
A major problem that affects all natural product screening programmes is dereplication. 
Dereplication is the process of rediscovering known compounds in different strains or species 
of organisms (Sarker et al., 2006). It was a major challenge faced during the Golden Age of 
Antibiotics, and, over time, fewer and fewer new natural products have been discovered. 
Between 1930 and 1962, 20 different classes of antibiotics were discovered (Coates et al., 
2011). Since then, only two new classes have been discovered. Between the 1970s and 1990s, 
the number of discovered natural products continued to increase, but most of them were 
analogues of known compounds (Bérdy, 2005). The cost of conducting this research had 
increased and, with the chances of discovering novel compounds diminishing, it was no longer 
viable for pharmaceutical companies to screen natural products. 
Today, natural products represent a much smaller proportion of drugs. For example, between 
1981 and 2002, only 5% of all drugs approved by the US Food and Drug Administration (FDA) 
were natural products and 23% were natural product derivatives (Newman et al., 2003). 
Synthetic methods, such as combinatorial chemistry, have replaced natural products in drug 
discovery. However, with the advent of new technology and techniques developed in many 
fields, such as chemistry, genomics, and metabolomics, it is possible to overcome these 
difficulties and increase the chances of finding natural products with novel structures. 
 
1.3.5 The Present and Future 
 
In the 1980s, many pharmaceutical companies shifted from natural product screening to 
synthetic approaches, such as semisynthesis and combinatorial chemistry, as a source of new 
drug compounds (Dias, et al., 2012).  
Semisynthesis is a type of synthesis that modifies known natural product structures to improve 
its efficacy and pharmacokinetics (Clardy and Walsh, 2004). While natural products can make 
excellent lead candidates in the drug discovery and development pipeline, they are rarely used 
in their original state (Guo, 2017). Modifications to the molecular structure of active candidates 
are often necessary to improve efficacy, reduce toxic side effects and improve its 
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pharmacokinetic profile such as by altering its lipophilicity or solubility. This can be achieved 
by removing redundant substructures that are not involved in the natural product’s activity or 
by adding more functional groups that change the nature of the compound. One example of a 
successful semisynthetic natural product derivative is telavancin from vancomycin. 
Vancomycin is an antibiotic isolated from Amycolatopsis orientalis in the 1950s which is 
effective against Gram-positive bacteria such as the pathogen Staphylococcus aureus (Levine, 
2006). Vancomycin is able to bind to the terminal D-alanyl-D-alanine moieties of the 
peptidoglycan bacterial cell wall which prevents its formation and results in cell death (Higgins 
et al., 2005). Vancomycin resistant bacteria have a D-lactate instead of a D-alanine terminal 
moiety which inhibits vancomycin’s action. In 2009, the semisynthetic lipoglycopeptide 
telavancin was approved by the FDA to combat vancomycin and combat drug resistant bacteria 
(Saravolatz et al., 2009). Telavancin acts by binding to growing D-alanyl-D-alanyl moieties of 
peptidoglycan chains and prevents transpeptidation which prevents cell wall formation and 
causes cell death (Higgins et al., 2005; Saravolatz et al., 2009). This makes telavancin effective 
against vancomycin and other drug resistant pathogens. For example, telavancin was shown to 
be inhibit methicillin resistant S. aureus (Higgins et al., 2005). Telavancin was synthesised by 
the addition of an aliphatic chain to vancomycin’s amino sugar moiety (Saravolatz et al., 2009). 
Additionally, a polar amino-phosphonic acid group is linked to vancomycin’s biphenyl moiety. 
These alterations allow telavancin to anchor into the lipophilic cell membrane which improves 
it stability at its target site and its affinity for peptidoglycan. Other examples of the use of 
semisynthesis to improve natural products include the artemisinin derivatives from artemisinin 
and aspirin from salicylic acid (Krishna et al., 2004; Der Marderosian and Beutler, 2014). 
Combinatorial chemistry uses different techniques to generate a large and diverse array of 
chemical molecules, known as a chemical library, by repetitive covalent linkage of a set of 
building blocks or precursors (Liu et al., 2017). Chemical libraries can produce millions of new 
compounds, and improvements in technology have facilitated the study of these massive 
libraries. The development of automated high throughput screening (HTS) of whole-cell and 
drug-target based assays allows these libraries to be screened in a matter of days (Dias et al., 
2012). This model offered the potential to solve several challenges faced by natural product 
screening, as combinatorial chemistry was faster, sourcing compounds was no longer an issue, 
and all the structures were known. It was predicted that these libraries could produce highly 
active molecules (Liu et al., 2017). Many drugs have been produced synthetically, such as 
Sorafenib, an anticancer drug that was approved by the FDA in 2005 (Kingston and Newman, 
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2005). However, over time it became clear that the chemical libraries produced could not match 
the chemical diversity of natural products and fewer drug candidates and leads have so far been 
developed by combinatorial chemistry than anticipated (Clardy and Walsh, 2004; Liu et al., 
2017; Harvey et al., 2015).  
Nature has spent billions of years evolving and developing diverse secondary metabolites to 
act in a variety of biological systems, so it is not surprising that matching this diversity and 
functionality is difficult (Basso et al., 2005; Cragg and Newman, 2013). What has been more 
effective is using natural products or their pharmacophores as the building blocks for chemical 
libraries (Brohm et al., 2002; Cragg and Newman, 2013). This was demonstrated by Brohm et 
al. (2002), who created a series of biologically-diverse analogues of the dysidiolide 
phosphatase inhibitors using solid phase synthesis techniques (Brohm et al., 2002). Natural 
products are already biologically validated, and their architecture could be a potent driving 
force in developing improved chemical libraries. Combinatorial chemistry could help modify 
natural products to improve their absorption, transport, and other in vivo parameters (Bérdy, 
2005). This is similar to semisynthesis of natural products, but on a much larger scale. This 
would never be possible without the development of combinatorial chemistry and efforts need 
to be made to combine the two systems. However, to achieve this, new and improved natural 
product libraries need to be created, which first requires isolation of new natural products.  
With the advent of modern technology, the past challenges of natural products can be 
overcome. Advanced chromatographic techniques developed to separate chemical libraries can 
be used to isolate natural products at an accelerated rate (Baker et al., 2007). The inaccessible 
biodiversity of microorganisms can be investigated with the use of genomic techniques, such 
as genome mining, and improved culture methods, such as the use of Ichip chambers that 
isolate unculturable species (Nichols et al., 2010; Liu et al., 2013). Detection methods, such as 
high resolution mass spectrometry (HRMS) and nuclear magnetic resonance spectroscopy are 
more sensitive than before and can be linked to much larger chemical libraries to identify new 
molecules and avoid the isolation of known molecules (Baker et al., 2007). Synthesis 
methodologies have also improved, making it possible to synthesise compounds previously out 
of reach (Bérdy, 2005). These techniques can be combined and even automated to streamline 
the drug discovery process (Dias et al., 2012). With the threat of drug resistance growing, not 
just in malaria, but in the majority of pathogens, new and improved methods and models need 
to be implemented (Bérdy, 2005). While there are still major challenges to be faced, the 




1.3.6 Natural Products in Malaria Drug Discovery 
 
In the context of malaria, natural products have been very successful drugs in the past (Guantai 
and Chibale, 2011; Dias et al., 2012). As discussed previously, quinine and artemisinin were 
both isolated from plants and developed into first-line treatments. There are other examples, 
such as the semisynthetic clindamycin and doxycycline, both of which are used as antibacterial 
antibiotics, but were also found to be effective antimalarials (Kremsner, 1990; Magill et al., 
2011). Currently, natural products are not being developed into antimalarials and there are 
currently no antimalarial compounds in clinical trials that have originated from natural products 
(Guantai and Chibale, 2011; Tse et al., 2019). With the availability of new methods and 
equipment, and the history of natural products in antimalarial drug discovery, natural products 
are a potential source of antimalarials.  
Plants have been the predominant source of natural products in antimalarial drug discovery, 
predominantly due to their importance in traditional medicines (Bourdy et al., 2008; Wells, 
2011). However, screening of plants has produced little success in recent years. From 2005 to 
2008, only 20 new highly active antimalarial compounds were isolated, and none were 
developed further (Bero et al., 2009). While plants represent a viable source of natural 
products, screening new sources of natural products may yield better results (Bérdy, 2005; 
Guantai and Chibale, 2011; Wells, 2011). As discussed previously, members of the phylum 
Actinobacteria are a well-known source of antibiotics and were key contributors during the 
Golden Age of Antibiotics. Despite this impressive history, their antimalarial producing 
potential is not well studied.  
 
1.4 Actinobacteria 
1.4.1 Taxonomy and Physiology 
 
The phylum, Actinobacteria, is composed of Gram-positive bacteria with a distinctive high 
guanine + cytosine DNA content (Barka et al., 2016). The phylum Actinobacteria represents 
one of the largest lineages of the domain Bacteria and includes a diverse array of species 
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ranging from the human pathogen Mycobacterium tuberculosis, the causative agent of 
tuberculosis, to the soil-dwelling saprophytic Streptomyces, a genus of antibiotic producing 
microorganisms. The actinobacteria display a range of morphologies, such as rods, cocci, and 
filamentous forms (Barka et al., 2016). The filamentous species are known as the 
actinomycetes and are the main source of bacterial bioactive compounds. For the purpose of 
this review, discussion and investigation, the focus will be on the filamentous actinobacteria. 
The actinomycetes are typically aerobic mesophiles, but there are exceptions (Lechevalier and 
Lechevalier, 1965). Actinomycetes are mostly free-living and can be found in both terrestrial 
and aquatic/marine environments. Some examples of actinomycete genera are Streptomyces, 
Kitasatospora, Salinispora, Actinomadura, Streptosporangium, Micromonospora, and 
Kribbella (Barka et al., 2016).  
Actinomycetes have a unique morphology, as they produce a mass of hyphae to form a 
mycelium and many reproduce by sporulation (Flärdh and Buttner, 2009; van Dissel  et al., 
2014). In the past, the actinomycetes were considered to be fungi or a transitional form between 
bacteria and fungi because of their filamentous morphology. Almost all actinomycetes form a 
substrate mycelium when grown on solid medium, with the only exception being members of 
the very rare genus Sporichthya (Flärdh and Buttner, 2009). Actinomycetes are also known to 
produce pigments with many different colours depending on growth medium and culture age 
(Lechevalier and Lechevalier, 1965).  
 Briefly, the actinomycete lifecycle (Figure 1.8) begins from a spore, which germinates and 
develops into branched multinucleoid vegetative hyphae, which form the substrate mycelium 
in the agar (Ohnishi et al., 2008). The substrate mycelium grows by tip extension and branching 
(Barka et al., 2016). When stressed, such as during nutrient starvation, actinomycetes produce 
aerial hyphae above the colony, which differentiate into spores for reproduction. The 
actinomycetes are sessile; therefore, in order to survive adverse conditions, they produce 
spores. Spores can be formed by subdivision of the aerial hyphae, fragmentation, swelling, or 
endogenous spore formation (Reponen et al., 1998). The end result is chains of uninucleoid 
spores (Ohnishi et al., 2008).  
The spore morphology, chain length, and number of spores produced all differ greatly between 
actinomycete genera (Barka et al., 2016). Spores are dispersed by air and water to places where 
they can germinate and grow when the conditions are favourable. Spores can remain dormant 
and viable for long time periods under a range of conditions (Reponen et al., 1998). To develop 
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aerial hyphae during adverse conditions, the actinomycetes trigger a programmed cell-death 
mechanism (Wildermuth, 1970; Miguélez et al., 1999). This programmed cell death breaks 
down the vegetative hyphae and scavenges its components. These include amino acids, 
polysaccharides, nucleic acids, lipids, and other nutrients required for aerial hyphae production 
and sporulation. This collection of nutrients is often targeted by neighbouring, competing 
microorganisms; therefore, during this time antibiotics are produced as a defence mechanism 
(Bibb, 2005). Antibiotics can be produced during other stages of the lifecycle, but the majority 
are produced during times of stress (Martin and Demain, 1980). 
 
 
Figure 1.8: Lifecycle of the actinomycetes (Barka et al., 2016). This image was used with 












The actinomycetes are one of the best sources of natural products in the world. They were 
heavily exploited during the Golden Age of Antibiotics, initiated by the discovery of 
streptothricin, streptomycin, and actinomycin from Streptomyces strains in the 1940s 
(Waksman and Woodruff, 1942; Waksman, 1947). Of the approximately 10 000 antibiotics 
known, an estimated 50% originate from actinomycetes (Subramani and Aalbersberg, 2012). 
In addition to their ability to produce such an array of compounds, actinomycetes, and 
microorganisms in general, have another advantage over other natural product sources. Once 
isolated, microorganisms can generally be cultivated on a larger scale and with higher 
production rates than plants, animals, and marine organisms (Bérdy, 2005). 
The bulk of the compounds produced by the actinomycetes, approximately 70%, originate from 
one genus, Streptomyces (Okami and Hotta, 1988; Bérdy, 2005). The genus Streptomyces 
consists of hundreds of species, and Streptomyces strains are the easiest actinomycetes to 
isolate and culture in a laboratory (Bérdy, 2005). 
Streptomyces are thought to be able to produce such an array of diverse secondary metabolites 
due to their extremely large genomes (Goshi et al., 2002). They contain hundreds of 
transcription factors, giving them fine control over their secondary metabolism. This allows 
Streptomyces to react and adapt to a range of environments. The list of antibiotics produced by 
the Streptomyces is too great for the scope of this review, but some examples include, 
aminoglycosides (e.g. streptomycin), macrolides (e.g. erythromycin), β lactams (e.g. the 
cephamycins), ansamycins (e.g. rifamycin) and tetracyclines (e.g. doxycycline) (Okami and 
Hotta, 1988; Liras, 1999; Gaynor and Mankin, 2003; Vakulenko and Mobashery, 2003; Kang 
et al., 2012). More examples are shown in Figure 1.9, which demonstrates the large number of 
antibiotics discovered in the 1960s and the subsequent decrease in the rate of discovery over 
time. 
Other actinomycete genera, known as the rare actinomycetes, because they are more difficult 
to isolate, are also capable of producing unique natural products (Bérdy, 2005). These genera 
represent a massive source of untapped microbial biodiversity. They have a history of 
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producing unique, and sometimes very complicated compounds, which display excellent 
bioactivity and selectivity. Some examples include Micromonospora purpurea, which 
produces the aminoglycoside gentamicin and Actinomadura verrucosospora subspecies 
neohibisca strain E-40, which produces the pradimicins (Furumai et al., 1993; Lazzarini et al., 
2000). There has been an increase in the study of the secondary metabolites of the rare 
actinomycetes over the past few years (Tiwari and Gupta, 2012). Genetically diverse 
actinomycetes have a greater potential to produce chemically diverse novel compounds. This 
makes developing new cultivation techniques and improving the understanding of the rare 
actinomycetes crucial when investigating potential antibiotics. 
 
 
Figure 1.9: Timeline and list of antibiotics from the 1940s until the 2000s (de Lima 
Procópio et al., 2012). Note how the majority were isolated from Streptomyces. This image 




While actinomycetes can produce many different antibacterial antibiotics through a variety of 
biosynthetic mechanisms, they can produce many different types of antimicrobial compounds. 
In a comprehensive biological and statistical review, Bérdy (2005) showed that the 
actinomycetes produce many compounds that are active against multiple pathogens, or exhibit 
multiple pharmacological effects. He estimated that of 10,100 bioactive secondary metabolites 
isolated from actinomycetes, 8,700 were antibacterial and 2,400 of these had other bioactivities 
(Bérdy, 2005). The remaining 1,400 were bioactive, but not antibacterial. According to Bérdy 
(2005), this was much greater than any other source of microbial secondary metabolites, such 
as fungi, but not as many as produced by plants.  
 
The actinomycetes are able to produce a range of antibiotics, not only those with antibacterial 
qualities. For example, the antifungal agent, validamycin A, was isolated from Streptomyces 
hygroscopicus var. limoneus in 1968 (Barka et al., 2016). Validamycin A was used to treat rice 
sheath blight disease (Rhizoctonia solani). Another antifungal agent is kasugamycin, which 
was isolated from Streptomyces kasugaensis and used to treat rice blast disease (Pyricularia 
oryzae cavara) (Umezawa et al., 1965). Actinomycetes also produce natural products with 
anticancer properties. One example is salinosporamide A, produced by the marine 
actinomycete Salinispora tropica (Feling et al., 2003). Salinosporamide A was found to be a 
proteasome inhibitor and submitted for Phase I clinical trials. Actinomycetes have also been 
shown to produce natural products with antiviral, herbicidal, and anti-inflammatory properties 
(Renner et al., 1999; Sacramento et al., 2004; Sousa et al., 2008). More interestingly, Bérdy 
(2005) estimated that actinomycetes produced 5000–10,000 inactive secondary metabolites. 
These inactive molecules share many structurally similarities with known active compounds, 
and it is hypothesized that these molecules do, in fact, have some inherent bioactivity. 
However, they have just not been screened against the correct targets (Bérdy, 2005).  
 
Expanding screening efforts may link unique structures and features with less well-studied 
disease pathways. This was seen in the past with hundreds of compounds originally classified 
as inactive molecules, but discovered to be active later when screened using different testing 
systems. Secondary metabolites are produced to adapt to an organism’s environment and, 
therefore, have evolved to exert some function, the exact function just needs to be determined.  
While the antibacterial antibiotic potential of the actinomycetes drew them into the scientific 
spotlight, it is clear that that is just a small part of what they are capable of. Theoretically, the 
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diversity and versatility of actinomycete natural products is inexhaustible. Due to this they 
represent one of the best chances to combat the threats of drug resistance we face today. 
 
1.4.3 Antimalarial Compounds from Filamentous Actinobacteria 
 
Actinomycetes have been shown to produce potent antimalarial compounds. For example, the 
semisynthetic antibiotics doxycycline, clindamycin, and azithromycin have all been shown to 
be effective antimalarials (Kremsner, 1990; Magill et al., 2011; van Eijk and Terlouw, 2011).  
Azithromycin is a semisynthetic derivative of erythromycin and clindamycin is a semisynthetic 
derivative of lincomycin (Birkenmeyer and Kagan, 1970; Jelić and Antolović, 2016). Both of 
which are produced by actinomycetes. Doxycycline is still used as a prophylactic treatment, 
but it is not recommended for children as it can disrupt bone growth (Magill et al., 2011). More 
recently, there has been an increase in the search for antimalarials produced by actinomycetes. 
For example, gancidin-W, a potent low-toxicity antimalarial, was isolated from the endophytic 
Streptomyces strain SUK-10 (Baba et al., 2015). Salinosporamide A was shown to be a very 
effective antimalarial in in vivo studies, with activity matching that of chloroquine (Prudhomme 
et al., 2008). While these examples indicate that actinomycetes can produce antimalarials, more 
research needs to be conducted. Most of the compounds mentioned were antibiotics repurposed 
as antimalarials, and little screening has been done solely on the antimalarial potential of the 
actinomycetes (Pérez-Moreno et al., 2016). Therefore, further work is required to fully explore 




With the threat of drug resistance, the spread of insecticide resistance, and the lack of a vaccine, 
progress towards the eradication of malaria has stalled (Feachem et al., 2019). New measures 
need to be implemented and developed to eradicate the disease. While it cannot be the only 
new measure, it is critical that novel drugs, with novel mechanisms of action, are developed. 
Historically, natural compounds have produced the best antimalarials. While interest has waned 
in natural products as drug sources, the advent of new technologies, methodologies, and 
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knowledge can allow us to overcome their past limitations. This makes natural products an 
ideal source for new antimalarial drugs.  
The filamentous actinobacteria have a long history of producing bioactive compounds and have 
been shown to be capable of producing unique compounds with different bioactivity profiles. 
However, limited research has been conducted on the antimalarial potential of the filamentous 
actinobacteria. This warrants further research to determine whether the filamentous 
actinobacteria produce natural products capable of being developed into novel and effective 
antimalarials. 
 
1.6 Scope of the Study 
 
The aim of this investigation was to screen filamentous actinobacteria for antiplasmodial 
activity, determine if  activity was due to novel antiplasmodial  compounds and if these novel 
compounds could be developed into new antimalarial compounds. This was to be achieved by 
pursuing four objectives: 
• The first objective was to screen filamentous actinobacterial strains for antiplasmodial 
activity against the drug-sensitive strain of P. falciparum, NF54. The activity of each 
strain was used to select the best candidate for further study.  
• The second objective was to purify the active compounds from the selected filamentous 
actinobacteria by bioassay-guided fractionation. The intention was to develop a 
purification method with as few steps as possible. 
• The third objective was to elucidate the structures of the active compounds and 
determine whether they are novel. This was achieved by using HRMS and NMR 
spectroscopy. 
• The final objective was to evaluate the isolated compounds antiplasmodial efficacy and 
host selectivity to determine if they are suitable for further development. This objective 
was subdivided into the following categories: 
1. Activity against the drug-sensitive strain and multi-drug resistant strain of P. 
falciparum, NF54 and K1 respectively. 
2. Mammalian cytotoxicity against the Chinese Hamster Ovary and HepG2 cell lines.  









Uncharacterized environmental actinobacterial strains from the Meyers laboratory (University 
of Cape Town, South Africa) culture collection and the type strains of new actinobacterial 
species identified and characterized in the Meyers laboratory, were screened for antiplasmodial 
activity against P. falciparum, NF54. The cultivation conditions selected for antiplasmodial 
compound production were the same as those shown to result in antibacterial antibiotic 
production. Liquid cultures were extracted using the mid-polar solvent, ethyl acetate, with the 
aim of discovering drug-like molecules that can be administered orally. Thirty-one strains of 
actinobacteria belonging to eight genera (Actinomadura, Amycolatopsis, Gordonia, Kribbella, 
Micromonospora, Nocardia, Nonomuraea, and Streptomyces) were screened revealing 
fourteen candidates. By applying strict in vitro conditions required to qualify for further 
investigation, eight strains were found to be suitable for antiplasmodial purification and 
isolation studies. Of these eight candidates, Streptomyces strain PR3 was selected as it showed 
excellent antiplasmodial efficacy, no cytotoxicity against the Chinese Hamster Ovary or liver 












The aim of the investigation was to screen filamentous actinobacteria metabolites for 
antiplasmodial activity. Actinobacterial strains were selected, cultivated in liquid medium, 
extracted, and tested for antiplasmodial activity. Crude extracts that showed promising activity 
were then evaluated further. 
Actinobacterial strains were not isolated as part of this investigation. Instead, strains from Dr 
Paul Meyers’ culture collection in the Department of Molecular and Cell Biology, University 
of Cape Town, were screened. These strains represent a unique biodiversity having never been 
screened for antiplasmodial activity. Only recently isolated, uncharacterized strains or novel 
strains isolated and characterized by Dr Meyers’ laboratory were selected. The intention behind 
selecting biodiverse strains was to improve the probability of isolating unique chemical 
molecules as biological diversity underpins chemical diversity. Genetic diversity enables 
strains to produce chemically-diverse molecules, which may be new secondary metabolites 
with unique functions (Bérdy, 2005; Tiwari and Gupta, 2012). Actinobacterial strains shown 
to have antibacterial or antifungal antibiotic potential were prioritized in the hopes of isolating 
compounds with activity against a spectrum of pathogens. However, strains with no known 
antibiotic activity were also screened. Only pure cultures of the strains were used, and purity 
was checked before, during and after cultivation by Gram staining and streaking for single 
colonies (Bartholomew and Mittwer, 1952; Shirling and Gottlieb, 1966).  
Due to the impressive record of Streptomyces strains as antibiotic producers, the bulk of the 
strains screened were novel isolates belonging to the Streptomyces genus (de Lima Procópio et 
al., 2012). Streptomyces species were also readily available from the culture collection. The 
other strains tested belonged to rarer, non-Streptomyces, genera. As discussed in Chapter 1, the 
rare actinomycetes are capable of producing unique and potent antibiotic compounds and 
warrant screening (Tiwari and Gupta, 2012). 
The simplest way to test the antiplasmodial activity of actinobacteria is to test the crude solvent 
extracts of each strain. To the author’s knowledge, there is no bioautographic overlay technique 
or similar technique available to accelerate antiplasmodial testing. 
To obtain crude extracts, strains were cultivated in liquid medium. The cultivation conditions 
required for antiplasmodial compounds were considered to be the same as the ones required 
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for antibacterial antibiotic production. This is an accepted assumption for all non-antibiotic 
secondary metabolites, such as pigments and plant growth factors (Martin and Demain, 1980). 
In nature, actinomycetes usually produce antibiotics under stress conditions, such as nutrient 
depletion. When grown in batch culture, actinomycetes grow exponentially during the 
exponential (log) phase, then enter the stationary phase as nutrients become limiting and 
growth slows down (Martin and Demain, 1980). In the stationary phase, primary metabolites 
produced during the log phase are used in the biosynthesis of antibiotics and other secondary 
metabolites. Therefore, culture incubation was set for a period shown to be suitable by the 
Meyers group to ensure sufficient time in the stationary phase (Meyers et al., 2003; Wood et 
al., 2007). 
Most actinomycetes are aerobic and require oxygen to grow and produce antibiotics; therefore, 
all cultures were shaken (Iwai and Omura, 1982). This ensures homogenous, well-aerated 
liquid cultures. 
Actinomycetes can be fastidious, and it is well known that they produce different secondary 
metabolites based on their growth and nutrient conditions (Martin and Demain, 1980). 
Therefore, it is possible that a selected strain can produce antiplasmodial compounds, but not 
in the medium or conditions it was exposed to. However, the chance of locating novel 
compounds is predicted to be higher when screening more strains simultaneously than fewer 
strains under different growth conditions (Tiwari and Gupta, 2012). Therefore, each strain was 
grown in the medium it was originally isolated in.  
Before extraction, the broth and cell mass were separated. This simplified the extraction, and 
if one source (the cells or the spent culture broth) was inactive, it could be discarded in future 
extractions. It is also possible that different compounds are found in the cells and the culture 
broth. Extraction is based on the partitioning of compounds into solvents with similar 
physiochemical properties, such as polarity (Zhang et al., 2018). When selecting extraction 
solvents to use, it is important to understand what type of molecules you need to isolate. As 
discussed in Chapter 1, new antimalarials ideally need to be administered orally. The 
lipophilicity of a compound has been shown to be an important factor in determining its 
absorption and distribution. Hydrophilic compounds are typically unable to penetrate the 
lipophilic cell membrane of the gastrointestinal tract (GIT) without cell transporters (Lipinski, 
2000). Conversely, lipophilic molecules can pass through the GIT cell membranes, but do not 
dissolve in water. Therefore, they may bind preferentially to proteins or food in the GIT or 
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remain in cells (Katzung et al., 2012).  Mid-polar compounds have been shown to be better 
oral drugs as they dissolve better in water and pass through lipophilic membranes (Lipinski, 
2004; Bhal, 2020). The partition coefficient (P) describes the likelihood of a neutral solute to 
dissolve in an immiscible biphasic system of fats (organic solvents, lipids) and water (Bhal, 
2020). If a solute has a positive logP it is hydrophobic/lipophilic while if it has a negative logP 
it has a higher affinity for aqueous environments. Solutes with a logP of 0 are mid-polar as 
they partition equally between the organic and aqueous layers. Solvents tend to extract solutes 
with the same logP following the old rule “like dissolves in like” (Zhang et al., 2018). 
Therefore, the selected solvent should have a similar logP value. Ethyl acetate (EtAc) was 
selected as the main extraction solvent as it has a logP of 0.7 (National Center for 
Biotechnology Information, 2020). This does not mean that all compounds extracted by EtAc 
will make good oral drugs, but it does increase the likelihood of extracting compounds with 
the correct lipophilicity. Methanol (MeOH), a polar solvent, was used in the first cell mass 
solvent wash with EtAc to disrupt hydration layers. This was predicted to improve the 
extraction as it allowed the EtAc to mix more efficiently with the actinobacterial hyphae. 
To test for antiplasmodial activity, a phenotypic assay against the asexual blood stage of P. 
falciparum was selected. This stage was used, because it is the easiest to culture in vitro, 
presents a number of druggable targets, and represents a large proportion of the parasite’s 
lifecycle (Cowman et al., 2016; Hovlid and Winzeler, 2016). Phenotypic or whole-cell assays 
are tests that expose the entire microorganism to drug candidates and changes in phenotype are 
monitored (Hovlid and Winzeler, 2016).  
The alternative to phenotypic screening is target-based screening. Target-based screening 
involves exposing purified protein targets required for the pathogen’s survival to drug 
candidates (Swinney, 2013). When screening natural products, phenotypic screens have several 
advantages over target-based screens (Hovlid and Winzeler, 2016). Firstly, compounds that are 
unable to penetrate cell membranes are eliminated. Secondly, molecules that act synergistically 
can be detected. Most importantly for natural-product screening, knowledge of the drug target 
is not required; therefore, the identity of the test molecule(s) is not necessary and unknown 
mechanisms of action can be discovered (Swinney, 2013; Katsuno et al., 2015). While not 
preferred for hit selection, target-based screens are very useful in discovering the targets of 
drug candidates during later development (Katsuno et al., 2015). 
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The parasite lactate dehydrogenase (pLDH) assay was used to measure antiplasmodial activity. 
The basis of this assay relies on the ability of the lactate dehydrogenase (LDH) enzyme of P. 
falciparum to use 3-acetyl pyridine (APAD) as a coenzyme to oxidize lactate to pyruvate 
(Makler et al., 1993). APAD is reduced to APADH, which subsequently reduces nitro blue 
tetrazolium (NBT) to a formazan precipitate. Reduction of the tetrazolium produces a colour 
change from yellow to purple, which can be measured spectrophotometrically and correlated 
to parasite survival. The greater the colour change, the greater the parasite survival (Makler et 
al., 1993).  
Human erythrocytes also contain the LDH enzyme; however, it carries out the same reaction 
at a much slower rate in the presence of APAD. Therefore, erythrocytes produce very little 
background signal. The pLDH assay can detect the presence of P. falciparum in vitro at 
parasitaemia levels of 0.02% (Makler et al., 1993). NB, when discussing efficacy results from 
in vitro assays, the activity is referred to as antiplasmodial activity (Fan et al., 2018). 
Antimalarial activity refers to activity seen against the disease as a whole, such as in in vivo or 
clinical studies. 
Each crude culture extract sample was tested for antiplasmodial activity against NF54, a fully 
drug-sensitive strain of P. falciparum (Dowler, 1995). A drug-sensitive strain was selected to 
establish baseline activity. Once purified, active compounds were tested against the multi-drug 
resistant strain, K1 (Thaithong et al., 1983). 
The basis of antibiotic drug therapy is selective toxicity, where drugs must selectively inhibit 
the pathogenic target without harming the human host (Peternel et al., 2009). Therefore, when 
screening natural products, it is important to discern between antiplasmodial activity and host 
cytotoxicity. Cytotoxicity refers to the effect of chemical compounds as evidenced by host cell 
death, cell growth inhibition, altered cell morphology or failure of cells to attach to surfaces 
(Slater, 2001).  
Cytotoxicity can be measured using a number of different techniques, and there is no single 
generally accepted method (Peternel et al., 2009).  In vitro assays are commonly used to 
determine cytotoxicity and have a number of advantages over in vivo studies (Stone et al., 
2009). They are faster and thus more suitable for high-throughput screening, relatively easy to 
maintain and analyse, less expensive than in vivo models and more ethical than testing on 
animals. The obvious disadvantage of in vitro cytotoxicity, and indeed many in vitro screening 
techniques, is that they do not represent the complex set of interactions between multiple organs 
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and cell types that occur in living systems. Drug candidates can be cytotoxic against a range of 
cell types at the same concentration or display cell-type-specific toxicity (Peternel et al., 2009). 
These toxic effects could be missed in vitro, and, ultimately, compounds of interest must be 
tested for in vivo toxicity in animal and human models to be declared safe. 
An important issue with early in vitro cytotoxicity results is interpretation. Crude extracts are 
a mixture of chemicals and mixtures may not display the same properties as pure compounds 
(Altenburger et al., 2003). Other components in the crude extract may exert a synergistic or 
antagonistic effect, which could lead to an increase or decrease in an active compound’s 
cytotoxicity, respectively. Concentrations are also affected in mixtures. For example, an 
antiplasmodial active compound may be cytotoxic, but could be diluted in a crude extract to 
the extent that cytotoxicity is not detected. Alternatively, the crude extract may contain 
compounds that are cytotoxic, but are not responsible for antiplasmodial activity of the mixture. 
For these reasons, in the past, cytotoxicity screening was left for when compounds were 
purified or close to pure (Peternel et al., 2009). However, this led to late toxicology 
identification and increased drug attrition rates, which could have been avoided by earlier 
cytotoxicity screening (Kola and Landis, 2004). Therefore, in this study cytotoxicity screening 
was employed at every major purification step. 
To better asses cytotoxicity, crude extracts, fractions, and pure compounds were tested against 
three different cell types. The first was the Chinese Hamster Ovary (CHO) cell line, an 
epithelial cell line derived from the ovary cells of Chinese hamsters (Lai et al., 2013). CHOs 
are widely used in cytotoxicity experiments during drug discovery and development projects. 
The second cell line tested was the HepG2 line, a human liver cancer cell line (Miret et al., 
2006).  
Cell viability was determined by the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay (Mosmann, 1983). This assay measures mitochondrial 
enzyme activity, such as succinate dehydrogenase, as a measure of cell viability (Stone et al., 
2009). In this assay, MTT is reduced to a purple formazan crystal by NADH in viable cells, 
and the colour change can be measured spectrophotometrically (Mosmann, 1983; Aslantürk, 
2018). Higher levels of cell viability generate a greater absorbance measurement. 
Lastly, cytotoxicity was also tested against human erythrocytes (O+). Although uncommon, 
some compounds display toxicity specific to erythrocytes, an effect known as haemotoxicity 
(Ziegler et al., 2002; Jilani et al., 2013). In these cases, the pLDH assay will a yield positive 
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results, but the mechanism of action of the tested compound is deprivation of the parasite of its 
host environment due to inhibition of the erythrocyte. This is a false-positive results and would 
lead to toxic host side effects if the tested compound was developed further. To measure 
haemotoxicity, an in-house assay was developed. This assay is relatively simple, in that it is a 
modified version of the pLDH assay. Uninfected blood was used instead of parasitized red 
blood cells. The experimental set-up was the same as the pLDH assay (i.e. complete medium 
was used to dilute drug samples and to make up haematocrit, the uninfected haematocrit was 
kept to 1% as per the pLDH assay etc). These conditions were maintained to obtain results that 
could be directly compared to antiplasmodial readings. Therefore, if similar results were 
obtained from both assays, antiplasmodial activity could be attributed to haemotoxicity, rather 
than selective action against the P. falciparum parasites.  
The ultimate goal of natural-product screening programs is not to identify the perfect candidate, 
but rather generate a list of potential hit compounds that can be chemically modified and 
improved during later drug development (Bugelski et al., 2000; Peternel et al., 2009). By 
running cytotoxicity screening in parallel with antiplasmodial screening, one can identify very 
toxic compounds early on and identify compounds that may be less potent, but safer. These 
compounds could theoretically be dosed at a higher concentration to improve their selective 
effect. 
 
The aim of this investigation was to: 
• Grow selected actinobacterial strains in liquid media until sufficient cell mass was 
produced. 
• Extract the broth and cell mass of each actinobacterial strain. 
• Determine and evaluate the antiplasmodial efficacy of each crude extract against 
the drug-sensitive strain of P. falciparum, NF54. 
• Determine and evaluate the in vitro cytotoxicity of selected candidates against the 






2.2.1 Cultivation of Actinobacteria 
 
Spore suspensions or 15% (v/v) glycerol stock solutions were used to inoculate 15 mL of liquid 
medium in a 250 mL Erlenmeyer flask, and incubated with shaking at 25 oscillations per 
minute at 30°C for 4–6 days. If sufficient growth had occurred during this time, the entire 
culture was used to inoculate 100 mL of the same liquid medium in a 1 L Erlenmeyer flask, 
which was incubated for 10–14 days at 30°C with shaking at 25 oscillations per minute. 
Four different liquid media were used depending on the strain tested. These were yeast extract-
malt extract medium (International Streptomyces Project medium 2; ISP-2) (Shirling and 
Gottlieb, 1966), DSMZ (German Culture Collection) medium #553 (German Culture 
Collection, 2007), Hacène’s Medium (HM) (Hacène and Lefebvre, 1995) and Japan Collection 
of Microorganisms (JCM) medium #61 (Ara and Kudo, 2007). All media were autoclaved 
before use to ensure sterility. Before inoculation, upscaling, and extraction, the purity of the 
culture was determined by streaking for single colonies on agar plates and by Gram staining 
(Bartholomew and Mittwer, 1952; Shirling and Gottlieb, 1966). 
 
2.2.2 Culture Extraction 
 
Once sufficient cell mass was obtained, the secondary metabolites could be extracted from the 
actinobacterial cultures. After culture purity was checked, the filamentous cell mass was 
separated from the culture medium (broth) by filtration through two coffee filters (size 1 x 4, 
House of Coffees, South Africa). The broth fraction was extracted by liquid-liquid extraction, 
where the broth (approximately 100 mL) was mixed with 30 mL of EtAc (≥ 98%, Merck, 
Darmstadt, Germany) and left to stand in a separating funnel at room temperature for 60 
minutes. The EtAc was removed and the broth was extracted with a second 30 mL of EtAc. 
The two EtAc layers obtained were pooled and allowed to stand in a separating funnel 
overnight. This separated any remaining water and emulsified layers from the EtAc layer. The 
EtAc layer was collected and allowed to dry in a glass beaker in a fumehood. 
63 
 
The cell mass was mixed with 5 mL of MeOH (>99%, Kimix Chemical and Lab Supplies, 
Cape Town, South Africa) and 50 mL of EtAc. The cell mass and solvents were mixed by 
gentle agitation in a Schott bottle on a Labnet™ Orbit 1000 multipurpose shaker at 120 rpm for 
60 minutes. The solvent was separated from the cell mass by filtration through two coffee 
filters. Another 50 mL of EtAc was added to the extracted cell mass and the extraction process 
was repeated. The two cell mass EtAc extracts were pooled and allowed to dry in a glass beaker 
in a fumehood. 
The broth and cell mass dried extracts were re-dissolved in 1 mL each of EtAc and transferred 
into a clean pre-weighed plastic benchtop tube (Inqaba Biotec, Pretoria, South Africa). One 
millilitre of MeOH was then added to each glass beaker to dissolve remaining compounds and 
transferred into a separate clean pre-weighed plastic benchtop tube. Based on the calculated 
mass of each crude extract, the concentration of each solution was adjusted to 2 mg/mL with 
the same solvent used to prepare the solution. This produced four crude extracts per strain: 
broth EtAc, cell mass EtAc, broth MeOH and cell mass MeOH. 
 
2.2.3 Plasmodium falciparum Cultivation 
 
The culture medium was made with 10.4 g/L RPMI 1640 (with glutamine and without 
NaHC03), 4 g/L glucose, 6 g/L Hepes buffer, 0.088 g/L hypoxanthine, 5 g/L albumax, and 102 
ml/L (0.05 g/L) gentamicin (Sigma-Aldrich, South Africa). The medium was filtered twice, 
first with 0.45 µm filters followed by filtration with 0.22 µm filters. Complete medium (CM) 
was made by adding 8.4 ml of 5% bicarbonate per 200 ml culture medium. 
The drug-sensitive strain of P. falciparum, NF54 was obtained from the Malaria Research and 
Reference Reagent Resource (MR4) depository (Dowler, 1995). P. falciparum was 
continuously cultured in human O+ erythrocytes as described by Trager and Jensen (Trager and 
Jensen, 1976). Human blood, donated by anonymous donors, was obtained from the Western 
Cape Blood Service (Cape Town, South Africa). Cultures were centrifuged at 700 x g for 3 
minutes, the resultant supernatant was aspirated, and a thin blood smear made.  
Smears were fixed with MeOH, stained with 10% Giemsa stain and left to stand for 5 minutes. 
Parasitaemia was estimated and blood-stage determined via light microscopy. The parasitaemia 
was calculated as the ratio of parasitized erythrocytes to uninfected erythrocytes. The 
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parasitaemia of each culture was estimated by counting 500-700 cells at 1000 X magnification. 
If cells were predominantly in the mature trophozoite phase, cultures were diluted to 
approximately 5% parasitaemia using red blood cells and 40 mL of CM. 
 If the culture was predominantly in the immature trophozoite phase (ring phase), it was 
subjected to sorbitol lysis to lyse mature trophozoites present and synchronise the culture. 
Mature trophozoite and schizont cells are more sensitive to changes in osmotic pressure than 
immature trophozoites, and thus sorbitol lysis ensures that only immature trophozoites are 
present and viable. Sorbitol lysis was conducted by adding 15 mL of 5% sorbitol, warmed to 
37ºC, to the culture and leaving it to stand for 10 minutes. Afterwards, the culture was 
centrifuged at 700 rcf for 3 minutes, the supernatant aspirated and 40 mL of CM was added.  
Each culture was gassed with a mixture of 3% O2, 4% CO2 and 93% N2 for 30–60 seconds in 
a sealed gassing chamber before incubation at 37°C. 
 
2.2.4 Parasite Lactate Dehydrogenase Assay 
 
The pLDH assay was performed according to a modified version of the method described by 
Makler et al. (1993). All crude extracts were weighed to 3 decimal places using an accurate 
mass balance and diluted to a stock concentration of 20 mg/mL. Crude extract and stock 
samples were diluted in CM, and the starting concentration was adjusted depending on the 
sample. However, during the initial screening of actinobacteria for antiplasmodial activity, 
crude culture extracts were tested at a starting concentration of 5 µg/mL. One hundred 
microlitres of CM was added to every row of a 96-well titration plate except row 3. Two 
hundred microliters of the test sample was added in quadruplicate to row 3. The sample was 
then serially diluted 2-fold from rows 3–12 to generate a concentration gradient.  
Only cultures of mature trophozoites were used. Cultures were counted (section 2.2.3) and 
diluted to a 2% suspension using CM, uninfected red blood cells, and parasitized red blood 
cells. One hundred microlitres of a 2% haematocrit solution served as a blank and was added 
to row 1. One hundred microlitres of the 2% parasitaemia suspension was added to row 2 and 
served as a positive control for parasite growth. One hundred microlitres of 2% parasitaemia 
was then added to each well in rows 3–12. Ten millilitres of the 2% parasitaemia suspension 
was required per 96-well plate tested. The final volume of each well was 200 µL and the final 
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parasitaemia was 1%. Each plate was covered with a lid, labelled and placed in a gassing 
chamber. 
The chamber was sealed and gassed for 2 minutes with a mixture of 3% O2, 4% CO2 and 93% 
N2. The chamber was incubated at 37ºC for 48 hours, one full blood stage lifecycle. After 
incubation, the red blood cells in the plates were lysed by freezing at -80°C for 1 hour, followed 
by thawing at 37°C. Next, the contents of each well were thoroughly resuspended with an 
automatic pipette to ensure each sample was homogenous. 
Malstat lysis buffer was prepared by adding 400 µL Triton*100, 4 g of L-lactate, 1.32 g 
tris(hydroxymethyl)aminomethane (Tris) buffer, 22 mg of APAD and the solution was adjusted 
to a pH of 9 in 200 mL Millipore water (Sigma-Aldrich, South Africa). 
One hundred microlitres of Malstat lysis buffer was added to each well on a new plate, and 15 
µL of each test sample was transferred to the corresponding well on the new plate. The new 
plates were left to stand for 30 minutes to ensure complete lysis of all the parasite cells in each 
well and thus an accurate reading. Bubbles were removed from the new plate by drying them 
with a hairdryer prior to reading. Bubbles interfere with absorbance readings and must be 
removed. Afterwards, 25 µL of NBT was added to each well. 
NBT was made by adding 160 mg NBT and 8 mg phenazine ethosulphate to 100 mL H2O. The 
plates were kept in a cupboard until they had fully developed, as NBT is light sensitive. Once 
developed, the absorbance was measured at 620 nm using a Turner BioSystems, Inc. Modulus™ 
II Microplate Reader. Nonlinear regression analysis of the data on the GraphPad PRISM 
version 4.00 program was used to determine the concentration of compound required to inhibit 
the absorbance signal by 50% (Maron et al., 2016). This value is known as the half maximal 
inhibitory concentration (IC50) and represents the concentration of the tested compound 
required to inhibit the growth of half of the population of the tested cell type.  
Chloroquine and artesunate were used as positive controls in each pLDH assay, as they are 
well described antimalarial compounds. The acceptable ranges of chloroquine’s and 
artesunate’s IC50s were considered to be 2–10 ng/mL and 0.5–8 ng/mL, respectively. If either 
of the controls displayed activity not within the selected ranges, the results were discarded, and 
the experiment repeated. Factors such as incorrect parasitaemia calculation, culture 




2.2.5 Cultivation of Cell Lines  
 
Both cell lines (CHO and HepG2) were continuously cultured by Mrs Sumaya Salie and Mr 
Virgil Verhoog at the Division of Clinical Pharmacology, Department of Medicine at the 
University of Cape Town. 
CHO cells were cultured continuously in cell-culture medium consisting of 10% foetal calf 
serum (FCS, Celtic Molecular Diagnostics, Mowbray, South Africa) 45% Dulbecos Modified 
Eagles Medium (DMEM, Highveld Biologicals, Lyndhurst, South Africa) and 45% HAMS-
F12 medium ( (1:1), Sigma, St Louis, MO, USA). HepG2 cells were cultured in 90% DMEM 
and 10% foetal calf serum. Both cell lines were kept in gas flow incubators at 37ºC, 5% CO2. 
Cells were subcultured in preparation for cytotoxicity assays, with only confluent cultures 
selected. Confluency of cells was checked periodically via microscopy, and if cultures were 
not confluent the medium was changed.   
If the cells were confluent, the medium present was poured off, and flasks were rinsed twice 
with 10 mL of sterile phosphate buffered saline (PBS). A 0.25% trypsin solution was warmed 
to 37ºC and added to the washed flasks. Trypsin is a protease that degrades the anchoring 
proteins causing cells to lift from the flask’s surface. The flasks were incubated with trypsin 
for 2 minutes and agitated slightly to lift cells. Care must be taken, as the cells must not be 
incubated with the trypsin for too long, to avoid extensive degradation. Once it was determined 
that all cells had lifted (via light microscopy), 5 mL of cell medium was added to inhibit the 
trypsin. The flasks contents were then transferred into a 50 mL centrifuge tube and centrifuged 
for 3 minutes at 700 rpm. The supernatant was poured off, and the resultant pellet was 
resuspended in 5 mL cell medium.  
 
2.2.6 MTT Assay 
 
Cytotoxicity assays were conducted by Mrs Sumaya Salie and Mr Virgil Verhoog at the 
Division of Clinical Pharmacology, Department of Medicine at the University of Cape Town. 
Twenty microlitres  of the selected confluent cell culture was transferred into a benchtop 
centrifuge tube and mixed with 20 µL of 1% crystal violet dye for cell counting. All of the 
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mixture was placed in a counting chamber, and the number of cells was counted via light 
microscopy. From the count, the cell concentration was determined, and a dilution was made 
to obtain a standard cell concentration of 105 cells/mL. Fifteen millilitres of the diluted cell 
suspension was used per plate. One hundred microlitres of cell suspension was  added to each 
well in rows A–G of a 96 well plate. One hundred microlitres of cell medium was then added 
to the same wells in rows A–G. Two hundred microlitres of cell medium was added to each 
well in row H, which served as a blank. The plates were incubated at 37ºC for 24 hours.  
Cells were checked by microscope to ensure that they had attached to the bottom of each well. 
Each test sample and control was diluted to generate 6 concentrations of 200, 20, 2, 0.2, 0.02, 
and 0.002 µg/mL. The medium was carefully aspirated from each well so that only a thin layer 
was left covering the cells. Two hundred microlitres of cell medium was added to each well in 
rows G and H. Row G served as the positive control for MTT reduction and therefore cell 
growth. One hundred microlitres of each drug dilution was added in triplicate to separate rows, 
starting with row E. One hundred microlitres of cell medium was added to each well in rows 
A–E. This generated a total volume of 200 µL in each well with a compound concentration 
range of 100–0.001 µg/mL. Plates were covered and incubated in gas flow incubators at 37ºC, 
5% CO2 for 48 hours.  
After incubation, plates were developed by adding 25 µL of sterile MTT to each well and 
further incubated for 4 hours at 37ºC. Plates were centrifuged at 200 rpm for 10 minutes, and 
the medium was aspirated off. One hundred microlitres of dimethyl sulfoxide (DMSO) was 
added to dissolve the MTT formazan derivative, and the plates were softly agitated for 2 
minutes to ensure a homogenous mixture. The plates were then read at 540 nm using a Turner 
BioSystems, Inc. Modulus™ II Microplate Reader. The data were analysed by nonlinear 
regression analysis using the GraphPad PRISM version 4.00 program to determine the IC50 of 
each compound. Once the IC50 has been calculated the selectivity index (SI), can be determined. 
The SI is the ratio of a compound’s cytotoxicity vs its antiplasmodial efficacy and is calculated 
using the equation below: 
Selectivity Index (SI) = Cytotoxicity (IC50)/ Antiplasmodial Efficacy (IC50)  
 
Emetine was used as a cytotoxicity control, and the acceptable IC50 range was set as less than 
30 ng/mL against both the CHO and HepG2 cell lines. If emetine did not display acceptable 
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cytotoxicity, the results were discarded, and the assay repeated. Incorrect cell counting or 
contamination could cause these results. 
 
2.2.7 Haemotoxicity Assay 
 
An in-house assay was developed to determine haemotoxicity by measuring the absorbance of 
haemoglobin present after 1% haematocrit was exposed to test samples for 48 hours. 
Haemotoxic compounds can cause apoptosis or disrupt the membrane of erythrocytes, which 
increases the amount of haemoglobin released into the environment (Hayter et al., 2014). 
Haemoglobin has a unique absorbance profile and absorbs light at 540 nm and 575 nm. This 
allows the amount of haemoglobin to be measured spectrophotometrically. Triton X-100 was 
used as a positive control for erythrocyte lysis. Triton X-100 is a non-ionic surfactant used to 
lyse cells for protein extraction or to permeabilize cell membranes (Borner et al., 1994).  
Human blood (O+) donated by anonymous donors, was obtained from the Western Cape Blood 
Service (Cape Town, South Africa). Ten millilitres of 2% haematocrit solution was made up 
per plate tested. Complete medium (CM) (section 2.2.3) was used to dilute all samples and test 
solutions. One hundred microlitres of CM was added to each well except row F. Drugs were 
diluted to 200 µg/mL in CM. Two hundred microlitres of each sample was added to row F in 
triplicate. The samples were then serially diluted two-fold to produce a concentration gradient 
of 100–0.001 µg/mL from row A–F. A 2% solution of Triton 100 was made up in CM, and 100 
µL was added to each well in row G. One hundred microlitres of the 2% haematocrit was added 
to each well to generate a final haematocrit of 1%, the same concentration tested in the pLDH 
assay (section 2.2.4). Row H consisted of only erythrocytes in CM to act as a blank and negative 
control for erythrocyte lysis. After incubation for 48 hours at 37°C, the plates were centrifuged 
at 200 rpm for 10 minutes. One hundred microlitres of the supernatant was transferred from 
each well to the corresponding wells in a clean 96 well plate. Care was taken not to disturb the 
pellet when transferring the supernatant. The absorbance was measured at 540 nm and 575 nm 
using a BMG Labtech® FLUOstar Omega multi-mode microplate reader. The data were 
analysed using nonlinear regression analysis in the GraphPad PRISM version 4.00 program to 
determine the IC50 of each compound. 
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2.3 Results and Discussion 
 
Each crude culture extract sample was tested at a starting concentration of 5 µg/mL. If 
inhibition greater than 50% was seen in all test rows, further studies, at lower starting 
concentrations, were conducted in certain cases, depending on the amount of extract available. 
Thirty-one actinobacterial strains were tested for antiplasmodial activity against the drug-
sensitive P. falciparum, NF54 during this investigation (Table 2.1). Fourteen strains showed 
antiplasmodial activity against NF54 (Table 2.2).  
Table 2.1: Antiplasmodial activity of actinobacterial strains against P. falciparum, 
NF54, N=1 biological repeat with 4 technical repeats. 
Strain Name Growth Medium Antiplasmodial activity 





















































 +  antiplasmodial activity with IC50 < 5 µg/mL was observed ,  






















+  antiplasmodial activity with IC50 < 5 µg/mL was observed ,  
   - antiplasmodial activity with IC50 > 5 µg/mL was not observed. 
 
Strain Name Growth Medium Antiplasmodial activity 
against P. falciparum, 
NF54 












Streptomyces strain CS1 JCM #61 - 
Streptomyces strain CS12 JCM #61 - 
Streptomyces strain CS18 JCM #61 - 
Streptomyces strain CS3 DSMZ #553 - 
Streptomyces strain CW2 DSMZ #553 + 
Streptomyces strain CW5 JCM #61 + 







Streptomyces strain PR3  ISP-2 + 
Streptomyces strain PR10 ISP-2 + 
Streptomyces strain RS3 DSMZ #553 + 
Streptomyces strain RS6 DSMZ #553 - 
Streptomyces strain RS7 DSMZ #553 +  
Streptomyces strain RS9 DSMZ #553 - 
Streptomyces strain RS13 DSMZ #553 + 
Streptomyces strain RS15 DSMZ #553 + 
Streptomyces strain RS18 DSMZ #553 - 
Streptomyces strain RS19 JCM #61 + 
Streptomyces strain UK1 HM + 
Streptomyces strain UK2 ISP-2 - 
Table 2.1 (continued): Antiplasmodial activity of actinobacterial strains against P. 
falciparum, NF54, N=1 biological repeat with 4 technical repeats. 
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Table 2.2: Antiplasmodial activity of each active actinobacterial strain, N=1 biological 
repeat with 4 technical repeats. 
 
Strain Name 






























< 125 311 > 5000 
Streptomyces strain 
CW5 
128 < 312 > 5000 > 5000 














110 147 80 2370 
Streptomyces strain 
PR10 
< 125 < 125 < 125 < 125 
Streptomyces strain 
RS3 
> 5000 3270 > 5000 > 5000 
Streptomyces strain 
RS7 
70 < 312 21 < 312 
Streptomyces strain 
RS13 
4493 > 5000  > 5000 > 5000 
Streptomyces strain 
RS15 
2293 > 5000 1631 2000 
Streptomyces strain 
RS19 
1933 2722 > 5000 > 5000 
Streptomyces strain 
UK1 
> 5000 > 5000 174 > 5000 




To simplify data presentation, the mean values of the positive controls (chloroquine and 
artesunate), from each pLDH assay done when screening the filamentous actinobacteria, are 
displayed separately (Table 2.3). The raw data for each experiment is displayed in a 
supplementary chapter (Table 8.1, Appendix ). The controls were within the acceptable ranges 
for all screening experiments. 
Table 2.3: Mean antiplasmodial activity of the positive controls, chloroquine and 
artesunate, obtained from the filamentous actinobacteria screening experiments, N=18 
biological repeats with 4 technical repeats. 
Control Antiplasmodial activity against P. falciparum, 
NF54 IC50 (ng/mL) 
Chloroquine 5.4 ± 1.4 
Artesunate 4.1 ± 1.3 
 
To ensure solvent toxicity was not responsible for the antiplasmodial activity measured, 100% 
solutions of EtAc and MeOH were diluted in CM in the same manner as the crude extracts, i.e. 
from 2 mg/mL stock concentration to 5 µg/mL test concentration. This correlates to a final 
concentration of 0.25% (v/v) and each diluted sample was tested for antiplasmodial activity 
(section 2.2.4). No antiplasmodial activity at 0.25% (v/v) or less, was seen in the solvent blanks 
(Table 8.2, Appendix). Therefore, the activity observed is solely due to compounds present in 
the crude extracts. The controls were within the acceptable ranges. 
Initial screens revealed a relatively high number of hits, 14 of the 31 actinobacterial strains 
screened showed antiplasmodial activity with IC50s less than 5 µg/ml. Twelve of the 14 active 
strains belong to the genus Streptomyces. Despite the focus on their antibacterial and antifungal 
capabilities, there are many examples of antimalarials from Streptomyces. The anticancer 
trioxacarcin series, isolated from Streptomyces ochraceus and Streptomyces bottropensis, were 
shown to be potent antiplasmodial compounds (Maskey et al., 2004). Triacsin C and D, two 
acetyl-CoA synthetase inhibitors isolated from Streptomyces aureofaciens, were shown to be 
potent antiplasmodial agents (Yoshida et al., 1982; Ahmad et al., 2017). One of the most recent 
antimalarials described from Streptomyces was gancidin W, isolated from Streptomyces strain 
SUK10 (Zin et al., 2017). The bafilomycins, munumbicins and coronamycins also represent 
antimalarials isolated from Streptomyces species (Jensen et al., 2002; Ezra et al., 2004; Castillo 
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et al., 2006; Ahmad et al., 2017). These compounds have unique structures with different 
mechanisms of action.  
There were few hits from the rarer actinomycetes, with only A. napierensis B60T and N. 
candida HMC10T displaying antiplasmodial activity. This is not the first time antiplasmodial 
activity has been seen in Actinomadura and Nonomuraea species. For example, kijanimicin 
was isolated from Actinomadura kijaniata strain SCC 1256 and displays potent antimalarial 
activity against Plasmodium berghei in vivo (Waitz et al., 1981). The antibiotic simaomicin A, 
produced by Actinomadura madurae subsp. simaoensis, was also shown to possess antimalarial 
activity (Carter et al., 1989; Ui et al., 2007). Maduramicin, isolated from Actinomadura rubra 
strain  ATCC 27031T, was shown to be a potent antiplasmodial agent, which acts on an ion 
transport mechanism in P. falciparum gametocytes (Fleck et al., 1978; Maron et al., 2016). 
Antibiotics affecting ion transport represent a new mechanism of action for antimalarials 
(Maron et al., 2016). Nonomuraea rhodomycinica NR4-ASC07T was shown to produce two 
compounds with weak activity against P. falciparum in vitro (Supong et al., 2018).  
As a relatively small number of strains were screened, it is difficult to assess the antiplasmodial 
potential of the filamentous actinobacteria overall. The relatively high hit rate observed in this 
work does, however, suggest that they are a good source of antiplasmodial compounds and 
further screening is warranted. This is supported by the literature on actinobacterial antimalarial 
compounds. 
The second aim of the investigation was to isolate the active compounds and identify them to 
determine if they are novel antiplasmodial compounds. This is a step towards revealing if the 
actinobacteria produce antiplasmodial agents that can be developed into effective, novel 
antimalarials drugs. It was not within the scope of this investigation to isolate each active 
compound from all the active extracts. Therefore, the best candidate was selected for further 
investigation based on its antiplasmodial efficacy.  
While the crude actinobacterial broth extracts were screened at 5 µg/mL, only extracts that 
displayed IC50s of 1 µg/mL or less were considered for further study. This is, according to 
many authorities on antimalarial drug development, such as Medicines for Malaria Venture 
(MMV),  Drugs for Neglected Disease initiative (DNDi), and the Bill and Melinda Gates 
Foundation a good target value for initial antiplasmodial activity screening (Pink et al., 2005; 
Wells, 2011; Katsuno et al., 2015). The same authorities state that pure compounds need to be 
active against both drug-sensitive and resistant strains of P. falciparum at a concentration of 
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100 ng/mL or less. These efficacy targets need to be strict for a few reasons. Firstly, few 
compounds are present in patients at concentrations near 1 µg/mL for a significant amount of 
time (Wells, 2011). Therefore, to be clinically relevant, compounds must be effective at lower 
concentrations. Secondly, as the efficacy cut off value is lowered, there are fewer chances of 
random, non-specific interactions within or between cells which reduces the chance of toxic 
off-target effects (Hann et al., 2001). Generally there are a high number of in vitro hits reported 
against P. falciparum, but very few molecules can be developed further (Katsuno et al., 2015). 
Thirdly, as the drug discovery and development pipeline is an expensive and timely process, 
by setting stringent in vitro requirements more time and resources can be assigned to hit 
candidates that have a better chance of being developed further. 
Considering these guidelines, the strains that displayed sufficient antiplasmodial activity to be 
considered for further investigation were; Actinomadura napierensis strain B60T, Streptomyces 
strain CW2, Streptomyces strain CW5, Streptomyces strain RS7, Streptomyces speibonae strain 
PK-BlueT, Streptomyces strain PR3, Streptomyces strain PR10, and Streptomyces strain UK1 
(highlighted in Table 2.2).  
Under the criteria set by MMV, DNDi, and the Bill and Melinda Gates Foundation, the 
minimum selectivity index  (SI) of a compound should be 10 minimum (Pink et al., 2005).  
Before selection for further study, the most active crude extract of strain PR3 (cell mass EtAc 
fraction) was tested for cytotoxicity and haemotoxicity (sections 2.2.6 and 2.2.7 respectively) 
(Table 2.5). The crude extracts of strain PR3 displayed no cytotoxicity up to 100 µg/mL against 
the CHO or HepG2 cell line nor any haemotoxicity against human erythrocytes. The 




Due to its potent antiplasmodial activity, lack of cytotoxicity and lack of haemotoxicity, and 
ease of cultivation, strain PR3 became the focus of this study. It should be noted that strain 
PR3 was selected as the lead strain very early on in the investigation. Further screening of new 
strains for antiplasmodial activity continued in parallel to the purification of strain PR3’s active 
compounds, to better evaluate the antiplasmodial potential of the actinobacteria. Additionally, 
strains that showed the required antiplasmodial efficacy for further study were kept in reserve 
75 
 
in case any problems were encountered with strain PR3 (e.g. the strain stopped producing its 
active compounds) and for future studies. 
 
Table 2.4: Mean antiplasmodial activity, cytotoxicity, and haemotoxicity of strain PR3's 




































90.0 ± 13 
 
> 100  
 
> 100  
 



























3 Bioassay-Guided Fractionation of the Crude Culture 




Bioassay-guided fractionation principles were followed to purify and isolate the antiplasmodial 
compounds produced by Streptomyces strain PR3. The cultivation and extraction processes 
were improved to increase the yields obtained from strain PR3. A variety of techniques, such 
as solid phase extraction and high performance liquid chromatography, were employed to 
purify and isolate the active antiplasmodial compounds. High resolution mass spectrometry 
and nuclear magnetic resonance spectrometry were used to estimate the purity of the isolated 
compounds. During bioassay-guided fractionation, two contaminants, compounds 540 and 
870, were mistakenly identified as the highly active compound produced by Streptomyces 
strain PR3. During method development compound 540 disappeared for unknown reasons, 
however compound 870 presented unique proton nuclear magnetic resonance and  mass spectra 




After selecting Streptomyces strain PR3 as a candidate producer of antiplasmodial compounds, 
the next goal was the isolation and purification of its antiplasmodial compounds by bioassay-
guided fractionation. Bioassay-guided fractionation is a general concept, also known as activity 
guided/directed fractionation or bioactivity screening (Weller, 2012). It involves the separation 
of the molecules in a complex mixture and the association of a fraction or compound, with 
biological activity at each step of the purification process. Multiple separation steps are often 
required to achieve purification of the biologically active compound. Once purified, the 
compound of interest is identified and characterised. Bioassay-guided fractionation can be used 




The goal of the separation steps is to avoid the simultaneous presence of multiple different 
compounds in the biologically-active fraction (Weller, 2012). Chromatographic techniques are 
the standard methods when it comes to separating complex mixtures. In chromatography, 
molecules are separated by their affinity between two layers, a stationary phase and a mobile 
phase (Coskun, 2016). The two phases have contrasting physiochemical properties, such as 
polarity or charge. The different affinity of each compound, in the mixture, for these phases 
leads to their separation. Two different types of chromatographic techniques are used: normal 
phase, where the stationary phase is polar and the mobile phase is non-polar, and reverse phase, 
where the stationary phase is non-polar, and the mobile phase is polar. 
The most widely used method of separation is liquid chromatography (LC), where a liquid 
sample is injected into liquid mobile phases, then passed through a solid stationary phase 
column (Coskun, 2016). Examples of LC are counter current chromatography (CCC), solid 
phase extraction (SPE) and high performance liquid chromatography (HPLC). In CCC, a liquid 
phase is held in place by centrifugal force in the column and interacts with the injected sample 
and other liquid phase (Berthod et al., 2009). In SPE, samples in solution are added to a solid 
stationary phase cartridge, and the mobile phase is passed through the cartridge at set volumes 
and concentrations in individual wash steps. Comparatively, in HPLC, pumps continuously 
wash mobile phase through the stationary phase column. An HPLC method can make use of a 
gradient, where the concentration of the components of the mobile phase changes over time, or 
isocratic, where the conditions are maintained throughout the method. LC conveys several 
advantages over other techniques. First, it can be automated and run repeatedly for long periods 
of time (Weller, 2012). Second, it can be coupled to fraction collectors, autosamplers, and 
detectors. This allows real-time tracking and identification of compounds of interest. However, 
LC also presents a number of challenges. Synergistic compounds can be missed due to 
intensive separation, volatile or labile samples may be lost, and the cost of equipment and 
solvents can be substantial. 
The principle method of detection at each separation step is biological activity. However, 
biological activity does not provide structural data and often cannot be used in real time. For 
example, the pLDH assay, used to determine antiplasmodial activity, requires a minimum of 
three days to produce a result and uses a moderate amount of material. A better method of 
detection is correlating a physiochemical signal to the active fraction. This signal could be a  
mass to charge ratios (m/z), ultraviolet-visible light (UV-Vis) or infrared (IR) absorbance.  This 
signal can be used to track the putative active compound(s) while enough material is collected 
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for further separation or elucidation. Care must be taken as the signal may not be from the 
active compound, but an impurity. To avoid collecting the incorrect sample, biological activity 
must be confirmed intermittently during collection and reproducibly measured at the beginning 
of each new separation step. 
When it comes to analysing small molecules in complex systems, the best analytical instrument  
available is a mass spectrometer (Cooke, 2003). Mass spectrometers detect ions based on their 
mass to charge ratios and broadly consist of three components. The first is the ioniser where 
the sample is vaporised and ionised, the second is the mass analyser which separates the ions 
based on their m/z, and the final component is the detector which measures the intensity of each 
ion. There are many different types of mass spectrometers that can analyse different samples. 
The most common types are triple quadrupoles, quadrupole ion traps, and time of flight (TOF) 
instruments. Quadrupoles are mass analysers consisting of two pairs of electricity-conducting 
rods that stabilise ions with selected m/z’s, when specific radio frequencies and direct currents 
are applied. Triple quadrupoles are made up of three sets of quadrupoles which allows them to 
perform full ion scans, single ion monitoring (SIM), neutral loss, precursor, and tandem scans 
(Cooke, 2003). In tandem mass spectrometry (MS/MS), a fragmentation chamber and second 
mass analyser are utilised. Compounds are separated by their m/z in the first mass analyser, 
then fragmented by bombardment by inert gases, such as N2, in the fragmentation chamber. 
These molecular fragments can then be analysed in the second mass analyser, providing more 
in-depth structural information about the sample and be used to separate molecules with the 
same parent m/z. An ion trap is a series of electrodes that concentrates ions of selected m/z’s 
(Cooke, 2003). Selected ions are then released to the detector by applying specific voltages to 
destabilise their orbits. This increases the sensitivity of the instrument as ions present in small 
amounts can be accumulated. TOFs involve accelerating a set of ions through a mass analyser 
at the same energy. The time taken for each ion to reach the detector is measured and can be 
used to calculate an m/z.  For example, heavier ions take longer to reach the detector. TOF 
instruments are more selective than other systems, which allow them to identify the exact mass 
of an ion and its fragments to four or more decimal points. This allows ions to be distinguished 
from other molecules with very similar masses. This is known as high resolution mass 
spectrometry (HRMS). A quadrupole can be coupled to TOF systems to fragment ions and 
increase selectivity even further. Mass spectrometers offer advantages over other detection 
methods in terms of improved selectivity and sensitivity and can be coupled to LC systems 
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with ease (Wolfender, 2009). However, these methods are destructive, and the equipment is 
very expensive. 
A common detector option that is non-destructive and suitable for unknown samples is 
ultraviolet-visible (UV-Vis) light detectors (Wolfender, 2009). UV-Vis detectors measure the 
absorbance of UV-Vis light (10–700 nm) by chromophore structures in a sample. Different 
chromophores absorb different wavelengths, which can be used to determine the identity of the 
sample. For example, the flavonoids absorb light at 350 nm (Hasler et al ., 1992). However, 
this technique relies on the presence of chromophores in a sample and suffers from lower 
sensitivity and selectivity compared to that of mass spectrometry.  
 
There are many other detector options, such as fluorescence and IR absorbance. Due to the 
structural diversity of natural products, there is no standard detection method for all molecules, 
and a range of detectors needs to be used (Adnani, et al ., 2012). Once purified, the structure 
of the active compound needs to be elucidated so that it can be determined whether it is a 
known or novel molecule. This is achieved using HRMS and nuclear magnetic resonance 
(NMR) analysis. These techniques are discussed in more detail in Chapter 4. 
 The aims of this investigation were to: 
1. Improve the cultivation conditions and extraction protocol of Streptomyces strain PR3, 
to increase the amount of active material produced. 
2. Develop a purification method for isolating the active antiplasmodial compound(s) 
produced by Streptomyces strain PR3. This method had to be reproducible and involve 
as few steps as possible. 
 
A wide array of methods were used during this stage of the investigation. An overview of the 
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Figure 3.1: Overview of the purification method development. Red lines and arrows represent 





3.2.1 Scaled Up Bacterial Cultivation 
 
Streptomyces strain PR3 glycerol stocks (15%, v/v) were used to inoculate 15 mL of ISP-2 
liquid medium in a 250 mL Erlenmeyer flask. The culture was incubated at 30°C with shaking 
at 25 oscillations per minute for 3–4 days. The entire culture was then used to inoculate 100 
mL liquid ISP-2 medium in a 1L Erlenmeyer flask. This culture was incubated at 30°C with 
shaking at 25 oscillations per minute for 3–4 days. After this time, the entire culture was used 
to inoculate 1 L of ISP-2 liquid medium in a 5 L Erlenmeyer flask. This third culture was 
incubated at 30°C for 10 days with shaking at 25 oscillations per minute. The purity of each 
culture was assured, at each upscaling and inoculation step, by Gram staining and streaking for 
single colonies on agar plates (Bartholomew and Mittwer, 1952; Shirling and Gottlieb, 1966). 
 
3.2.2 Modified Extractions 
3.2.2.1 Extraction of Upscaled Culture 
 
The bacterial cell mass was separated from the broth (culture medium) by filtration through 
two coffee filters. Fifty millilitres of methanol (MeOH) and 200 mL of ethyl acetate (EtAc) 
were added to the filtered cell mass, and the mixture was agitated on a Labnet™ Orbit 1000 
multipurpose shaker at 120 rpm for 90 minutes at room temperature. The bacterial cell mass 
was separated from the solvent using two coffee filters, and the solvent was collected in a glass 
beaker. A second volume of 200 mL EtAc was added to the already-extracted cell mass and 
agitated on a Labnet™ Orbit 1000 multipurpose shaker at 120 rpm for a further 90 minutes at 
room temperature. The EtAc was separated from the cell mass by filtering through two coffee 
filters, the solvent was pooled with the first solvent wash (MeOH and EtAc) in the glass beaker, 
and the combined extracts were left to dry in a fume hood at room temperature. 
The broth (spent culture medium), approximately 1 L, was shaken vigorously with 250 mL of 
EtAc in a 2 L separating funnel and left for 90 minutes at room temperature to allow the phases 
to separate. The EtAc and aqueous culture broth layers were collected in separate glass beakers. 
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The culture broth was extracted with a second 250 mL volume of EtAc, placed in the 2 L 
separating funnel, shaken vigorously and the phases were allowed to separate for 90 minutes 
at room temperature. The EtAc layer and broth layers were collected in separate glass beakers. 
The two EtAc fractions (culture broth extracts) were combined and placed in a clean 2 L 
separating funnel and left overnight at room temperature to allow separation of the EtAc from 
the residual aqueous component. The final EtAc fraction was collected in a glass beaker and 
allowed to dry in a fume hood at room temperature. The broth crude extract was redissolved in 
5 mL of EtAc and transferred into clean pre-weighed plastic benchtop tubes. 
 
3.2.2.2 XAD-16N Resin Extraction 
 
Fourteen to sixteen hours before extraction of the strain PR3 culture, 50 g of XAD-16N was 
added to each 1 L culture, under nonsterile conditions. The XAD-16N resin consists of a 
styrene-divinylbenzene matrix with a mean pore size of 200 Å (Sigma, 1998). XAD-16N resin 
is non-polar and adsorbs organic materials from aqueous or polar systems. XAD-16N binds to 
molecules with small to medium molecular weights. These properties make it ideal for 
compound extraction from liquid bacterial cultures. After 14-16 hours, the culture and resin 
were filtered through coffee filters and the culture broth was discarded. Two hundred millilitres 
of MeOH was added to the filtered cell mass plus resin and agitated on a Labnet™ Orbit 1000 
shaker at 140 rpm for 60 minutes at room temperature. The MeOH was then recovered by 
filtering through two coffee filters, and the MeOH was discarded. 
Two hundred millilitres of EtAc was added to the cell mass plus resin and agitated on a Labnet™ 
Orbit 1000 shaker at 140 rpm for 90 minutes at room temperature. The EtAc was filtered from 
the cell mass and resin with two coffee filters and collected in a glass beaker. Another 200 mL 
of EtAc was added to the filtered cell mass plus resin and agitated on a Labnet™ Orbit 1000 
shaker at 140 rpm for 90 minutes at room temperature. The EtAc was recovered (as before) 
and combined with the first EtAc wash in a glass beaker. The pooled EtAc fractions were left 
in a fume hood overnight to dry at room temperature. Each crude extract was redissolved in 20 




3.2.2.3 Blank Extraction 
 
The ISP-2 and JCM #61 blank samples were created by incubating 1 L of uninoculated ISP-2 
or JCM #61 media in a 5 L Erlenmeyer flask for 10 days at 30°C with shaking at 25 oscillations 
per minute. These conditions mimic the conditions under which strain PR3 was cultured and 
extracted. Next, the medium was extracted as if it were a broth (section 3.2.1). Fifty millilitres 
of MeOH was added to mimic the cell mass extraction conditions. 
 
3.2.3  Solid Phase Extraction (SPE) 
3.2.3.1 SPE Method #1: Reverse Phase 
 
The SPE cartridges used were Phenomenex® Strata™ X-33 µm Reverse Phase C18 SPE 
cartridges (Separations, Johannesburg, South Africa) with a sorbent mass of 200 mg and a total 
volume of 3 mL. A SPEEDISK® 48 manifold was used to wash solvents and dissolved crude 
extract samples through the C18 cartridge under pressure. The C18 cartridges were equilibrated 
before use by washing 2 mL MeOH (99.9%, Honeywell, Johannesburg, South Africa) through 
each cartridge followed by 2 mL water under pressure. The crude extracts were dissolved in 2 
mL of water and passed through the equilibrated C18 cartridge under pressure. Thirty to fifty 
milligrams  of crude extract sample was used per cartridge. After the sample had been washed 
onto the column, 2 mL of solvents, of decreasing polarity, were added one after another. The 
solvents, in order of use, were water, water/MeOH (1:1), MeOH, Acetonitrile (ACN, 99.9%, 
Honeywell, South Africa) dichloromethane (DCM, 99.9%, Honeywell, Johannesburg, South 
Africa), hexane (≥ 97%, Sigma-Aldrich, Johannesburg, South Africa) and acetone (99.8%, 
Honeywell, Johannesburg, South Africa). Acetone was used last, despite not being the most 
non-polar solvent, as it cleans the cartridge, which allows for repeated uses. Each fraction was 






3.2.3.2 SPE Method #2: Reverse Phase 
 
The cartridges and equipment used are the same as described in section 3.2.3.1. Thirty to fifty 
milligrams of crude extract sample were used per cartridge. The crude extract sample was 
dissolved in 2 mL water/MeOH (1:1) then passed through the C18 cartridge under pressure. 
Solvents of decreasing polarity were used. The solvents used, in order, were water/MeOH (1:1), 
water/MeOH (2:3), water/MeOH (3:7), water/MeOH (1:4), water/MeOH (1: 9), MeOH and 
acetone. Acetone served to clean the cartridges for repeated use of the cartridges. Each C18 
cartridge was used three times before being discarded. 
 
3.2.3.3 SPE Method #3: Reverse Phase 
 
The cartridges and equipment used were the same as described in section 3.2.3.1. Thirty to fifty 
milligrams of crude extract sample were used per cartridge. The crude extract sample was 
dissolved in 2 mL water/MeOH (1:1) then passed through the C18 cartridge under pressure. 
Two millilitres water/MeOH (1:1) was passed through the cartridge and the fraction discarded. 
Next, 2 mL water/MeOH (1:4) was passed through the cartridge and the fraction discarded. 
The active compound was eluted with 2 mL MeOH, and the fraction was collected. Finally, the 
cartridge was washed with 2 mL acetone to ensure as much inactive material was removed so 
that the cartridge can be used again. Cartridges were used three times before being discarded. 
 
3.2.3.4 SPE Method #4: PHREE 
 
To remove lipids, Phenomenex® phospholipid removal (PHREE) cartridges (Separations, 
Johannesburg, South Africa) were used. A SPEEDISK® 48 manifold was used to pass solvents 
and dissolved samples, through the C18 cartridge under pressure. The MeOH fraction produced 
by SPE Method #3 (section 3.2.3.3) was dried under N2 at 37°C and redissolved in 200 µL of 
MeOH. This was added to a PHREE cartridge along with 800 µL of MeOH/1% formic acid. 
The samples were passed through the PHREE cartridges under pressure, dried under N2 at 37°C 




3.2.3.5 SPE Method #5: Normal Phase 
 
The SPE cartridges used were ISOLUTE® silica SPE cartridges (Shimadzu, Roodepoort, South 
Africa) with a sorbent mass of 200 mg and a total volume of 3 mL. SPE cartridges were 
equilibrated by passing 2 mL of MeOH followed by 2 mL of hexane. Samples were dissolved 
in 2 mL hexane/EtAc (9:1) and washed through the silica cartridges by gravity. After adding 
the sample, solvents of increasing polarity were passed through the silica cartridges. The list 
of solvents in order of use was: hexane, hexane/EtAc (2:1), hexane/EtAc (1:1), EtAc, 
EtAc/MeOH (4:1), EtAc/MeOH (2:1) and MeOH. When using silica cartridges, the sorbent 
was not allowed to dry as this alters the retention of compounds in the subsequent wash steps. 
Therefore, 2.5 mL of solvent was added in each step, and approximately 0.5 mL of each solvent 
was left behind (i.e. only 2 mL of each fraction was collected). 
 
3.2.4 Nuclear Magnetic Resonance Spectrometry 
 
Samples were submitted to two different institutes for 1H and 13C NMR analysis depending on 
availability. 
The institutes, analysts and methods were: 
Mr Kojo Acquah (Ph.D. student) with assistance from Dr Godwin Dziworn, from the 
Department of Chemistry at the University of Cape Town. Samples were dissolved in 
deuterated MeOH. A BRUKER Ascend 600 NMR spectrometer was used with a Prodigy 
cryoprobe at to obtain NMR spectra. 
Dr Jaco Brandt from the Central Analytical Facility, University of Stellenbosch, South Africa. 
The samples were dried and dissolved in deuterated acetone and transferred into a new NMR 
tube. An AgilentUnityInova 600 NMR spectrometer with a 5 mm dual-channel IDpfg probe was 





3.2.5 High Performance Liquid Chromatography - Mass Spectrometry 
3.2.5.1 HPLC-MS Method #1 
 
An AB Sciex® X500R QTOF coupled to an AB Sciex® Exion LC system was used for high 
resolution analysis. The Exion LC system consisted of a column oven, autosampler, solvent 
valve, degasser, controller, and two pumps. Spectral data was obtained using information 
dependent acquisition (IDA). Samples were scanned from 50–1200 Da. All methods, batches, 
and data were processed using OS Sciex® v1.2. The declustering potential was 80 V, the curtain 
gas (N2) was at 25 pounds per square inch (psi), the ion spray voltage was 5500 V, and the 
source temperature was 450°C. Ion source gas 1 and 2 were at 45 and 55 psi, respectively. The 
collision energy was 10 eV for the MS scans and 20-50 eV for MS/MS scans. The IDA intensity 
threshold was 50 cycles per second. An in-house HPLC method, developed in the Division of 
Clinical Pharmacology, University of Cape Town, by Ms Alicia Evans, was used for HPLC-
QTOF analysis. This method is a routine drug screening HPLC method; used to separate a wide 
range of molecules with different polarities. The aqueous mobile phase used was 1 mM 
ammonium formate in water, and the organic mobile phase was MeOH/0.5% formic acid. The 
method was a gradient method starting at 2% organic and ending at 98% organic phase, with a 
flow rate of 600 µL/min and a run time of 18 minutes. A Kinetex® Evo C18 LC column (5 µm, 
100 Å, 50 mm x 2.1 mm), with a column protector was used. All solvents were sonicated for 
10 minutes before use to remove bubbles. Nontarget regression analysis was used to analyse 
the MS, and MS/MS spectra obtained. 
 
3.2.5.2 HPLC-MS Method #2 
 
A SCIEX® API 2000 mass spectrometer coupled to an Agilent™ 1260 Infinity binary pump 
system and an Agilent™ 1100 autosampler was used for Q1 mass analysis. The declustering 
and entrance potential were set to 50 V and 10 V, respectively. The curtain gas (N2) was set at 
20 psi, the ion spray voltage was 5500 V, and the source temperature was 300°C. Ion source 
gas 1 and 2 were set to 60 and 40 psi, respectively. All methods, batches, and data were 
processed using Analyst® v1.6.2. A semi-preparative Luna® C18 column (5 µm, 100 Å, 250mm 
x 4.6 mm) with a column protector was used. Water was the aqueous mobile phase and MeOH 
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was the organic phase. A gradient at flow-rate of 1 mL/min was used (Table 3.1). All solvents 
were sonicated for 10 minutes before use to remove bubbles. 
Table 3.1: Gradient method used for HPLC-MS Method #2. 
Time (minutes) Aqueous (%) Organic (%) 
0 90 10 
7 10 90 
45 10 90 
45.1 90 10 
50 90 10 
 
3.2.5.3 HPLC-MS Method #3 
 
A modified version of HPLC Method #2 (section 3.2.5.2) was used with a change in gradient 
method. The maximum organic concentration was increased to 95% (Table 3.2). 
Table 3.2: Gradient method used for HPLC-MS Method #3. 
Time (minutes) Aqueous (%) Organic (%) 
0 95 5 
7 5 95 
45 5 95 
45.1 95 5 
50 95 5 
 
3.2.5.4 HPLC-MS Method #4 
 
A modified version of HPLC Method #2 (section 3.2.5-.2) was used. Changes were made to 
the gradient method and mobile phase composition. Water was used as the aqueous phase and 
the organic phase was 95% MeOH, and 5% water. The organic phase concentration was 
increased from 95% to 100% (Table 3.3). 
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Table 3.3: Gradient method used for HPLC Method #4. 
Time (minutes) Aqueous (%) Organic (%) 
0 90 10 
7 0 100 
45 0 100 
45.1 90 10 
50 90 10 
 
3.2.6 MZMine2 Data Processing 
 
Raw HRMS data produced by HPLC-MS Method #1 was converted to mzXML format by 
ProteoWizard tool MSconvert (version 3.0.10051, Vanderbilt University, United States) 
(Chambers et al., 2012). The converted data was then analysed using the processing software 
MZMine2 (Pluskal et al., 2010). The parameters set were based on the recommendations of 
MZMine2. After the raw data was imported the peaks were detected using the Mass Detection 
feature. For MS 1 detection, centroid data was selected, and the noise level cut-off was set to 
500. For MS2 peak detection, centroid data was also selected, and the noise level cut-off was 
set to 5. Next a chromatogram was created using the ADAP Chromatogram Builder feature 
(Myers et al., 2017). To generate chromatograms the detected mass features were selected and 
the minimum group size in number of scans was set to 5, the group intensity threshold was set 
to 250, the minimum highest intensity was set to 500 and the m/z tolerance was set to 0.1. At 
this point the m/z  signals had been detected for MS1 and MS2, and a chromatogram had been 
created using these signals. Next, isobars (atoms of different chemical elements with the same 
number of nuclei) need to be removed by deconvoluting the chromatograms. This was achieved 
by using the Chromatogram Deconvolution feature. The baseline cut-off algorithm was 
selected, and the minimum peak height was set to 1000, peak duration was set to 0.1-3.0 min 
and baseline level was 500. For the remaining settings, the m/z center calculation was set to 
median, m/z range for MS2 scan pairing was set to 0.02 and the retention time range for MS2 
scan pairing was set to 0.1 min. Lastly, isotopic peaks were grouped to remove redundancies, 
using the Isotope Peak Grouper function. The m/z tolerance was set to 0.1, the retention 




3.3 Results and Discussion 
3.3.1 Upscaled Actinobacterial Cultivation and Modified Extraction 
 
In many natural product screening projects, the amount of active material is a major limiting 
factor (Basso et al., 2005). To manage this challenge, the cultivation conditions and extraction 
methodologies for Streptomyces strain PR3 were investigated. A new cultivation method  was 
used to grow two 1 L cultures of strain PR3 (section 3.2.1). Volumes of ISP-2 larger than 1 L 
could not be used as larger Erlenmeyer flasks were not available and the shaker in the 30°C 
incubator lacked the space for larger flasks. Both cultures were extracted separately using a 
modified extraction method (section 3.2.2.1) and the broth and cell mass crude extracts 
produced were tested for antiplasmodial activity against P. falciparum, NF54 (section 2.2.4). 
The results revealed that larger crude extract masses were obtained, and the antiplasmodial 
activity of the crude extracts was maintained (Table 3.4). The assay controls, chloroquine and 
artesunate, displayed activity within the acceptable ranges. 
Both culture broth and cell mass crude extracts redissolved in MeOH were less active than the 
EtAc samples (Table 2.2). Due to this, they were discarded and instead, multiple EtAc washes 
were performed. 
Despite upscaling to a larger culture volume, the amount of material remained a limiting factor. 
As it was not possible to upscale to larger volumes, the extraction protocol was further 
developed. To improve yields, an extraction resin was added to the cultures prior to extraction. 
The resin selected was Amberlite® XAD-16N 20-60 mesh (Sigma, 1998).  
To determine if the XAD-16N resin improved extraction yields and maintained antiplasmodial 
activity, two 1 L cultures of strain PR3 were grown (section 3.2.1) and extracted with a 
modified extraction method which included XAD-16N resin (section 3.2.2.2). The crude 
extracts were tested for antiplasmodial activity against P. falciparum, NF54 (section 2.2.4). 
The antiplasmodial activity results showed that the MeOH cell mass extract was inactive, the 
EtAc cell mass extract was moderately active, and the EtAc broth extract was inactive (Table 




Table 3.4: Mean antiplasmodial activity against P. falciparum, NF54 of strain PR3 crudes 
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Table 3.5: Mean antiplasmodial activity of XAD-16N crude extracts against P. 
falciparum, NF54, N=2 biological repeats with 4 technical repeats. 
Crude Extract Antiplasmodial activity against P. falciparum, 
NF54 IC50 (ng/mL) 
Cell Mass MeOH > 2000 
Cell Mass EtAc 361.0 ± 52.0 
Broth EtAc > 2000 
Chloroquine 4.8 ± 1.9 
Artesunate 4.1 ± 0.5 
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The adsorption of the active antiplasmodial compound(s) to the XAD-16N resin was interesting 
and suggested that it is mid to non-polar. The active compound(s) had greater affinity for the 
non-polar resin than the polar culture broth and could not be washed off the resin with polar 
MeOH. This is shown by the lack of activity displayed by the MeOH cell mass and EtAc broth 
extracts (Table 3.5). 
Using the XAD-16N resin improved the amount of sample extracted and streamlined the 
extraction method. Yields were erratic as the amount of cell mass varied from culture to culture, 
but overall yields were greater than those seen without the resin and ranged from 70–90 mg 
(compare with Table 3.4). Weaker activity was seen in the crude extracts, however, this was 
likely due to the increased amount of material extracted, not a change in the biosynthesis of the 
compound(s) by strain PR3 (compare with Table 3.4). The broth EtAc extract was believed to 
be inactive due to the active antiplasmodial compound(s) adsorbing to the resin. Due to this the 
broth extract could be discarded which decreased the number of steps involved in the extraction 
process, which allowed more cultures to be extracted simultaneously. Four 1 L cultures of 
strain PR3 could be extracted at the same time, allowing the accumulation of even more crude 
extract than was previously feasible. When following the previous method without resin, both 
the broth and cell mass extracts required extracting. Therefore only two 1 L cultures could be 
effectively extracted at once, and less material was obtained per 1 L culture. 
 
3.3.2 Reverse Phase Solid Phase Extraction 
 
Initial fractionation of strain PR3’s crude extracts was achieved using reverse phase (RP) SPE. 
The goal was to develop a purification method where the active compound is retained on the 
SPE cartridge, allowing inactive polar material to be washed off using polar solvents. The 
active compound could then be eluted with mid-polar solvents leaving more non-polar 
constituents on the cartridge, allowing significant purification. Crude extract samples were 
fractionated using SPE Method #1 (section 3.2.3.1) and each sample was tested for 
antiplasmodial activity against NF54 (section 2.2.4). From the results, it is clear that the active 
compound eluted exclusively in the MeOH wash step (Table 3.6). Both controls were within 
the acceptable ranges. Further study investigated if the active compound could be eluted with 
different combinations of MeOH and water, to improve selectivity of the SPE method. 
92 
 
Table 3.6: Antiplasmodial activity against P. falciparum, NF54 of RP SPE fractions 
obtained by SPE Method #1, N=1 biological repeat and 4 technical repeats. 
SPE Wash Step Antiplasmodial activity against P. falciparum, NF54 IC50 
(ng/mL) 
Water (#1) > 5000 
Water/MeOH (1:1) (#2) > 5000 
MeOH (#3) < 125 
 ACN (#4) > 5000 
DCM (#5) > 5000 
Hexane (#6) > 5000 
Acetone (#7) 1414 
Chloroquine  5 
Artesunate  5 
 
A modified SPE protocol, SPE Method #2 (section 3.2.3.2) was developed and each fraction 
was tested for antiplasmodial activity against NF54 (section 2.2.4). Improved dissolution of all 
crude extract samples was seen when the starting solvent combination was water/MeOH (1:1). 
This is advantageous, as solid material can block the SPE cartridge and hinder separations. As 
the ACN, DCM, and hexane wash steps produced inactive fractions, they were omitted from 
SPE Method #2. The results found that that the active compound still eluted in the MeOH 
fraction as it was the most active fraction with a mean IC50 of 40.0 ± 1.5 ng/mL (Table 3.7). 
However, the MeOH fraction was not the only active fraction as the water/MeOH (1:9) step 
displayed  moderate activity with a mean IC50 878 ± 123 ng/mL. This activity suggested that 
the active compound was partially eluting in the water/MeOH (1:9) wash step. The controls in 
these assays were within the acceptable ranges. 
Taking this into account, a final RP SPE  method was generated, referred to as SPE Method #3 
(section 3.2.3.3). Two washes of water/MeOH (1:1) were used to remove polar compounds. 
The water/MeOH (1:4) step was added to further remove inactive material, without the risk of 





Table 3.7: Mean antiplasmodial activity against P. falciparum, NF54 of SPE Method #2 
fractions, N=2 biological repeats with 4 technical repeats. 
SPE Wash Step Antiplasmodial activity against P. 
falciparum, NF54 IC50 (ng/mL) 
Water/MeOH (1:1) (#1) > 2000 
Water/MeOH (2:3) (#2) > 2000 
Water/MeOH (3:7) (#3) > 2000 
Water/MeOH (1:4) (#4) > 2000 
Water/MeOH (1:9) (#5) 878 ± 123 
MeOH (#6) 40.0 ± 1.5 
Acetone (#7) 1532 ± 130 
Chloroquine 6.2 ± 1.3 
Artesunate 3.7 ± 0.8 
 
One milligram of the RP SPE MeOH fraction obtained from SPE Method #3 (section 3.2.3.3) 
was submitted for 1H NMR analysis at the University of Cape Town (section 3.2.4). The 
annotated 1H NMR  spectrum of the RP SPE MeOH fraction is shown in Figure 3.2. Briefly, 
NMR spectrometry involves disturbing the precession of isotopic nuclei such as 1H in a 
constant magnetic field using radio waves of differing frequencies (Silverstein et al., 2005). 
This alters the spin state of the nuclei which generates a signal that can be detected by an NMR 
spectrometer. The circulation of electrons around these nuclei alters their chemical 
environment, therefore different chemical groups generate different signals. Therefore, the 
NMR spectrum of a sample can provide information on the chemical groups present and their 
location in the molecule (Dayrit and Dios, 2017). In Figure 3.2, strong signals were observed 
in the δH 3.3-3.7 range and  δH  0.9-1.4 range. The signals from δH 3.3-3.7 are represent protons 
that are deshielded suggesting they are attached to or located close to heteroatoms such as 
oxygen or nitrogen (Silverstein et al., 2005). Therefore, these signals could be from protons 
attached to ether groups or be protons with neighbouring amine or hydroxyl groups. The signals 
from δH 0.9-1.4 represent shielded proton signals suggesting they are from methyl or methylene 
groups situated in a hydrocarbon chain or a 5-6 membered ring. Alternatively, they could be 
protons attached to a free amine group without any neighbouring functional groups (Silverstein 
et al., 2005). A signal at δH 4.8 was also detected, and is believed to be from water not removed 
from the sample. Unfortunately, many peaks of different intensities were detected in these 
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ranges on the spectrum making further analysis difficult. Once an 1H NMR spectrum has been 
obtained the next step would have been to integrate each peak to determine the number of 
protons present in each signal. However, due to the overlapping bases and varying signals in 
the 1H NMR spectrum, it was not possible to accurately integrate each peak or identify which 
peaks are related to the active compound(s) and which ones are not. This suggested that the 
sample contained impurities not linked to the active compound and further purification steps 
were required.  
 
Figure 3.2: 1H NMR spectrum of RP SPE MeOH sample (SPE Method #3). 
 
It was hypothesised that lipids were present in the sample due to the strong signal seen in the 
aliphatic regions of the 1H NMR spectra of the RP SPE MeOH sample (Dayrit and Dios, 2017). 
Phospholipids form the bulk of the bacterial cell membrane and were likely extracted from the 
cell mass (Sohlenkamp and Geiger, 2016). It was predicted that phospholipids could have 
eluted in the RP SPE MeOH wash and contaminated the sample. To remove these lipids, a 
Phenomenex® phospholipid removal (PHREE) cartridge was used according to SPE Method 
#4 (section 3.2.3.4) (Phenomenex, 2013). 
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Before further NMR analysis, samples were taken before and after being passed through the 
PHREE cartridge and tested for antiplasmodial activity against NF54 (section 2.2.4). The 
results show that the active compound did not retain to the PHREE SPE cartridge as 
antiplasmodial activity was unchanged (Table 3.8). The RP+PHREE SPE fraction was tested 
for in vitro cytotoxicity (section 2.2.6) and haemotoxicity (section 2.2.7). The RP SPE MeOH 
fraction displayed no cytotoxicity up to 100 µg/mL and had calculated selectivity indices (SI) 
greater than 100 (Table 3.9). This suggested the active compound(s) present are selectively 
targeting the Plasmodium parasites and further study was warranted. 
 
Table 3.8: Mean antiplasmodial activity against P. falciparum, NF54 of RP SPE MeOH 
(SPE Method #3) sample before and after PHREE separation (SPE Method #4), N=2 
biological repeats with 4 technical reports.  
Sample Antiplasmodial activity against 
P. falciparum, NF54 IC50 
(ng/mL) 
Before PHREE 40.0 ± 5.0 
After PHREE 39.7 ± 4.0 
Chloroquine 5.1 ± 2.0 
Artesunate 4.7 ± 1.0 
 
To determine if contaminants and background material had been removed, and if more 
structural data could be obtained 1H NMR spectrometry was undertaken. One and half 
milligrams of the RP+PHREE SPE MeOH sample was submitted for 1H NMR analysis at the 
University of Cape Town (section 3.2.4). The 1H NMR spectrum of the RP+PHREE SPE 
MeOH fraction is shown in Figures 3.3. The signals observed in the PHREE 1H NMR spectrum 
are very similar to the signals from the RP SPE MeOH fraction (compare Figure 3.2). Strong 
signals were observed in the δH 3.3-3.7 range and δH 0.9-1.4 range which was the same as the 
signals observed in the SPE MeOH fraction (compare Figure 3.2). The 1H NMR of the MeOH 
sample was repeated under the same conditions used to analyse the PHREE sample to allow an 
accurate comparison (section 3.2.4). The two spectra were overlaid and compared (Figure 3.4). 
Weaker signals in the 1H NMR spectrum of the PHREE sample were seen at δH 1.15, 1.3 and 
3.65. It is likely that these signals are linked to phospholipids or aliphatic compounds as that is 
what the PHREE SPE cartridges target (Phenomenex, 2013). The decrease in aliphatic signals 
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and unchanged antiplasmodial activity suggested that the PHREE SPE was able to remove 
impurities without affecting the active compound(s). However, the 1H NMR spectrum of the 
active PHREE SPE sample still contained too many overlapping and varied peaks to accurately 
integrate the signals and further purification was required to elucidate the structure of the active 
compound.  
Table 3.9: Mean antiplasmodial and cytotoxicity data of RP+PHREE SPE MeOH 
fraction against NF54, CHO, HepG2, and human erythrocytes, N=2 biological repeats 




























































Figure 3.3: 1H NMR spectrum of RP+PHREE SPE MeOH sample.
 
Figure 3.4: Comparative overlay of  RP SPE MeOH and RP PHREE SPE active 
samples.  
Protons attached to or 
surrounded by 
heteroatoms such as OH 
and NH2 groups 
 
Protons from CH3 or CH2 
groups from hydrocarbon 
or 5-6 membered rings 
Water peak 
Stronger signals in RP 
SPE MeOH fraction than 
in PHREE SPE fraction 
at δH 1.15, 1.3 and 3.65 
98 
 
3.3.3 HPLC-MS Guided Purification 
 
At this stage of the investigation, the active compound(s) was still impure and, more 
importantly, very little structural information was known. To identify the mass of the active 
compound and gain structural data, HRMS analysis, with a quadrupole time of flight (QTOF) 
instrument, was conducted using HPLC-MS Method #1 (section 3.2.5.1). 
Samples were processed by independent data acquisition (IDA) scanning. The first step in an 
IDA method is a survey scan where all ions are passed through the first mass analyser, in radio 
frequency (RF) only mode (Sciex, 2017). In RF only mode, only ions with a m/z greater than a 
set limit will pass through the mass analyser. In the case of this investigation, the set limit was 
a m/z greater than 50 Da. The ions are scanned and pass through the collision cell, with very 
low collision energy, so no fragmentation occurs. Next, the ions pass through the TOF mass 
analyser, onto the detector and each ion is assigned an accurate m/z. QTOFs generally display  
a mass error less than 10 ppm (Kind and Fiehn, 2007). Next, precursor ions are selected from 
the survey scan based on intensity and exclusion parameters and transmitted through the first 
mass analyser again. These are scanned, then fragmented in the collision cell and analysed in 
the TOF chamber before reaching the detector. This results in high-resolution MS and MS/MS 
data on ions and their fragments in complex mixtures. It also separates signals from different 
molecular ions with the same m/z. The MS, MS/MS and retention times can then be used to 
identify or aid elucidation of the compound. IDA produces very accurate MS data on almost 
all ions present; however, because such a large quantity of data is obtained, it can be difficult 
to analyse unknown compounds. To solve this issue, non-target screening analysis can be 
conducted. In this analysis, an active sample and an inactive blank sample are processed in the 
same manner by HPLC-QTOF IDA, and the MS, MS/MS data and retention times are overlaid. 
Ions seen in the active sample, but not in the blank, are potentially responsible for 
antiplasmodial activity. If the active sample is pure, then the blank can simply be the solvents 
used to dilute the active sample. In the case of this investigation, NMR had shown that the 
active RP+PHREE SPE MeOH sample still contained impurities with the active compound(s), 
so a more sophisticated blank was required. 
An ISP-2 blank was created as discussed in section 3.2.2.3. Next, the extracted blank was 
fractionated by RP+PHREE, using SPE Methods #3 and #4 (sections 3.2.3.3 and 3.2.3.4 
respectively). A sample of the blank liquid medium was streaked on an ISP-2 agar plate before 
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extraction, and no growth was observed, indicating no microbial presence in the blank. 
Theoretically, this extracted sample contains almost all the molecules from the growth medium 
and solvents used to prepare the active sample, without any bacterial cell components or 
metabolites. 
Ten microlitres of a 10 µg/mL sample of the RP+PHREE SPE MeOH active and blank sample 
were analysed using HPLC-MS Method #1 (section 3.2.5.1). Molecular ions that appeared at 
moderate to high intensities in the active sample and were not present in the blank sample were 
selected as candidate ions that could be the active compound. Candidate ions were selected in 
this fashion because the RP+PHREE SPE sample displayed potent antiplasmodial activity (see 
Table 3.9) and therefore m/z signals linked to the active compound should be present at 
relatively high concentrations. This was supported by the improvement in antiplasmodial 
efficacy of the fractionated active sample compared to the original activity of the crude extract 
(compare Table 3.5 and Table 3.9). It was possible that selected candidate compound   ions 
were not responsible for antiplasmodial activity. To overcome this, after selection all candidate 
ions were separated by HPLC and tested for antiplasmodial activity. 
Three candidate ions were selected for further purification: m/z 285.0758, m/z 301.0711 and 
m/z 540.3823 (Figures 3.5, 3.6, and 3.7, respectively). Once selected, candidate ions had to be 
isolated and tested to determine which were responsible for  antiplasmodial activity.  
 
Figure 3.5: The high-resolution mass spectrum, predicted formulae and MS/MS 





Figure 3.6: The high-resolution mass spectrum, predicted formulae and MS/MS 
spectrum of candidate compound with m/z 301. 
 
 
Figure 3.7: The high-resolution mass spectrum, predicted formula and MS/MS 
spectrum of candidate compound with m/z 540. 
 
A HPLC-MS method was developed to separate the three candidate ions. The method used was 
HPLC-MS Method #2 (section 3.2.5.2). From the SPE experiments, it was known that the 
active compound(s) adsorbed strongly to a C18 column and only eluted at close to 100% 
MeOH. Therefore, the final organic concentration reached was set to 90% MeOH which, from 
the SPE experiments, was shown to elute the active compound (see Table 3.7). The gradient 
was held at 90% MeOH for the bulk of the HPLC run to ensure the candidate ions eluted. One 
hundred microlitres of 20 mg/mL RP+PHREE SPE MeOH fractionated sample was injected. 
HPLC-MS Method #2 was unable to elute m/z 540 with m/z 285 and 301 (Figure 3.8 and 3.9). 
A MeOH blank was injected onto the column directly after the RP+PHREE SPE sample to 
determine if  m/z 540 could be washed off. If it could then the HPLC method needed to be 
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altered. One hundred microlitres of MeOH was injected and processed using HPLC-MS 
Method #2 (section 3.2.5.2) as a blank run. This blank MeOH injection was able to elute m/z 
540 (Figure 3.10). This suggested that m/z 540 required a higher MeOH concentration to elute 
in the same method as m/z 285 and 301, and the method was altered to HPLC-MS Method #3 
(section 3.2.5.3). In this method, the maximum MeOH concentration was increased to 95%. 
With the new method, m/z 540 eluted with the other candidate ions, m/z 285 and 301 (Figure 
3.10). 
One hundred microlitres of 20 mg/mL RP+PHREE SPE MeOH fractions was injected, and 
each candidate ion was collected. When one of the candidate ion peaks was detected, the waste 
line was run into a glass collection tube, and the sample was dried under N2 gas at 37°C. 
Approximately 95% of the sample was diverted to waste, which allowed larger sample 
injection volumes without risking contaminating the source of the mass spectrometer. 
Candidate ions m/z 285 and 301 eluted close together with no baseline separation, so were 












XIC of +Q1 MI (4 ions): 285.000 Da from Sample 1 (DJW#2) of 09062018SET1.wiff (Turbo Spray) Max. 1.8e6 cps.
























































Figure 3.9: Blank injection after active sample showing  m/z 540 (green) eluting 
due to incorrect chromatography conditions. 
 
Figure 3.10: Chromatogram of candidate ions (HPLC-MS Method #3). The blue peak 
represents  m/z 285, the red represents m/z 301, and the green peak represents  m/z 540. 
 
XIC of +Q1 MI (4 ions): 285.000 Da from Sample 2 (Blank) of 09062018SET1.wiff (Turbo Spray) Max. 2.2e4 cps.




































The two samples (fractions 285+301 and 540) were tested for antiplasmodial activity against 
NF54 (section 2.2.4). Not only was the fraction containing m/z 540 the only sample to display 
antiplasmodial activity, but it displayed potent activity with a mean IC50 of 27 ± 7 ng/mL (Table 
3.10). The ISP-2 blank displayed no antiplasmodial activity proving that the compounds 
responsible for the inhibition of the Plasmodium parasites was being produced by strain PR3. 
The controls were within the acceptable ranges.  
Table 3.10: Mean antiplasmodial activity of HPLC-MS purified fractions, N =2 
biological repeats with 4 technical repeats.  
Fractions Mean antiplasmodial activity against P. 
falciparum NF54 IC50 (ng/mL) 
285+301 > 2000 
540 27.0 ± 7.0 
ISP-2 Blank > 5000 
Chloroquine 6.7 ± 2.0 
Artesunate 4.2 ± 0.5 
 
This HPLC-MS purification method (section 3.2.5.3) allowed a mass ion to be associated with 
antiplasmodial activity, which greatly improved the purification process. Once antiplasmodial 
activity had been correlated to a m/z signal, it was possible to track the active compound during 
future separations without needing to carry out antiplasmodial testing each time a new culture 
was grown and fractionated. 
Fraction 540 was tested for cytotoxicity (section 2.2.6) and haemotoxicity (sections 2.2.7) and 
displayed SIs greater than 100, which suggests its activity is parasite selective (Table 3.11). 
The control emetine displayed cytotoxicity within the acceptable range. Once fraction 540 was 
shown to be active against P. falciparum and non-toxic against the CHO, HepG2 and 
erythrocytes up to 100 µg/mL, further purification was undertaken to collect more material for 
further study. A modified HPLC method, HPLC-MS Method #4 (section 3.2.5.4) was 
implemented for the purification of fraction 540. The organic phase was changed to 95% 
MeOH + 5% water, and the maximum organic concentration was set to 100%. The mixing of 
the mobile phases, water and MeOH leads to an exothermic reaction, which generates bubbles 
that can affect both chromatography and equipment over long repeated runs. As little active 
sample was recovered from each HPLC-MS run (approximately 2%), many injections and long 
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run times were required. To reduce this effect, water and MeOH were mixed as the organic 
phase and degassed by sonication before use. 
Table 3.11: Mean antiplasmodial and cytotoxicity data of fraction 540 against CHO, 


































































The purified fraction 540 was analysed by HRMS by injecting 10 µL of 10 mg/mL sample 
using HPLC Method #1 (section 3.2.5.1). The X500R’s OS Sciex software features were 
unable to provide a molecular formula or any other information about the m/z 540 signal. 
Further study was conducted by processing the raw data using MZMine2 (section 3.2.6) and 
screening the m/z 540 in the Massbank, Pubchem and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) databases (Pluskal et al., 2010). Both KEGG and Massbank matched 
exclusively to the aminoglycoside apramycin (Figure 3.11). Apramycin has a mass of 539.2802 
Da and a chemical formula of C21H41N5O11 (MassBank, 2016). This represents a close match 
to fraction 540’s observed mass of 539.3809 Da with a small mass error of 0.0907. The 
aminoglycosides are a well-known group of  antibiotics produced by the filamentous 
actinobacteria and include streptomycin, gentamicin and neomycin (Kotra et al., 2000). The 
aminoglycosides act by inhibiting protein synthesis through binding to the 16S rRNA subunit 
and causing conformation changes. This leads to codon misreading which results in the 
production of faulty protein products and ultimately kills the cell. The aminoglycosides exert 
105 
 
an antibacterial effect on a wide range of Gram positive and negative bacterial pathogens 
(Krause et al., 2016). For example, the first isolated aminoglycoside was streptomycin, which 
is still used to treat M. tuberculosis (Waksman et al., 1946). The use of the aminoglycosides 
has been limited in humans due to potent ototoxicity and nephrotoxicity as well as drug 
resistance in parts of the world (Krause et al., 2016). The aminoglycosides are structurally 
characterized by a group of amino sugars bound by glycosidic linkages to one or more dibasic 
aminocyclitols (Mingeot-Leclercq et al., 1999). Apramycin is a broad spectrum antibiotic used 
to treat a veterinary infections in livestock and was originally isolated from Streptomyces 
tenebrarius in the 1977 (Ryden and Moore, 1977). Apramycin contains a unique central 
deoxygenated bicyclic octose moiety flanked by a 5-amino pyranose sugar and a 
monosubstituted 2-deoxystreptamine (Figure 3.11) (Walton, 1978). This is not seen in most 
aminoglycoside antibiotics and allows apramycin to retain activity against aminoglycoside 
resistant bacteria and to display reduced ototoxicity in animal studies (Matt et al., 2012; Hao 
et al., 2020). Apramycin has no recorded antimalarial activity according to the current 
literature. This may be solely to a lack of study on the antiplasmodial activity of apramycin as 
other aminoglycosides have been shown to have antiplasmodial properties. Gentamicin and 
amikacin were both shown to repress the growth of the blood stage of P. falciparum in vitro 
(Krugliak et al., 1987). Their predicted mechanism of action is the inhibition of the parasite’s 
phospholipase which has been linked to the feeding mechanism of P. falciparum. It is possible 
that apramycin exerts a similar effect to gentamicin and amikacin and is the active compound 
produced by strain PR3. 
While the precursor mass of compound 540 and apramycin are a close match with a low mass 
error, the consensus MS/MS spectrum from  Massbank of apramycin (Figure 3.12) does not 
match m/z 540’s MS/MS spectrum (Figure 3.14). Figure 3.13 shows the MS/MS spectrum of 
apramycin from Massbank when analysed with a collision energy of 30 eV, which is similar to 
the collision energy used in HPLC Method #1 (MassBank, 2016). There are a number of peaks 
missing from compound 540’s MS/MS spectrum which could identify it as apramycin, such as 
the typical m/z 217 and 378 peak which represents the loss of one half of the central octose 
moiety and the 5-amino pyranose ring respectively (Kaufmann and Maden, 2005; MassBank, 
2016). The mass shifts in the major peaks of apramycin’s and 540’s MS/MS spectra are also 
different. For example the double 175 Da mass shift (see Figure 3.14) seen in 540’s spectrum 
is not seen in apramycin’s. Overall, this suggests that apramycin is not compound 540, despite 
the precursor ion match to the KEGG and Massbank databases. Analysis of compound 540’s 
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MS/MS spectrum shows a mass shift of 46 Da, 44 Da and two shifts of 175 Da. It is possible 
that the mass shift of 46 Da corresponds to a CH2O2 group which could signify the presence of 
carboxylic acids (Ma et al., 2014). Another possibility is that the 46 Da mass shift corresponds 
to a NO2 unit which could suggest that 540 contains a nitroamine. The mass shift of 44 Da is 
commonly seen as the loss of a CO2 group which could signify the presence of carboxylic acids 
or aldehydes (Ma et al., 2014). The double mass shift of 175 Da does not match any commonly 
lost structures nor do the mass fragments m/z 319.2 and 144.1. However, the repeated mass 
shift suggests that compound 540 could be a dimer or have a cyclic structure (Jia et al., 2006). 
 
Figure 3.11: Annotated molecular structure of apramycin (Chemicalize, 2019). 
 
 
Figure 3.12: : Library match results showing that m/z 540 matched to apramycin 
























Figure 3.14: Annotated MS/MS spectrum of m/z 540. Arrows indicate a mass shift between major peaks 
and are annotated with the size of the mass shift. 
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Despite the close analysis of compound 540’s MS/MS spectrum, very little structural 
information could be obtained. To obtain more structural data, large volumes of strain PR3 
were cultured (section 3.2.1), extracted (section 3.2.3) and fractionated by RP+PHREE SPE 
(sections 3.2.3.3 and 3.2.3.4 respectively) to obtain enough material for 1H NMR analysis. One 
hundred microlitres of 20 mg/mL RP+PHREE SPE MeOH fractions were repeatedly injected 
and separated until 1.1 mg of fraction 540 had been collected for 1H NMR analysis at the 
University of Cape Town (section 3.2.4). The annotated 1H NMR spectrum of fraction 540 is 
displayed in Figure 3.15. Signals from δH 0.75-1.5 represent shielded protons and were 
predicted to be from protons from methyl or methylene groups from hydrocarbon chains or 5-
6 membered rings, or from protons bound to free amine groups (Silverstein et al., 2005). 
Signals from δH 3.25-3.75 represented deshielded signals due to protons bound to or 
neighbouring heteroatoms such as oxygen or nitrogen. The signal at δH 4.75 represents water 
not removed from the sample. These signals are very similar to the previous 1H NMR spectra 
obtained from RP SPE and PHREE SPE (see Figures 3.2 and 3.3). While the 1H NMR provided 
some structural data, a precise integration of the peaks was not possible as there were too many 
signals in the spectrum. Despite predicting some structural features from both the HRMS and 
NMR analysis of fraction 540, not enough data was available to accurately elucidate that active 
compound’s structure. Therefore, further modifications and additions to the purification 




protons from CH3 
or CH2 groups 
from hydrocarbon 
chains or 6-5 
membered carbon 
rings, or protons 





hydroxyl and amine 
groups  
Figure 3.15: 1H NMR spectrum of fraction 540 
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3.3.4  Culture Medium Alteration 
 
It was hypothesised that, by altering the growth medium of strain PR3, the purity of fraction 
540 could be improved by reducing the number of molecules co-extracted with the 
antiplasmodial molecules from the culture medium. Streptomyces strain PR3 was cultured and 
extracted (sections 2.2.1 and 2.2.2 respectively) in 100 mL of four media,  DSMZ #553 
(German Culture Collection, 2007), Czapek solution agar (CZ) (Atlas, 2010), JCM #61 (Ara 
and Kudo, 2007) and HM (Hacène and Lefebvre, 1995). The crude extracts were then tested 
for antiplasmodial activity against NF54 (section 2.2.4). The results showed that strain PR3 
produced antiplasmodial active crude extracts when cultured in DSMZ #553, JCM #61 and 
HM with activity against P. falciparum, NF54 similar to that of ISP-2 extracts (Table 3.12). 
The controls were within the acceptable ranges. HM was not selected as it contains the same 
components as ISP-2, in addition to NaCl, so its use would not reduce the number of unwanted 
molecules extracted. When grown in DSMZ #553, strain PR3 grew slowly, and very little cell 
mass was produced, making it a poor choice, despite the antiplasmodial activity displayed. 
Therefore, JCM #61 was selected for further study as it has fewer complex nutrient components 
than ISP-2 and led to the production of crude extracts with matching antiplasmodial efficacy 
against P. falciparum strain NF54. ISP-2 medium is composed of yeast extract, malt extract, 
and glucose (Shirling and Gottlieb, 1966). JCM #61 is composed of starch, yeast extract, 
MgSO4, and K2HPO4 (Ara and Kudo, 2007). 
To determine if strain PR3 produced its antiplasmodial active compounds in larger JCM #61 
volumes, two cultures of strain PR3 were cultured in 1 L volumes of JCM #61 (section 3.2.1), 
extracted with XAD-16N resin (section 3.2.3) and tested for antiplasmodial activity (section 
2.2.4). The results showed that when strain PR3 was grown in JCM #61 it produced active 
extracts (Table 3.13). When the JCM #61 crude extracts were separated using RP+PHREE SPE 
(sections 3.2.3.3 and 3.2.3.4 respectively), good activity was seen, but it was weaker than the 
activity displayed by previous ISP-2 RP+PHREE SPE MeOH fractions. This was an 
unexpected and undesirable result, as it suggested that the  JCM #61 samples were less pure 
than when ISP-2 was used as the growth medium. However, the difference was not significant 
enough to discard the JCM#61 samples and further purification was carried out in the hope that 
HPLC-MS purification would isolate the compound responsible for antiplasmodial activity.  
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Table 3.12: Antiplasmodial activity of crude extracts from strain PR3 grown in 
different growth media, N=1 biological repeat with 4 technical repeats. 
Sample Antiplasmodial activity against P. 
falciparum NF54 IC50 (ng/mL) 
ISP -2 Broth Extract 150 
ISP-2 Cell Mass Extract < 125 
JCM #61 Broth Extract < 125 
JCM #61 Cell Mass Extract < 125 
CZ Broth Extract > 2000 
CZ Cell Mass Extract > 2000 
HM Broth Extract < 125 
HM Cell Mass Extract 134 





Table 3.13: Mean antiplasmodial activity against P. falciparum, NF54 of ISP-2 and JCM 
#61 crude extracts and SPE+PHREE MeOH fractions, N=2 biological repeats with 4 
technical repeats. 
Sample Antiplasmodial activity against P. 
falciparum, NF54 IC50 (ng/mL) 
ISP-2 Cell Mass XAD16-N Extraction 361 ± 50 
ISP-2 RP+PHREE SPE MeOH 40 ± 1.5 
JCM #61 Cell Mass XAD16-N Extraction 497 ± 14 
JCM #61 RP+PHREE SPE MeOH 129 ± 23 
Chloroquine 7.3 ± 1.8 






Another possibility for the change in activity was a change in antibiotic synthesis. When the 
JCM #61 RP+ PHREE SPE fractions were purified using HPLC-MS Method #4, the m/z 540 
signal was not detected. This was corroborated by HRMS analysis of the JCM #61 grown 
RP+PHREE SPE MeOH fraction. 
The change in antiplasmodial activity and disappearance of m/z 540 suggested that, under the 
new cultivation conditions, strain PR3 was producing a new antiplasmodial compound. This 
would explain why antiplasmodial activity was weaker in JCM #61 fractions compared to ISP-
2 fractions and why m/z 540 disappeared. 
As discussed in Chapter 1, antibiotic synthesis usually occurs as nutrients are depleted, and 
cells enter the stationary phase. During the log phase, utilization of simple nutrient sources are 
favoured to promote cell growth (Rafieenia, 2013). To ensure that the nutrients are not diverted 
from being used for cell growth, simple and rapidly metabolised carbon, nitrogen, and 
phosphate sources can inhibit antibiotic biosynthesis. Inhibition can occur by many different 
pathways, such as transcriptional inhibition or inhibition of enzymes required for biosynthesis 
(Sánchez et al., 2010). As these rapidly-utilized nutrients are depleted, cell growth slows, this 
inhibitory effect weakens, and secondary metabolism is activated. This explains why antibiotic 
production is often associated with slow growth rates (Sánchez et al., 2010). 
Along with the amount and nature of carbon, nitrogen, and phosphate sources present, aeration, 
pH, ion concentration, cultivation time, light, and temperature are also major factors that can 
influence secondary metabolism (Sánchez et al., 2010). When changing the growth medium of 
strain PR3, the same cultivation times, temperature, shaking speed, and light exposure were 
used (cultures were incubated in the dark). The pH of the culture medium was maintained as 
well, as the pH of ISP-2 and JCM #61 are very similar, 7.3 and 7.2, respectively (Atlas, 2010; 
Shirling and Gottlieb, 1966).  
The main change in strain PR3’s biosynthesis was possibly caused by the change in carbon 
source from glucose in ISP-2 to starch in JCM #61. Glucose is a well-known inhibitor of 
antibiotic biosynthesis and inhibits a variety of transcriptional and metabolic pathways. For 
example, glucose inhibits actinorhodin produced by Streptomyces lividans, by inhibiting 
mRNA synthesis required for its biosynthesis (Kim et al., 2001). When the carbon source for 
S. lividans was changed to glycerol, this effect was not observed. Using polysaccharides, such 
as starch, is more suitable for antibiotic production as it is utilized at a slower rate (Rafieenia, 
2013). While starch is hydrolysed to glucose, the free glucose concentration is much lower, 
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therefore, it applies a weaker inhibitory effect. High phosphate concentrations promote growth, 
as phosphate is an essential component in RNA, DNA, and protein biosynthesis. Many 
antibiotics are only synthesised when phosphate becomes a limiting factor (Rafieenia, 2013). 
It is difficult to predict the effect of the change in phosphate sources between the two media as 
the concentration of phosphate in ISP-2 is unknown. The yeast extract concentration was 
identical in the two media; therefore it would not have influenced antibiotic production. Yeast 
extract acts as an excellent nitrogen source for antibiotic production, as due to its complex 
nature, it is utilized at a slow rate (Rafieenia, 2013).  
It is impossible to accurately state how the changes in the cultivation medium altered the 
antiplasmodial biosynthesis by strain PR3 with the data at hand. To begin to understand this 
change, the focus of the investigation shifted, with the aim to isolate the active compound in 
fraction 540 and the JCM #61 RP+PHREE SPE MeOH samples. Once their structures had been 
elucidated, they could be compared to determine if they were related or not. To achieve this, 
strain PR3 was cultivated in both ISP-2 and JCM #61 liquid media. 
When strain PR3 was cultured and extracted in ISP-2 (sections 3.2.1 and 3.2.3 respectively), 
the RP+PHREE SPE MeOH samples showed antiplasmodial activity comparable activity to 
extracts with m/z 540 (data not shown), but the m/z 540 itself was not be detected. This occurred 
despite culturing strain PR3 cultures under the same conditions with 15% (v/v) glycerol frozen 
stocks of cultures which had produced active extracts that contained the m/z 540 signal in the 
past. During cultivation, conditions that produced active crude extracts were strictly adhered 
to, as the fastidious nature of the actinomycetes is well-known. This suggested that m/z 540 
was never produced by strain PR3 or that strain PR3 had lost the ability to produce it. It was 
theorized that m/z 540 was a contaminant however comparison to other common MS 
contaminants such as plasticizers and media revealed no matches (Fisher Chemicals, 2020). 
Overall, the loss of the m/z 540  signal remains unexplained, fortunately activity was not lost 
in any fractions from ISP-2 or JCM #61 cultures of strain PR3 and therefore the loss of m/z 
540 did not impede the investigation. Additionally, the study of m/z 540 led to the development 






3.3.5 High-Resolution Mass Spectrometry Analysis of JCM #61 
Samples 
 
With the loss of the primary candidate, more in-depth mass spectrometry analysis was required 
to identify the correct active compound. JCM #61 samples were selected for analysis instead 
of ISP-2 grown samples, because of the reduced background. 
A JCM #61 blank was generated (section 3.2.2.3) and fractionated by RP+PHREE SPE 
(sections 3.2.3.3 and 3.2.3.4 respectively). Ten microlitres of a 10 µg/mL sample of the 
RP+PHREE SPE MeOH active and blank sample were analysed using HPLC-MS Method #1 
(section 3.2.5.1). The best candidate ion that was present at a high intensity in the active sample 
(and absent from the blank) was an ion with m/z of 888.6620. This was shown to be an 
ammonium adduct (M+NH4
+) with an observed mass of 870.6271 Da. The source of the 
ammonium ions is believed to the aqueous phase, ammonium formate in water. Note, that the 
HPLC-MS purified sample will be referred to as fraction 870 and the m/z signal used to monitor 
fraction 870 was m/z 888. The MS and MS/MS data of m/z 888 did not match any known 
compounds after processing by MZMine 2 and screening in the KEGG, Massbank and 
Pubchem databases (Pluskal et al., 2010). Another reason for selecting fraction 870 as the new 
lead candidate was that m/z 888 was found in the HPLC-MS purified 540 fraction, but had been 
overlooked because it appeared at a lower intensity than m/z 540. This correlated 
antiplasmodial activity with the presence of m/z in multiple active samples from different 
sources. Analysis of the MS/MS spectrum of m/z 888 (Figure 3.16) revealed a repeating mass 
shift of 58 units. m/z 888’s true mass is 870.6274  Da, which is wholly divisible by 58 to give 
15. This suggests that m/z 888 is a polymer with 15 subunits, however the structure of the 
monomer was unknown. To obtain more structural information about the monomer fraction 




Figure 3.16: MS/MS spectrum of fraction 870. Black arrows represent repeated mass shifts 
of 58 Da. 
 
JCM #61 crude extracts were separated by RP+PHREE SPE (sections 3.2.3.3 and 3.2.3.4), 100 
µL of 20 mg/mL was injected and analysed using HPLC-Method #4 (section 3.2.5.4). Fraction 
870 was collected and tested for antiplasmodial activity (section 2.2.4). Fraction 870 displayed 
good antiplasmodial activity with a mean IC50 128 ± 12 ng/mL (Table 3.14). The JCM #61 
blank was also tested and displayed no antiplasmodial activity confirming that the active 
compound in the extracts are natural products produced by strain PR3. Fraction 870 was tested 
for cytotoxicity and haemotoxicity (sections 2.2.6 and 2.2.7 respectively) and displayed no 
toxicity up to 100 µg/mL, which strongly suggested it was selectively targeting the P. 
falciparum parasites (Table 3.15). The antiplasmodial and cytotoxicity controls were within 




Table 3.14: Mean antiplasmodial data of fraction 870 and JCM #61 blank, N=2 
biological repeats with 4 technical repeats. 
Sample Antiplasmodial activity P. falciparum, 
NF54 IC50 (ng/mL) 
Fraction 870 128.0 ± 12 
JCM #61 Blank > 5000 
Chloroquine 10.1  ± 2.0 
Artesunate 4.2 ± 0.3 
 
Dozens of 1 L cultures of strain PR3 were cultured in JCM #61 and extracted (sections 3.2.1 
and 3.2.3). The crude extracts were separated by RP+PHREE SPE (sections 3.2.3.3 and 3.2.3.4 
respectively) and the MeOH fraction was separated by HPLC-MS Method #4 (section 3.2.5.4). 
This was done continuously until 1.8 mg of fraction 870 had been collected for NMR analysis. 
Fraction 870 was submitted for 1H NMR analysis at University of Stellenbosch (section 3.2.4). 
The annotated 1H NMR spectrum of fraction 870 is displayed in Figure 3.17. Much like the 1H 
NMR spectra of the previous active fractions (see Figures 3.2, 3.3 and 3.15) strong signals were 
detected from δH 0.75-1.5 and δH 3.25-3.75. These could represent protons from methyl or 
methylene groups from hydrocarbon chains or 5-6 membered rings and protons attached to or 
surrounded by heteroatoms such as OH and NH2 groups respectively (Silverstein et al., 2005). 
However, additional signals were detected in this NMR analysis not seen in the previous 
spectra. Signals from δH 1.8-2.3 were detected at a greater intensity in fraction 870 than in 
previous samples and could be protons from methyl or methylene groups bound to alkenes or 
aldehydes. Signals were detected at δH 4.0-4.15 and could be from protons attached to methine 
or methylene groups conjugated or in close proximity to other functional groups (Silverstein et 
al., 2005). The signals at δH 6.89, 7.15 and 7.45 could be from protons attached to nitrogens in 
amide bonds. This suggests that a peptide could be present in the sample. However, the signals 
are extremely weak and may be from an impurity. Despite this improvement in the 1H NMR 
spectrum of the active sample, the spectrum peaks could still not be integrated or correlated 
accurately. Therefore, no structural information could be garnered to aid the identification of 







Table 3.15: Mean antiplasmodial and cytotoxicity data of fraction 870 against P. 
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3.3.6 Normal Phase Solid Phase Extraction 
 
After the use of several reverse phase SPE and HPLC methods, normal phase SPE was utilized 
to fractionate the active samples. While the HPLC-MS technique was very useful at assigning 
a m/z to the antiplasmodial compound, the yield of material was very low. For both fraction 
540 and 870, dozens of HPLC injections of 20 mg/mL RP SPE MeOH samples were required 
to obtain just over a milligram of active sample. To reduce the time required to purify fraction 
870, normal phase (NP) SPE was used after RP SPE. PHREE separation was not used as NP 
was predicted to be capable of separating lipids and non-polar molecules from fraction 870. 
The active MeOH fraction generated by SPE Method #3 (section 3.2.3.3) was separated by NP 
SPE using SPE Method #5 (section 3.2.3.5). 
Each fraction was collected, dried under N2, and made to 10 µg/mL in MeOH and 10 µL of 
each NP SPE was injected and scanned by IDA using HPLC-MS Method #1 (section 3.2.5.1). 
The results were analysed by nontarget regression analysis with the JCM #61 blank. The only 
fraction that contained m/z 888 was NP SPE EtAc fraction (#4).  
Each NP SPE fraction was tested for antiplasmodial activity against P. falciparum, NF54 
(section 2.2.4) to confirm that the activity of the pure compound 870 sample matched the 
HPLC-MS acquired fraction 870. A small sample of the RP SPE MeOH fraction was not 
purified and kept for antiplasmodial testing, to verify that the previous fractions were active. 
The activity of compound 870, found in the EtAc fraction (#4) and highlighted in red, did not 
match the activity of the HPLC-MS fraction 870 sample (Table 3.16). Fraction 870 displayed 
good antiplasmodial activity with a mean IC50 128 ± 12 ng/mL, while the pure compound 870 
displayed much weaker activity with a mean IC50 of 1873 ± 308 ng/mL. The controls were 
within the acceptable ranges. This suggested that compound 870 was not the main active 
antiplasmodial compound produced by strain PR3. 
However, as compound 870 displayed novel MS and MS/MS spectra further study was 
undertaken. Ten 1 L cultures of strain PR3 were grown in JCM #61 and extracted (sections 
3.2.1 and 3.2.3 respectively). These crude extracts were then separated by RP+NP SPE 
(sections 3.2.3.3 and 3.2.3.5 respectively). A total of 1.6 mg of fraction 870 was obtained and 
submitted for 1H NMR analysis at the University of Cape Town (section 3.2.4). The 1H NMR 
spectrum of fraction 870 (Figure 3.18) revealed that the sample was pure enough to attempt 
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structural elucidation. This can be seen by the low number of overlapping base signals and 
similar signal intensities (Silverstein et al., 2005). 
As this is now a relatively pure sample it will henceforth be referred to as compound 870. 
Compound 870 was then submitted for more advanced 2D NMR spectrometry and the 
structural elucidation of compound 870 is discussed in detail in Chapter 4.  
Table 3.16: Mean antiplasmodial activity of the crude MeOH RP fraction, NP SPE 
fractions and compound 870, N=2 biological repeats with 4 technical repeats. Fraction 
containing compound 870 is highlighted in red.  
NP SPE Fraction Antiplasmodial activity against P. 
falciparum NF54 IC50 (ng/mL) 
Fraction 870 128 ± 12 
RP SPE MeOH 152 ± 13 
Hexane (#1) > 5000 
Hexane/EtAc (2:1) (#2) 117 ± 7.0 
Hexane/EtAc (1:1) (#3) 686 ± 61 
Compound 870/EtAc (#4) 1873 ± 308 
EtAc/MeOH (4:1) (#5) > 5000 
EtAc/MeOH (2:1) (#6) > 5000 
MeOH (#7) > 5000 
Chloroquine 6 ± 2.1 









In summary, many methods were developed in an attempt to purify the antiplasmodial 
compounds produced by Streptomyces strain PR3. The final purification method for compound 
870 met the requirements set at the beginning of this chapter in that it uses two different SPE 
methods, which are quick, reproducible and can produce a pure sample. However, 
antiplasmodial tests revealed that compound 870 is not the major antiplasmodial compound 
produced by strain PR3.  
The next objectives of the investigation were the structural elucidation of compound 870 and 
the identification of the main active compounds produced by strain PR3. Because the 1H NMR 
and high-resolution mass spectra of compound 870 did not match that of any known 
compounds, it was studied further. Once the compound responsible for antiplasmodial activity 
in the JCM #61 fractions had been identified, the ISP-2 fractions could be analysed to determine 
if the same antiplasmodial compound(s) was present. The elucidation and identification of 
compound 870 is discussed in detail in Chapter 4. The identification of the main antiplasmodial 
active compound(s) produced by strain PR3 is discussed in Chapter 5. 
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During bioassay-guided fractionation studies, compound 870 was associated with 
antiplasmodial activity and subsequently purified. Upon purification, it was discovered that 
compound 870 displayed weak antiplasmodial activity and was not responsible for the potent 
antiplasmodial activity exhibited by Streptomyces strain PR3. However, compound 870 
displayed unique HRMS and 1H NMR spectra, which did not match any known compounds. 
Due to this, it was studied further and discovered to be a new class of crown ether derivatives, 
here named methylated crown ethers (MCE). These MCEs were found to be derivatives of 
polypropylene glycol (PPG) found in the XAD-16N extraction resin and not natural products. 
The MCEs were shown to form by the cyclization of PPG oligomers, possibly by nucleophilic 
substitution in the presence of proton donators. The MCEs displayed weak antiplasmodial 
activity and exhibited no cytotoxicity against the Chinese Hamster Ovary, HepG2 cell lines or 
human erythrocytes, unlike crown ethers and PPG. This is the first time these structures have 




After the isolation of compound 870, the next step was its structural identification and 
elucidation. Structural identification is the process where the spectra of a compound under 
investigation are compared to that of known compounds (Elyashberg, 2015). If these spectra 
do not match any known compounds, then the compound is considered novel, and the next step 
is structural elucidation. The term structural elucidation refers to a full de novo characterization 
of the structure resulting in a complete molecular connection table with correct stereochemical 
assignments (Kind and Fiehn, 2010). 
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The optimum approach to structural identification and elucidation is through the use of a set of 
independent techniques to obtain stereochemical information. The two best techniques in this 
regard are NMR and HRMS. 
Many atomic nuclei rotate about their own axis in a process known as spin (Dayrit and Dios, 
2017). The spin of charged nuclei generates a magnetic field and creates their own magnetic 
moment. At a molecular scale, each atom spins in a random direction, and their magnetic fields 
generally cancel each other out (Bruker, 2019). However, the magnetic moments of these 
nuclei allow them to be aligned when exposed to a strong magnetic field. In NMR 
spectroscopy, a sample is exposed to a strong magnetic field forcing the nuclear magnetic 
moments to align parallel to this field. These nuclear magnetic moments are extremely weak 
and therefore do not interfere with the orientation and movement of atoms in a molecule; thus, 
NMR spectroscopy does not alter the molecule’s structure. This is one of the benefits of using 
NMR in structural elucidation. While exposed to this magnetic field, the sample is irradiated 
with a short burst of radio waves containing well-defined resonance frequencies, a process 
known as Fourier transform. Specific resonance frequencies deflect different nuclear magnetic 
moments, which starts a rotational movement known as precession. These frequencies can be 
detected by an NMR spectrometer and are known as the chemical shift. The local circulation 
of electrons around a nucleus can shield it from the external magnetic field which alters the 
precession frequency of nuclei depending on the electrons around them (Silverstein et al., 
2005). Therefore, nuclei in different chemical groups or with different neighbouring atoms will 
have different electron circulation and will generate unique, characteristic chemical shifts. This 
allows functional groups to be detected and correlated to elucidate structures (Silverstein et al., 
2005). Shielded nuclei signals will be observed at lower precession frequencies (to the right of 
the NMR spectrum) and deshielded are observed at a higher precession frequency (to the left 
of the NMR spectrum) (Wehrli and Wirthlin, 1976).  
There are different types of NMR analyses that can be conducted, each providing different 
kinds of information. The standard NMR approaches are 1H and 13C NMR spectroscopy, also 
known as one dimensional NMR (1D-NMR). Hydrogen is present in almost all organic 
molecules in its major isotopic form (1H) (Dayrit and Dios, 2017). 1H has an abundance of 98.9 
% and displays a unique resonance frequency depending on its location in the molecule and 
couplings to other atoms in the same molecule. The term couplings refers to the interaction 
between magnetic nuclei. The chemical shifts generated by these unique 1H atoms can be used 
to provide an immense amount of structural data. 12C lacks nuclear spin and cannot be measured 
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by NMR spectroscopy, therefore, the 13C isotope is analysed. 13C is only present in an 
abundance of 1.1% and thus generates weaker signals than 1H. This means greater amounts of 
sample and longer processing times are required for 13C NMR than 1H NMR spectroscopy. 
However, as 13C atoms can be surrounded by more than one pair of electrons, they generate a 
wider range of unique chemical shifts. Therefore, 13C NMR spectroscopy provides more 
accurate structural data than 1H NMR. 1D-NMR provides very useful data about molecular 
structures, which makes it a very effective tool in the study of natural products. In Chapter 3, 
1H NMR spectroscopy was used to estimate the purity of purified fractions. However, even 
when the sample is pure 1D-NMR can still produce spectra with overlapping signals. To 
elucidate structures, 2D-NMR techniques are required. 
2D-NMR spectroscopy provides information plotted on two frequency axes instead of one 
(Elyashberg, 2015). This allows overlapping signals to be separated. There are many forms of 
2D-NMR spectroscopies, but the ones used in this investigation were heteronuclear single 
quantum coherence (HSQC), correlation spectroscopy (COSY) and heteronuclear multiple-
bond coherence (HMBC) (Berger and Braun, 2004). HSQC displays direct heteronuclear 
correlations  between 13C and protons (Berger and Braun, 2004). COSY analysis provides 
information about homonuclear correlations between vicinal hydrogens separated by three 
bonds. This allows the identification of neighbouring carbon atoms separated by a chemical 
bond. HMBC analysis reveals heteronuclear correlations between 1H and 13C separated by two 
or three chemical bonds. These techniques allow each signal from 1H and 13C NMR to be 
correlated to one another and allows the determination of the two dimensional structure of the 
molecule. 
NMR has a number of advantages over other techniques, such as its non-destructive nature, 
simpler sample preparation requirements, and ability to analyse any sample as long as it 
contains hydrogen and carbon atoms (Dayrit and Dios, 2017). However, the equipment 
required is expensive, the analysis is complicated, milligrams of material are required, 
processing times can be lengthy, and it can suffer from limited sensitivity. Due to these 
limitations, HRMS needs to be used in combination with NMR to accurately elucidate 
molecular structures. As discussed in Chapter 3, HRMS is extremely sensitive, can analyse 
samples at intensities in parts per million, provides data about parent and fragment ions, and 
predicts molecular formulae.  
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In this chapter, the structural elucidation of compound 870 is discussed. The aims of the chapter 
were to: 
1. Elucidate the structure of compound 870 by NMR and HRMS analysis. 
2. Determine if compound 870 is a known or novel compound. 
3. Evaluate the antiplasmodial efficacy, cytotoxicity and haemotoxicity of compound 870. 
 
4.2 Methodology  
4.2.1 High Performance Liquid Chromatography-Mass Spectrometry 
4.2.1.1 Method #5 
A modified version of HPLC-MS Method #1 (section 3.2.5.1) was used to obtain accurate 
MS/MS data. The only variation in the method was the increase in collision energy (CE) to 55-
85 eV. 
4.3 Results and Discussion 
4.3.1 Structural Elucidation of [150]crown-15 
 
By the end of the investigations described in Chapter 3, a set of methods had been developed, 
which allowed purification of compound 870. Analysis of the purified sample by 1H NMR 
spectroscopy (section 3.2.4) confirmed that the sample was pure enough to elucidate the 
structure of compound 870. At this stage, the 1H NMR and MS and MS/MS spectra of 
compound 870 did not match those of any known compound in the ChemSpider, Mass Bank, 
or SciFinder databases. The final structure was elucidated by 1D and 2D NMR (section 3.2.4) 
and HRMS. HRMS analysis was conducted using HPLC-MS Method #1 and HPLC-MS 
Method #5 (sections 3.2.5.1 and 4.2.1 respectively). HPLC-MS Method #5 used a higher 
collision energy to obtain more structural data. 
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Compound 870 was isolated as a brown amorphous solid with an observed mass of  870.6271 
Da based on HRMS analysis. As discussed previously, analysis of compound 870’s MS/MS 
spectrum (Figures 3.16 and 4.1) revealed a repeating pattern of 58 Da which suggested it was 
a polymer. Analysis of the MS/MS spectrum of compound 870 at a higher collision energy 
(section 4.2.1) revealed repeating mass shift of 58 Da adding further evidence that compound 
870 was a polymer (Figure 4.2). 
 
Figure 4.1: MS/MS spectrum of [150]crown-15 obtained by HPLC-MS Method #1 










Figure 4.2: MS/MS spectrum of [150]crown-15 obtained by HPLC-MS Method #5 
(higher collision energy). Black arrows represent neutral loss pattern of 58 Da. 
However, no other information about the monomer could be obtained from the mass spectra. 
To identify the monomer and other possible groups that constitute compound 870, 1H, 13C, 
HSQC, COSY and HMBC NMR analysis were undertaken at the University of Cape Town 
(section 3.2.4). The major signals detected from the 1H NMR spectrum of compound 870 
(Figures 3.16 and 4.3) were δH 0.70, 1.16 and 1.30, 3.48, 3.55 and 3.63. The signals at δH 0.70 
and 1.16 represent shielded signals as they are lower on the NMR spectrum and were predicted 
to be from protons in free methyl groups (Silverstein et al., 2005). The signal at δH 1.30 was 
predicted to correspond to a methylene group (Silverstein et al., 2005). The signals at δH 3.48, 
3.55 and 3.63 were predicted to be signals corresponding to methylene and methine groups 
attached to either of the heteroatoms, oxygen or nitrogen. The 13C NMR spectrum (Figure 4.4) 
revealed three main signals, one at δC 16.22 which represents a shielded carbon signal and 
corresponds to a carbon in a methyl group (Silverstein et al., 2005).  Another signal was present 
at δC  29.00 which was predicted to correspond to the carbon in a free methylene group (Wehrli 
and Wirthlin, 1976). Two signals were detected at δC 72.87 and 75.3 which were believed to 
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correspond to the carbons in a methylene and methine group respectively. These chemical 
shifts represent deshielded signals and suggest that the methylene and methine groups are 
attached to a heteroatom, in this case the specific chemical shifts suggest an oxygen group 
(Silverstein et al., 2005, Wehrli and Wirthlin, 1976). The HSQC spectrum correlated the three 
signals at δC  16.22, 72.87 and 75.3 from the 
13C NMR spectrum to the signals at δH 3.48, 3.55, 
3.63 and 1.16 from the 1H NMR spectrum (Figure 4.5). The HSQC spectrum also correlated 
both methylene signals at δH 3.48 and 3.55 to one carbon which suggested that they are two 
diastereotopic protons attached to a chiral carbon. The HSQC revealed that the signal at δC 
29.00 is an impurity as it was not linked to any other signals. The 1H-COSY spectrum shows 
that the methine group is linked to the methylene and methyl group and that the two methylene 
signals at δH 3.48 and 3.55 are linked together (Figure 4.6). This corroborates the results 
obtained from the HSQC spectrum. The HMBC provides further support for these correlations 
and links the methyl group to the methine and the methylene signals to the methine group 
(Figure 4.7). The other signals detected in the 1H and 13C NMR spectra are therefore impurities 
as they did not correlate to any other signals in the 1H-COSY, HSQC or HMBC. From the 
NMR spectra it was deduced that a methyl, a methylene and a methine group were present and 
linked together. From the 13C NMR spectrum (Figure 4.4) it was hypothesised that the 
methylene and methine were attached to an oxygen group. This generates a molecular formula 
of C3H6O which has a theoretical mass of 58.041 Da. This matched perfectly to the predicted 
monomer seen in HRMS. The signals from the 1H and 13C NMR spectra (Figure 4.3 and 4.4) 
were not properly resolved which suggested that the signals were generated by the same groups  
in different parts of the molecule. This suggests that these groups are repeated many times in 
the compound 870 which supported the hypothesis that compound 870 is a polymer. Analysis 
of the groups suggested that the monomer that constitutes compound 870 is an ether as the 
methylene and methine groups are bound to an oxygen, but no other groups were detected. The 
proposed ether monomer’s structure is displayed in Figure 4.8 with corresponding 1H-COSY 
and HMBC signals and has been annotated onto the 1H, 13C, 1H-COSY, HSQC and HMBC 
NMR spectra (Figures 4.3-4.7). The NMR results for the ether monomer are summarized in 
Table 4.1. It was previously predicted that compound 870 was comprised of 15 58 Da subunits 
as its mass is equal to 15 multiplied by 58. This implies that compound 870 is cyclic, only 
comprised of repeating subunits as no capping or tail end groups were detected by HRMS and 
NMR. Therefore, the final proposed structure of compound 870 is a cyclic polyether comprised 





Figure 4.3: 1H NMR spectrum of compound 870 annotated with protons linked to ether 
monomer and impurities. The structure of the ether monomer is presented with each group 
numbered. 
The proposed structure of compound 870 is displayed in Figure 4.8 Compound 870 resembles 
a crown ether and, therefore, was named following crown ether convention. Crown ethers are 
named as [m]crown-n, where m represents the total number of atoms and n represents the 
number of oxygens present in the macrocycle (Liu et al., 2017). Henceforth, compound 870 
will be referred to as [150]crown-15. [150]crown-15 has a chemical formula of C45H90O15 with 


















Figure 4.5: 13C NMR spectrum of compound 870 annotated with carbon signals from 









 group linking doublet proton signals to a single 
carbon (2). 
CH proton signal linked to CH carbon (1). 
CH
3
 proton signal linked to CH
3
 carbon (3). 
Figure 4.4: HSQC NMR spectrum of compound 870 annotated with proton carbon signal correlations. 




Figure 4.6: 1H COSY spectrum of compound 870 annotated with each correlation. The 
structure of the ether monomer is presented with each group numbered. 
 
Figure 4.7: HMBC spectrum of compound 870 annotated with signal correlations. 
 
Signal links 1 to 3
 
 
Signal links 3 to 1 
Signal correlates 2 to 1 and both   
diastereotopic protons to each other. 
Correlates 3 
to 2 and 1 
Correlates 1 to 2 
Correlates 2 to 1 




Correlates 3 to 1 
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Table 4.1: Selected 13C, 1H, COSY and HMBC data for [150]crown-15. 
Position 13C 1H mult 13C-1H COSY 13C-1H HMBC 
1 75.3, CH 3.63 m 2,3 2,3 
2 72.87,CH2 3.55 
3.48 m 
1 1,3 
3 16.22, CH3 1.16 m 2 1,2 
 
 
Figure 4.8: Structure and COSY (▬) and HMBC (→) correlations for C3H6O 
monomer. This image was provided by K. Acquah. 
 
 
Figure 4.9: Predicted structure of [150]crown-15. The ether monomer is highlighted by the 







4.3.2 Characterization of the Methylated Crown Ethers 
 
Crown ethers are synthetic macrocyclic oligomers of ethylene oxide with the formula (-
CH2CH2O-)n  where n is 4 or greater (Liu et al., 2017). They are named crown ethers, as they 
look like a crown on the head of a monarch. Crown ethers can bind alkaline earth and transition 
metal cations, such as Na+ and K+ (Pedersen, 1967). Stable complexes are formed with the 
cation in the centre of the ether ring by ion-dipole interactions between the ion and oxygen 
atoms (Hayvali et al., 2014) (Figure 4.10).  
Changes in the ring size and adding functional groups to the core crown ether motif change the 
cation affinity (Gokel et al., 2004). For example, [18]crown-6 has a high affinity for K+ ions, 
while [15]crown-5 has a higher affinity for Na+ ions. Crown ethers are neutral ionophores, 
which means they lack their own ionisable groups, but can bind cations and transport them 
through hydrophobic environments such as lipid membranes. This has led to many applications 
in chemistry, as the discovery of crown ethers triggered massive development in the synthesis 
and development of macrocycles. This development led to an improved understanding of 
molecular recognition, binding, and mechanics. Crown ethers also have a biological effect and 
display a range of antibiotic properties, such as antibacterial, antifungal, antiviral, and 
anticancer activity (Ziedan et al., 2010; Flipo et al., 2011; Hayvali et al., 2014). 
Transport of molecules and ions across cell membranes is an important function of cellular 
physiology (Campbell et al., 2008). It is essential in maintaining homeostasis by bringing in 
nutrients, transporting wastes, and maintaining electrochemical gradients. In a cell, a delicate 
balance of ions on each side of the lipid membrane produces a voltage across the membrane 
known as the membrane potential. The membrane potential drives the transport of ions in and 
out of the cell. The voltage of the membrane potential ranges from -50 to -200 mV, therefore 
the cytosol of a cell is negatively charged compared to the exterior of the cell. This membrane 
potential favours the transport of cations into the cell and anions out of the cell.  
Ions also move down a chemical concentration gradient typically from the exterior to the 
interior of the cell. These two forces create an electrochemical gradient, which is essential for 
cell survival. If there is a pH difference between the interior and exterior of the cell, it produces 
another driving force across the cell membrane known as the proton motive force (Fong, 2016).  
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Crown ethers and other neutral ionophores bind cations and facilitate their passive diffusion 
down the electrochemical gradient. The increased transport of cations into the cell decreases 
the membrane potential across the cell membrane. This collapses the electrochemical gradient, 
which alters ion transport and has downstream cytotoxic consequences. This is why the crown 
ethers display activity against such a wide range of microorganisms and cells. 
 
Figure 4.10: [18]Crown-6 ether forming a stable complex with a K+ ion in the centre of 
the ring (OChemPal). 
After searching literature and multiple databases (SciFinder, Pubchem, Chemspider, KEGG 
and Massbank), one match was found reporting the same formula and mass spectra as those of 
[150]crown-15 (Rindelaub et al. 2019). 
In an investigation of the extractable profiles of 3D printed medical implants, plastic oligomers 
were isolated that had the same formula and mass spectra as [150]crown-15 (Rindelaub et al., 
2019). In this investigation, medical implants were exposed to three different solvents: water, 
isopropyl alcohol, or hexane, while shaking at 50°C for 72 hours. The extracts were then 
analysed by LC-HRMS and GC-MS. The MS and MS/MS results of the isopropyl alcohol 
samples matched those of [150]crown-15. This sample was reported to contain polypropylene 
glycol (PPG) oligomers, which leached out of the implants. PPG is comprised of the same 58 
Da subunit as [150]crown-15, with a hydroxyl group at each end of the chain. PPG has a variety 
of applications in many fields. It is used as a plasticizer, lubricant, and intermediate in the 
synthesis of polyurethane (Oudhoff et al., 2003). PPG is copolymerized with polyethylene 
glycol (PEG) to create a stronger composite plastic used to manufacture many plastic products. 
In addition, PPG has uses outside the manufacturing of plastics. For example, PPG-PEG has 
been used as a vessel in drug delivery and been shown to improve drug solubility in vivo (Yapar 
and Ýnal, 2013).  
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To confirm if [150]crown-15 was an oligomer of PPG, the next step was to determine if 
Streptomyces strain PR3 was producing [150]crown-15 or if it was being isolated from 
background components. To achieve this, a new blank of JCM #61 medium was created. The 
previous JCM #61 blank (section 3.3.5) did not contain [150]crown-15 and was not active 
against P. falciparum, NF54 (Table 3.14). However, the previous JCM #61 blank sample had 
not been processed with the XAD 16-N resin or separated by NP SPE. Therefore, the new  JCM 
#61 blank was generated with XAD 16-N resin and fractionated liquid medium was incubated 
for 10 days at 30°C, while shaking, extracted with XAD-16N resin (section 3.2.2.2 and 3.2.2.3), 
fractionated by RP+NP SPE (sections 3.2.3.3 and 3.2.3.5). Each fraction was collected, dried 
down, re-dissolved, and 100 µL of 10 µg/mL was injected and processed by HPLC-MS Method 
#1 (section 3.2.5.1). A sample was taken from the JCM #61 blank, Gram stained and streaked 
for single colonies. No microbial growth or presence was detected verifying that only the media 
components were present. The HRMS results revealed that [150]crown-15 was present in the 
crude blank, RP SPE MeOH fraction and the NP SPE EtAc (#4) blank. This proved that 
[150]crown-15 was not a natural product produced by strain PR3, but was likely a PPG 
oligomer. 
PPGs are routinely used to calibrate mass spectrometers, as they display characteristic MS and 
MS/MS signals, such as a neutral loss pattern of 58 Da and a peak of m/z 175 Da (Matsuo et 
al., 1979; Rindelaub et al., 2019). A calibration sample of PPGs (Sciex®, Johannesburg, South 
Africa) at a concentration of 1*10-5 M, was tested using HPLC-MS Method #1 (section 3.2.5.1). 
[150]crown-15 was found to be present in this PPG calibration sample. The more typical, linear 
form of PPG were also detected. MS/MS spectra characteristic of linear PPGs, with 175 Da 
peaks and neutral losses of 58 Da, were detected in the PPG calibration sample (Figure 4.11) 
(Rindelaub et al., 2019). These linear chains were not found in the JCM #61 blank or strain 






Figure 4.11: Linear PPG MS/MS with characteristic m/z peak of 175 Da and neutral 
loss pattern of 58 Da. Black arrows represent mass shifts of 58 Da. 
 
At this point in the investigation, it had been confirmed that [150]crown-15 was not a natural 
product, but likely an oligomer of PPG. However, there were two major questions that needed 
to be answered. 
Firstly, what was the source of [150]crown-15? [150]crown-15 was found in the crude blank 
sample extracted from JCM #61 medium. This showed that it was coming from a component 
used in the extraction process and not leaching out of plastic products, such as pipette tips and 
benchtop centrifuge tubes, during fractionation. 
Each component used in the crude extraction was examined by HRMS to identify the source 
of [150]crown-15. Ten microlitres of each of the solvents used in the extraction process (MeOH 
and EtAc) were injected directly, without dilution, and analysed using HPLC-MS Method #1 
(section 3.2.5.1). The coffee filters and XAD-16N resin used in the extraction methods were 
washed repeatedly with the same extraction solvents separately and tested in the same manner. 
None of these samples contained [150]crown-15. 
135 
 
The ingredients used to make the growth media for strain PR3 were also examined. 
[150]crown-15 was found in both ISP-2 and JCM #61 media, and the only ingredient common 
to both media was the yeast extract. Therefore, 5 g of dry yeast extract was washed with 50 mL 
of EtAc for 30 minutes. The solvent was filtered through coffee filters into a glass beaker, then 
reconstituted in a glass vial, and 10 µL of a 100 µg/mL sample was tested using HPLC-MS 
Method #1 (section 3.2.5.1). This sample also lacked [150]crown-15. 
The second question was, if [150]crown-15 is a PPG oligomer, how is it cyclizing? PPG is a 
linear chain made up of propylene oxide monomers capped by a hydroxyl group at each end 
(Rindelaub et al., 2019). As discussed earlier, the HRMS and NMR strongly suggested that 
[150]crown-15 is cyclic. This meant that either the data was incorrect and the molecules were 
linear, or [150]crown-15 is formed by the cyclization of PPG oligomers during the extraction 
process. 
Both questions were answered in collaboration with Dr Joel Rindelaub from the Department 
of Chemistry at the University of Auckland, New Zealand. He hypothesised that the PPG 
oligomers could indeed cyclize by nucleophilic substitution and this would likely occur in the 
presence of proton donators, such as under aqueous or acidic conditions. Dr Rindelaub 
proposed a mechanism of cyclization (Figure 4.12). To determine if this mechanism was 
correct, 100 µL volume of water was added to the EtAc and MeOH-washed samples (filters, 
resin and yeast extract). Ten microlitres of each mixed sample was resubmitted for HRMS 
analysis by HPLC-MS Method #1 (section 3.2.5.1). [150]crown-15 was found in the MeOH 
and EtAc XAD-16N resin samples after water was added. 
 
Figure 4.12: Possible mechanism of cyclization of PPG chains into methylated crown 
ethers. This diagram was provided by J. Rindelaub. 
 
Thus, the mystery of the origin of [150]crown-15 was solved. It was now known that the XAD-
16N resin was the source of [150]crown-15, which explains why it was not in the original JCM 
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#61 blank. XAD-16N resin was not used in the preparation of that blank sample. The PPGs 
could not have come from the resin itself, as the resin has a styrene-dibenzyl structure and 
shares no structural similarity with PPG oligomers (Sigma, 1998). Proton donators such as 
water, are required for the nucleophilic substitution reaction, which is why [150]crown-15 was 
only seen in the EtAc and MeOH washed resin when water was added. It also could explain 
how [150]crown-15 forms in terms of the extraction process followed. When extracting the 
culture broth of strain PR3, the XAD-16N resin is added to the liquid culture prior to solvent 
extraction, then the PPGs introduced with the resin are exposed to the required aqueous 
environment and cyclize. The resulting MCEs are then extracted into the organic solvent and 
purified during the SPE purification steps. 
Rindelaub et al. (2019) reported multiple oligomers with a mass difference of 58 Da between 
them. Using the IDA explorer tool on OS Sciex, the HRMS sample containing [150]crown-15 
was analysed for other compounds with similar fragmentation patterns. The search parameters 
were set to find compounds that contained the major fragments of [150]crown-150: m/z 57, 
157, 215 and 331, as well as fragments with a neutral loss of 58 Da. 
A range of compounds with matching MS/MS patterns were seen (Figure 4.13). Each 
compound had a mass difference of 58 Da from the next and a unique retention time, which 
implies that they are distinct and separate molecules and not fragments of a larger compound. 
The series of compounds related to [150]crown-15 is annotated in the blue ellipse in Figure 
4.13. Each of these is an ammonium adduct and contains the same MS/MS fragmentation 
pattern as [150]crown-15. This suggests that there are multiple MCEs present. This correlates 
with the unresolved peaks signals seen in the NMR data. The NMR signals from the ether 
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subunit were not only generated multiple times from within one structure, but from many 
structures. 
Figure 4.13: The series of methylated crown ethers is presented. The blue ellipse shows 
the series of singly charged methylated crown ethers. The red ellipse highlights the series of 
multiply charged methylated crown ethers. The numbers next to each data point are the 
accurate mass and retention time. 
A smaller series of MCEs was seen running parallel to the main series at a later retention time. 
This parallel series is shown in the red ellipse and was reported to have a lower m/z than the 
larger series shown in blue. This is contradictory to our understanding of these compounds, 
because larger MCEs would be more non-polar and therefore should have a later retention time 
when separated by reverse phase chromatography. Further analysis showed that the compounds 
in the parallel series, shown in the red ellipse, were carrying multiple charges. Therefore, they 
had a larger true mass than the ones indicated by the blue ellipse, but displayed a lower m/z. 
Ten microlitres of a 100 µg/mL solution of the purified sample containing [150]crown-15 and 
the related compounds were analysed by HPLC-MS Method #1 (section 3.2.5.1). The method 
was modified by changing the mass range from 50–1200 Da to 1000–2000 Da. The same 
fragmentation search parameters were applied as before, and more related MCEs were detected 
(Figure 4.14). The number of different related compounds produced is erratic, however, there 
were at least 16 different MCEs with the same structural motif as [150]crown-15 detected 
(Figures 4.13 and 4.14). All the m/z’s represent ammonium adducts and, thus, their true mass 
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is their ionised mass – 18.0347 Da divided by 58. The smallest MCE observed had a m/z 
366.2865, composed of 6 subunits. The largest MCE observed had a m/z of 1566 Da, which is 
composed of 27 subunits. The empirical formula of these compounds is C3nH6nOn, where n 
is the number of 58 Da monomers.   
 
Figure 4.14: Series of larger (m/z >1000 ) methylated crown ethers. The numbers next to 
each data point are the accurate mass and retention time. 
The MS PPG calibration sample was also examined for multiple MCEs. The PPG calibration 
sample contained the same MCE series as seen in the isolated fraction (Compare Figure 4.15 
to Figures 4.13 and 4.14). This provides further evidence that the MCEs originate from PPG. 
In summary, the data presented strongly suggests that the compounds isolated in Chapter 3 are 
a series of MCEs formed by the cyclization of PPG oligomers in the presence of proton 
donators. It must be noted that the presented mechanism is only a proposed mechanism of 
cyclization and, while it seems proton donators such as water, are required for cyclization; the 
exact mechanism could be different and needs to be studied further. 
While the NMR and HRMS spectra suggest that the structure of [150]crown-15 is accurate, the 
exact three-dimensional structure is unknown. Molecular models have predicted that PPG 
oligomers can form a doughnut shape, which correlates to the crown ether structures, or a disc-
coil shape (Sandell, 1970). These models were determined mathematically, and no NMR data 
was generated on these oligomers in solution, so a direct comparison with the isolated MCEs 
is impossible. Other than those predictions, to the author’s knowledge, MCEs and the 
cyclization of PPG oligomers into MCEs have not been reported. PPG is an extremely common 
and well-known molecule; therefore it is odd that this phenomenon has not been described. It 
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is possible that these MCEs have been found by other researchers, but were not separated from 
linear PPG chains or did not display any interesting characteristics, so were not studied further. 
Figure 4.15: Series of methylated crown ethers displayed in PPG calibration sample. 
The numbers next to each data point are the accurate mass and retention time. 
 
4.3.3 Antiplasmodial Efficacy and Selectivity of the Methylated Crown 
Ethers 
 
The discovery of the MCEs has potential significance in the field of chemistry. More work 
needs to be done to understand if these structures have other applications. While the cyclization 
of the PPGs into the MCEs is an interesting phenomenon, it is not the main focus of this 
investigation and to determine if the MCEs could be lead drug candidates, they were tested for 
antiplasmodial activity against NF54 (section 2.2.4). 
The PPG MS calibration sample was used as a comparison in these studies as it contained both 
the linear PPGs and MCEs according to HRMS analysis (Figures 4.13, 4.14, and 4.15). If no 
difference in activity between the two samples was detected, this would suggest that the MCEs 
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are solely responsible. Alternatively, a difference in antiplasmodial activity would suggest that 
the linear PPGs are active against P. falciparum. RP+NP SPE Fraction #4 produced by SPE 
Method #5 (section 3.2.3.5), shown to contain the pure MCEs was used for antiplasmodial 
activity determination (section 2.2.4). The MCEs displayed weak antiplasmodial activity with 
a mean IC50 of 1873 ± 308 ng/mL (Table 4.2). PPG displayed good antiplasmodial activity 
with an IC50 of 190 ± 20 nM. The controls were within the acceptable ranges. 
Table 4.2: Mean antiplasmodial activity of the methylated crown ethers against 
P. falciparum NF54, N=2 biological repeats with 4 technical repeats. 
Sample Antiplasmodial activity against P. 
falciparum, NF54 IC50 (ng/mL) 
Methylated Crown Ethers 1873 ± 308 
Polypropylene Glycol 190 ± 20 
Chloroquine 5 ± 1.1 
Artesunate 2 ± 0.5 
 
The MCEs are predicted to act as neutral ionophores due to their proposed ring structure which 
is the active pharmacophore in other crown ether species (Gokel et al., 2004). The MCEs lack 
ionisable groups but, were able to form adducts. For example, [150]crown-15 formed multiple 
adducts detected by MS, the m/z 888.6659 Da (M+NH4
+) was the dominant ion, likely due to 
the high concentration of ammonium formate in the mobile phase. The other adducts seen were 
proton, m/z 871.6368 Da (M+H+), sodium, m/z 893.6148 Da (M+Na+) and potassium, m/z 
909.5994 Da (M+K+). This is supported by Rindelaub et al. (2019) who reported that the 
leached PPGs oligomers formed NH4
+, Na+, K+ and H+ adducts. These adducts are likely 
forming by stable dipole interactions between the cation and oxygen groups in the centre of the 
crown ether ring, as discussed earlier. Their ring structure and adduct formation strongly 
indicates that the MCEs are also ionophores. 
Ionophores are known to possess antimalarial activity and a series of ionophores, including 
gramicidin D, nigericin, lonomycin, and monensin, were found to display potent antimalarial 
activity in vitro and in vivo (Gumila et al., 1997). The Plasmodium parasites rely on a suite of 
ion gradients in the human erythrocyte. As discussed in Chapter 1, the Plasmodium parasites 
remodel the human erythrocyte. Part of this remodelling is a large-scale increase in cation 
transport capacity. Some examples of the change in cation transport systems are increases in 
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K+, Na+, and Cl- transport systems and the inhibition of erythrocyte ATPase membrane pumps 
(Ginsburg, 1994). This creates a list of targets that could be used to selectively inhibit P. 
falciparum infected erythrocytes. For example, the breakdown of globin into its peptide 
constituents produces ammonium wastes, which has been shown to be lethal to the parasites if 
not removed (Zeuthen et al., 2006). Binding to NH4
+ ions and transporting them back into the 
parasite or preventing their removal could be an effective mechanism of action for an 
antiplasmodial drug. Changes in intracellular Na+ concentrations have been shown to impact 
the development of P. falciparum and disrupt lifecycle stage transitions (Vaidya et al., 2014). 
The list of possible ionophore targets in P. falciparum is very long, and further investigation is 
required to determine the exact mechanism of action of these MCEs. 
The PPG calibration sample was only available as a mixture of PPG chains with an unknown 
percentage of each oligomer. The concentration provided by the distributor stated that the 
mixture had a concentration of 10 µM. Therefore it was assumed that the sample stock 
concentration was 10 µM. The PPG MS calibration sample displayed surprisingly good 
antiplasmodial activity with an IC50 of 190 ± 20 nM against NF54. As this is a mixture of 
compounds this antiplasmodial activity cannot be assumed to be accurate. To determine exact 
IC50’s each PPG chain would have to be purified and retested. This was not within the scope 
of this investigation and the antiplasmodial result obtained was used as an estimate for activity.  
The exact molecular mass of the MCEs and PPG samples is unknown, so the IC50s cannot be 
converted into the same units. Using the results obtained it was estimated that the PPG 
calibration sample was more active than the MCEs. This suggested that the linear forms of PPG 
are contributing to this increased activity, as they are not present in the MCE sample. This 
could be due to a cytotoxic effect induced by the PPGs rather than selective inhibition of the 
P. falciparum parasite. However, these can only be used to estimate activity and further study 
on each pure individual PPG chain and cyclic oligomer would have to be done to allow a direct 
comparison. 
 To determine if the MCEs and the PPGs were selectively targeting the P. falciparum parasite, 
cytotoxicity and haemotoxicity studies (sections 2.2.6 and 2.2.7 respectively). The MCEs 
exhibited no signs of cytotoxicity or haemotoxicity in vitro up to 100 µg/mL (Tables 4.3 and 
4.4). The PPGs showed no cytotoxicity at 5 µM, but did display moderate haemotoxicity with 
an IC50 of 4.22 ± 0.4 µM (Tables 4.3 and 4.4). The PPGs could not be tested at a higher 
concentration as they were only available at a maximum concentration of 10 µM, which was 
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diluted by a minimum of 2 fold during the MTT assay (section 2.2.6). The control emetine 
displayed toxicity within the acceptable ranges in all experiments. 
Studies have shown that short- to moderate-sized PPG molecules (200–1200 Da) have acute 
oral toxicity (Bingham and Cohrssen, 2012). The much longer chains (MW >2000) are much 
less cytotoxic. PPG has also been shown to cause haemolysis of human erythrocytes (Reed and 
Yalkowsky, 1985). This supports the data reported here (Table 4.4). The haemotoxicity 
reported here suggests that the linear PPGs are interfering with the human erythrocyte. This 
may be why the PPG MS calibration sample was estimated to have a greater antiplasmodial 
effect than the MCEs. 
 
Table 4.3: Mean antiplasmodial activity against P. falciparum NF54 and mean 
cytotoxicity against CHO and HepG2 of the methylated crown ethers and 
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Table 4.4: : Mean antiplasmodial activity against P. falciparum, NF54 and mean 
haemotoxicity against human erythrocytes of the methylated crown ethers and 
polypropylene glycol, N=2 biological repeats with 4 technical repeats. 
 
An interesting quality of the MCEs compared to other crown ethers is their lack of toxicity in 
vitro. Crown ethers are known to be cytotoxic to mammalian cells and cause acute central 
nervous system failure in mice (Hendrixson et al., 1978; Arenaz et al., 1992). The MCEs 
presented SIs greater than 100 with no signs of cytotoxicity or haemotoxicity up to 100 µg/mL, 
indicating that the MCEs are selectively targeting the P. falciparum parasites in the erythrocyte. 
This implies that the MCEs could have biomedical applications by modifying ion gradients or 
ionophores safely in living systems. However, these tests are simple in vitro assays, and more 
study needs to be done to verify that the MCEs are, in fact, non-toxic. 
Despite their selectivity, the discovery of compounds with such weak antiplasmodial activity 
would usually have eliminated them from further investigation. However, further study 
suggested that the addition of MCEs to the most active NP SPE fraction of strain PR3 led to a 
synergistic improvement in antiplasmodial activity. This is of great interest, and the 
identification of the active component in this NP SPE fraction and the relationship between it 
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5 Identification of Cyclodepsipeptides and their 
Relationship with the Methylated Crown Ethers 
 
Abstract 
After isolating and purifying the methylated crown ethers, the compounds responsible for the 
high antiplasmodial activity remained unknown. Through molecular networking, genome 
mining, and nuclear magnetic resonance  analysis, a group of cyclodepsipeptides was 
successfully identified as the active compounds. These included the well-known valinomycin, 
montanastatin and other analogues recently identified in literature. Study of their tandem mass 
spectrum (MS/MS) spectra, comparison to literature and knowledge of their biosynthesis 
allowed the elucidation of the structures of two new cyclodepsipeptides. Unfortunately, it was 
found that the cyclodepsipeptides could not be purified further with the chromatographic 
method developed. The most active solid phase extraction fraction containing the 
cyclodepsipeptides was tested for antiplasmodial activity against drug-sensitive and resistant 
strains of P. falciparum, cytotoxicity against the HepG2 and Chinese Hamster Ovary cell lines, 
and haemotoxicity against human erythrocytes. While the results were promising, they showed 
similarity to pure valinomycin, which presents host toxicity, and, without further purification, 
it is unknown if the cyclodepsipeptide analogues could be lead candidates for further 
development. However, the tested cyclodepsipeptide fraction displayed suitable antiplasmodial 
activity with mean IC50s of  25 ± 3.5 ng/mL and 101 ± 1.0 ng/mL against the drug-sensitive, 
NF54 and multidrug-resistant, K1 strains of P. falciparum respectively. The cyclodepsipeptide 
fraction also displayed favourable host selectivity with no cytotoxicity against the CHO cell 
line nor human erythrocytes and moderate toxicity against the HepG2 cell line. Overall, these 
results suggest that further study and purification of the cyclodepsipeptides is warranted. 
Lastly, antiplasmodial activity of past impure samples from earlier in the investigation was 
found to be comparable to the purest active cyclodepsipeptide fraction. High-resolution mass 
spectrometry analysis revealed the presence of the cyclodepsipeptides and MCEs in the active 
impure samples. This association led to the hypothesis that the methylated crown ethers and 
cyclodepsipeptides interacted in a synergistic manner. Combination studies using two models 
suggested that combining the methylated crown ethers with the cyclodepsipeptides elicits a 






At this stage of the investigation, the compound(s) responsible for the potent antiplasmodial 
activity displayed by Streptomyces strain PR3’s crude extracts and partially-purified fractions, 
was still unknown. Bioassay-guided fractionation supported by nontargeted high resolution 
mass spectrometry (HRMS), had led to the discovery of the novel methylated crown ethers 
(MCE). However, it was later shown that the MCEs were not entirely responsible for activity, 
but were thought to be co-eluting with the unknown active compound(s). The nontargeted 
HRMS approach that was adopted in Chapter 3 was deemed too crude, and a more direct mass 
spectrometry approach supported by additional methods of detection was needed to correctly 
identify the active compound(s). To this end, a set of systems biology approaches were 
implemented. 
Systems biology is the integrated study of the molecular components within a biological 
system, at different scales (organism, organ, tissues, cells), and their connection to 
physiological functions and phenotypes through quantitative reasoning, computational models, 
and high throughput experimental technologies (Tavassoly et al., 2018). Systems biology 
approaches involve several fields such as genomics, proteomics, and metabolomics. The two 
approaches that suited this investigation were metabolomics and genomics. 
Metabolomics is a relatively new field in systems biology and refers to the study of all the 
metabolites produced by an organism at a specific time and under specific conditions (Tawfike 
et al., 2013). In metabolomics, metabolites are analysed by spectroscopic methods such as 
HRMS, nuclear magnetic resonance (NMR), ultraviolet-visible light (UV-Vis), or infrared 
(IR), and the results are processed by computational tools and statistical models. This allows 
metabolites to be identified by the use of spectral libraries, the relationship between metabolites 
to be studied, and even the discovery of new molecules by comparison to known compounds. 
Metabolomics is used in a variety of fields such as toxicology, physiology, and of course, 
natural products chemistry.  
A recently created metabolomic platform is the Global Natural Products Social molecular 
networking (GNPS) (https://gnps.ucsd.edu/) . GNPS is an online open-access knowledge base 
for the sharing of raw, processed and identified mass spectrometry (MS) and tandem mass 
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spectrometry (MS/MS) data from thousands of researchers around the globe (Wang et al., 
2016). GNPS links to other well-known MS libraries and repositories such as MassBank, and 
mzCloud. After validation, researchers can upload their own findings to GNPS, which creates 
a living database that is continuously growing and learning. This allows improved library 
searches to identify unknown compounds and therefore easy dereplication. One of the most 
useful tools provided by GNPS is molecular networking (Wang et al., 2016). Molecular 
networking is a spectral correlation and visualization approach that matches MS/MS spectra to 
known spectra. A molecular network is visualized in the form of nodes clustered and linked to 
one another. Each node represents a mass spectrum and each link or edge represents a spectrum 
to spectrum alignment. By comparing fragmentation patterns of compounds, novel analogues 
with different parent masses and additional groups can still be matched, allowing the 
discovering of new compounds without the need to purify them (Allard et al., 2016). It can also 
aid dereplication by easily and accurately identifying known compounds, which saves time and 
resources during fractionation studies. Alternatively, it could highlight a new molecule of 
interest and direct fractionation studies (Allard et al., 2016; Wang et al., 2016). 
Another system biology approach seeing increased application in natural products screening is 
genomics. Genomics is the study of the function, mapping, and evolution of an organism’s 
genome (Trivella and de Felicio, 2018). All natural products are produced by metabolic 
processes, which are governed by an organism’s genetics. In the filamentous actinobacteria, 
these biosynthetic genes are organised into clusters known as biosynthetic gene clusters (BGC). 
BGCs are the core organisation of the biosynthetic pathways at a genomic level in bacteria and 
encode proteins, such as multidomain enzymes and binding factors, which are required to 
create and tailor metabolites (Tietz and Mitchell, 2016; Trivella and de Felicio, 2018). 
Analysing a genome sequence to identify known BGC sequences is known as genome mining 
and can be used to predict or identify structures present in a crude extract or fraction. Natural 
products are broadly made in a two-step process where a core backbone or scaffold is made 
and then tailored. Therefore, analogues can be predicted or identified if known genes are 
located in new BGCs. Conversely, chemical knowledge of a molecule can be used to analyse 
the biosynthetic genes of an organism. 
In the past, whole genome sequencing (WGS) was incredibly expensive and difficult, but 
advances in understanding and technology have made WGS relatively inexpensive and faster 
(Tietz and Mitchell, 2016). Today, thousands of genomes have been sequenced and are 
available online for comparison through platforms, such as the National Center for 
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Biotechnology Information’s (NCBI) GenBank (Benson et al., 2012). Genome sequences can 
then be analysed by programs such as antiSMASH, which searches for natural product 
biosynthesis signatures (Medema et al., 2011). antiSMASH provides sequence information on 
a wide range of different natural product classes, such as similarity to known BGCs and closely-
related genes, making it a very robust and useful tool. Overall, genome mining can be used in 
conjunction with biological, physiochemical, and spectrometric techniques to accelerate or 
improve natural product screening (Tietz and Mitchell, 2016). 
Resources such as GNPS and antiSMASH are the reason natural products are again a viable 
source of novel compounds in drug discovery. The challenges of the past, such as dereplication, 
time consuming and laborious fractionation and misidentification of active compounds can 
now be avoided or reduced (Tawfike et al., 2013; Allard et al., 2016). 
Aims of this investigation: 
1. Prove that the main antiplasmodial active compound(s) in the active fractions are 
produced by Streptomyces strain PR3 and are not background impurities. 
2. Modify the normal phase solid phase extraction methodology to improve the purity of 
the antiplasmodial active compound(s) produced by Streptomyces strain PR3. 
3. Identify the active antiplasmodial compound(s) produced by Streptomyces strain PR3 
by molecular networking and genome mining. 
4. Determine whether there is a synergistic relationship between the methylated crown 













5.2.1 SPE Method #6: Normal Phase 
 
The SPE cartridges used were ISOLUTE® silica SPE cartridges with a sorbent mass of 200 mg 
and a total volume of 3 mL. SPE cartridges were equilibrated by passing 2 mL of MeOH 
followed by 2 mL of hexane through each cartridge. Samples were dissolved in 2 mL 
hexane/ethyl acetate (EtAc) (9:1) and passed through the silica cartridges by gravity. After 
adding the sample, solvents of increasing polarity were passed through the silica cartridges. 
The list of solvents in order of use was: hexane, hexane/EtAc (8:1), hexane/EtAc (7:1), 
hexane/EtAc (6:1), hexane/EtAc (5:1), hexane/EtAc (4:1), hexane/EtAc (3:1), hexane/EtAc 
(2:1), hexane/EtAc (1:1), EtAc, EtAc/methanol (MeOH) (4:1), EtAc/MeOH (2:1) and MeOH. 
When using silica cartridges, the sorbent was not allowed to dry, as this alters the retention of 
compounds in the subsequent wash steps. Therefore, 2.5 mL of solvent was added in each step, 
and approximately 0.5 mL of each solvent was left behind (i.e. only 2 mL of each fraction was 
collected). 
 
5.2.2 Global Natural Products Social Molecular Networking 
 
Raw HRMS data produced by HPLC-MS Method #1 was converted to mzXML format by 
ProteoWizard tool MSconvert (version 3.0.10051, Vanderbilt University, United States) 
(Chambers et al., 2012). The converted files were uploaded to the GNPS molecular networking 
server and analysed by the molecular networking workflow published by Wang et al., 2016. A 
molecular network was created using the online workflow (https://ccms-
ucsd.github.io/GNPSDocumentation/) on the GNPS website (http://gnps.ucsd.edu). The data 
were filtered by removing all MS/MS fragment ions within +/- 17 Da of the precursor m/z. 
MS/MS spectra were window filtered by choosing only the top 6 fragment ions in the +/- 50 
Da window throughout the spectrum. The precursor ion mass tolerance was set to 2.0 Da with 
a MS/MS fragment ion tolerance of 0.5 Da. A network was then created where edges were 
filtered to have a cosine score above 0.7 and more than 6 matched peaks. Further, edges 
between two nodes were kept in the network if, and only if, each of the nodes appeared in each 
other's respective top 10 most similar nodes. Finally, the maximum size of a molecular family 
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was set to 100, and the lowest scoring edges were removed from molecular families until the 
molecular family size was below this threshold. The spectra in the network were then searched 
against GNPS' spectral libraries. The library spectra were filtered in the same manner as the 
input data. All matches kept between network spectra and library spectra were required to have 
a score above 0.7 and at least 6 matched peaks. The results were visualized using Cytoscape 
v3.7.2 (Shannon et al., 2003). 
 
 
5.2.3 Whole Genome Sequencing  
 
Streptomyces strain PR3 was submitted to the Belgian Co-Ordinated Collection of 
Microorganisms/Laboratorium voor Microbiologie (BCCM/LMG; Ghent, Belgium) for WGS 
and analysis. Strain PR3 was recovered on ISP-2 and checked for growth and purity after 1 day 
of incubation at 28°C under aerobic conditions. Genomic DNA was isolated using a Maxwell® 
16 Tissue DNA Purification Kit (cat.# AS1030) and a Maxwell® 16 Instrument (cat.# AS2000) 
after a prior enzymatic lysis step. The integrity and purity of the DNA were evaluated on a 
1.0% (w/v) agarose gel and by spectrophotometric measurements at 234, 260, and 280 nm. A 
Quantus™ fluorimeter and a QuantiFluor™ ONE dsDNA System (Promega Corporation, 
Madison, WI, USA) were used to estimate the DNA concentration. WGS analysis was 
performed by the Oxford Genomics Centre (University of Oxford, United Kingdom). Library 
preparation was performed using an adapted protocol of the NEB prep kit. Paired-end sequence 
reads (PE150) were generated using the NovaSeq 6000 platform (Illumina Inc., San Diego, 
CA, USA). Quality checking trimming of the raw sequence reads and genome assembly (de 
novo) were performed using the Shovill pipeline (https://github.com/tseemann/shovill), aiming 
at an average genome coverage of 100x. Contigs shorter than 500 base pairs (bp) were excluded 
from the final assembly. Quality checking of the assemblies was performed using QUAST 





5.2.4 antiSMASH and BLASTP Analysis 
 
Putative biosynthetic gene clusters in the sequenced genome were identified using antiSMASH 
5.0 (Blin et al., 2019). The corresponding amino acid sequence of genes of interest were then 
analysed by BLASTP v2.10.0+ (Altschul et al., 1997) against the NCBI database 
(https://www.ncbi.nlm.nih.gov/). This allowed the identification of protein products encoded 
by the identified gene clusters. 
 
5.2.5 Cultivation and Antiplasmodial Efficacy Against the 
Multidrug-Resistant Strain of P. falciparum, K1 
 
The P. falciparum K1 strain, which is resistant to chloroquine, cycloguanil, sulfadoxine and 
pyrimethamine, was obtained from the Malaria Research and Reference Reagent Resource 
(MR4) depository. The K1 strain was originally isolated from a patient in Thailand in 1982 
(Thaithong et al., 1983). The cultivation of, and antiplasmodial efficacy testing against, the K1 
strain of P. falciparum was conducted by Mrs Sumaya Salie and Mr Virgil Verhoog at the 
Division of Clinical Pharmacology, University of Cape Town (sections 2.2.3 and 2.2.4). 
The acceptable range of artesunate remained the same as the one selected for P. falciparum, 
NF54 activity determination (0.5–8 ng/mL), as it is not affected by any of the resistance 
mechanisms of K1. The K1 strain of P. falciparum is chloroquine resistant, therefore the 
efficacy of the chloroquine control was an indicator of resistance. The acceptable efficacy 
range of the chloroquine control was 150–250 ng/mL. If the efficacy of the chloroquine control 








5.2.6 Fixed-Ratio Isobologram Method  
 
Combination studies were conducted using a modified version of the method described by 
Fivelman et al., 2004. Briefly, drug stock solutions were made up such that their approximate 
IC50s are obtained after 3–5 two-fold dilutions. The drug stocks were then mixed to make six 
different volumetric ratios. The ratios and concentrations of each sample are displayed in Table 
5.1. The antiplasmodial activity against P. falciparum, NF54  of each compound, in each 
mixture, was determined using the pLDH methodology (section 2.2.4).  
Table 5.1: Fixed fraction ratios and concentrations of the methylated crown ethers and 
cyclodepsipeptide fractions, used in the modified fixed-ratio isobologram method from 




















1 5:0 1.6 0 
2 4:1 1.28 8 
3 3:2 0.96 16 
4 2:3 0.60 24 
5 1:4 0.32 32 
6 0:5 0 40 
 
 
5.2.7 Determination of Synergy by CompuSyn 
 
Raw data obtained from the fraction combination studies (section 5.2.6) were inputted into 
CompuSyn version 1.00 (Chou and Martin, 2005). Combination index (CI) values were 
generated for each fixed drug ratio (Table 5.1). 
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5.3 Results and Discussion 
5.3.1 Cultivation, Extraction and Fractionation in Glass 
 
At this stage in the investigation, the identity of the main antiplasmodial active compound was 
still unknown. The detection of the MCEs suggested that plastics and other impurities were 
contributing to the antiplasmodial inhibition displayed by extracts and fractions of strain PR3. 
To prove that strain PR3 was producing an antiplasmodial active compound and background 
impurities were not responsible for the potent antiplasmodial activity observed,  two 1 L 
cultures of strain PR3 were grown in JCM #61 (section 3.2.1), extracted without XAD-16N 
resin (section 3.2.2.1) and fractionated by RP+NP SPE (sections 3.2.3.3 and 3.2.3.5 
respectively). Great care was taken to avoid sample exposure to plastics. Only glass containers 
such as beakers and HPLC vials, and no plastic containers, such as benchtop centrifuge tubes, 
were used. The only possible source of plastic contamination was predicted to be from 
automatic pipette tips and SPE cartridges. The RP+NP SPE fractions were tested for 
antiplasmodial activity against the drug-sensitive strain of P. falciparum, NF54 (section 2.2.4). 
Comparing the antiplasmodial results of the NP SPE fractions from the standard methodology 
(with XAD-16N resin and no avoidance of plastics) to the fractions from the glass methodology 
(no XAD-16N resin and minimal use of plastics) revealed only one major difference (Table 
5.2). The EtAc fraction of the standard methodology displayed weak antiplasmodial activity 
which as discussed previously is proposed to be due to the MCEs. The EtAc fraction in the 
glass methodology was inactive, suggesting that the MCEs are not present. HRMS analysis of 
the glass methodology EtAc fraction confirmed the absence of the MCEs. This supports the 
results discussed in Chapter 4. The most active fractions from each methodology were from 
the Hexane/EtAc (2:1) wash step with mean IC50s of 117 ± 7 ng/mL and 110 ± 5.0 ng/mL from 
the standard methodology and glass methodology fractions respectively. All controls were 
within the acceptable ranges. These results strongly suggest that strain PR3 is producing an 






Table 5.2: Mean antiplasmodial activity of NP SPE fractions (Method #5) obtained by 
extraction and fraction using the standard developed methodology and a glass 
methodology which limited exposure to plastics, N=2 biological repeats with 4 technical 
repeats. 
 
NP SPE Fraction 
Antiplasmodial activity against P. falciparum NF54 IC50 
(ng/mL) 
Standard Methodology Glass Methodology 
Hexane (#1) > 5000 > 5000 
Hexane/EtAc (2:1) (#2) 117 ± 7.0 110 ± 5.0 
Hexane/EtAc (1:1) (#3) 686 ± 61 575 ± 78 
EtAc (#4) 1873 ± 308 > 5000 
EtAc/MeOH (4:1) (#5) > 5000 > 5000 
EtAc/MeOH (2:1) (#6) > 5000 > 5000 
MeOH (#7) > 5000 > 5000 
Chloroquine 6.1 ± 2.1 7.3 ± 0.9 
Artesunate 2.4 ± 1.5 5.2 ± 2.0 
 
5.3.2 Improved Normal Phase Solid Phase Extraction Purification 
 
To purify the antiplasmodial active compound produced by strain PR3 the NP SPE 
methodology was improved. Previous experiments had shown that the hexane/EtAc (2:1) wash 
step of SPE Method #5 ( section 3.2.3.5) contained the active antiplasmodial compound (Table 
5.2). Due to the active compound eluting in this fraction, additional washes of hexane and 
EtAc, with a higher percentage of hexane, were used (section 5.2.1). It was hypothesized that 
this would remove inactive material and selectively elute the active compound(s).  
Four litres of  strain PR3 culture were grown (section 3.2.1), and extracted (section 3.2.3), then 
fractionated by RP SPE Method #3 (section 3.2.3.3). As the results had shown that background 
molecules were not responsible for antiplasmodial activity (section 5.3.1, Table 5.2), the 
standard extraction methodology, with the XAD-16N extraction resin, was used to obtain more 
material. Finally, SPE Method #6 (section 5.2.1) was used and each fraction was evaporated 
under N2 at 37°C, weighed, and tested for antiplasmodial activity against NF54 (section 2.2.4). 
By increasing the concentration of hexane in the initial hexane/EtAc washes, the new SPE 
method was able to separate the active component to a greater extent than before. Four highly 
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active fractions were identified with the most active fractions being the hexane/EtAc (7:1) (#3) 
and hexane/EtAc (6:1) (#4) fractions (Table 5.3). These fractions displayed mean IC50s of 31.3 
± 4.0 and 63.5 ± 17 ng/mL, respectively, values which are significantly lower than the previous 
NP SPE active fraction obtained by SPE Method #5 (section 3.2.3.5), which displayed an IC50 
of 117 ± 7.0 ng/mL (Table 5.2). This suggested that the fraction’s purity had increased. The 
controls were within the acceptable ranges for these pLDH assays. Note that the EtAc fraction 
(#10) displayed weak antiplasmodial activity with an IC50 of 2105 ± 146 ng/mL. The MCEs 
were detected in this fraction by HRMS and were believed to be the source of this activity. 
The detection of strong antiplasmodial activity in four consecutive fractions suggested that 
multiple compounds were present. It was possible that these compounds were analogues of one 
another with the same pharmacophore. Due to this, they were eluting from the silica cartridge 
under similar conditions. It was also possible that one compound was eluted in the different 
wash steps and the SPE methodology was not selective enough to purify the active compound.  
Table 5.3: Mean antiplasmodial activity of NP SPE Method #6 fractions against P. 
falciparum, NF54, N=2 biological repeats with 4 technical repeats. 
Sample Antiplasmodial activity against P. 
falciparum, NF54 IC50 (ng/mL) 
Hexane (#1) > 5000  
Hexane/EtAc (8:1) (#2) 150 ± 53 
Hexane/EtAc (7:1) (#3) 31.3 ± 4.2 
Hexane/EtAc (6:1) (#4) 63.5 ± 17 
Hexane/EtAc (5:1) (#5) 287 ± 14 
Hexane/EtAc (4:1) (#6) >5000 
Hexane/EtAc (3:1) (#7) >5000 
Hexane/EtAc (2:1) (#8) >5000 
Hexane/EtAc (1:1) (#9) >5000 
EtAc (#10) 2105 ± 146 
EtAc/MeOH (4:1) (#11) >5000 
EtAc/MeOH (2:1) (#12) >5000 
MeOH (#13) >5000 
Chloroquine 7.1 ± 2.1 




To determine if the structure of the active compound could be identified or elucidated, more 
material was obtained by culturing three 1 L cultures of strain PR3 in JCM #61 (section 3.2.1) 
followed by extraction (section 3.2.2.1) and fractionation by RP+NP SPE Methods #3 and #6 
(sections 3.2.3.3 and 5.2.1 respectively). The most active fractions, hexane/EtAc (7:1) (#3) and 
hexane/EtAc (6:1) (#4) from each culture were pooled and submitted for 1H NMR analysis at 
the University of Cape Town (section 3.2.4). The 1H NMR spectra of the two active fractions 
are displayed in Figures 5.1 and 5.2, respectively. Comparison of the 1H NMR spectra revealed 
them to be nearly identical, which strongly suggested that the same molecules were present in 
both fractions. Both spectra had signals at δH 0.9 and 1.0 which were predicted to correspond 
to methyl groups either attached to a 5-6 carbon ring or hydrocarbon chain (Silverstein et al., 
2005). Signals at δH 1.3, 1.4 and 2.3 were present in both spectra and believed to be from 
protons in methylene groups (Silverstein et al., 2005). Signals at δH 4.3, 4.4, 4.6 and 5.3 were 
also seen in both spectra and are proposed to be from methine groups attached to heteroatoms 
(Silverstein et al., 2005). Both 1H NMR spectra were overlaid (Figure 5.3) to allow comparison 
and it was found that the spectra are extremely similar suggesting they contain the same 
compound(s). The similar antiplasmodial activity (Table 5.3) supports this observation. 
However, the 1H NMR spectra also suggested that multiple analogues were present, as the base 
peaks of the most intense signals displayed overlapping signals and were not clearly resolved. 




Figure 5.1: 1H NMR spectrum of combined fraction #3 (hexane/EtAc 7:1) produced by 
SPE Method #6. 
 
Figure 5.2: 1H NMR spectrum of combined fraction #4 (hexane/EtAc 6:1) produced by 
SPE Method #6. 
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Figure 5.3: Overlaid 1H NMR spectra of fraction #3 (green) and fraction #4 (red) from 
NP SPE. 
 
5.3.3 Identification of Cyclodepsipeptides by Molecular 
Networking, 1H NMR and Genome Mining 
 
The two most active fractions produced by SPE Method #6 (section 5.2.1), fractions #3 and #4, 
were diluted to 10 µg/mL in MeOH and 10 µL of each were injected and analysed by HPLC-
MS Method #1 (section 3.2.5.1) to obtain HRMS data. Molecular network analysis was 
conducted on NP SPE Method #6 fractions #3 and #4 using the GNPS workflow (sections 5.2.1 
and 5.2.2 respectively).  A molecular network is visualized in the form of nodes clustered and 
linked to one another. Each node represents a mass spectrum and each link or edge between 
nodes represents a spectrum to spectrum alignment (Wang et al., 2016). Therefore, spectra with 
similar fragmentation patterns will be linked together. The length of the edge is not 
representative of the similarity of the spectra. As discussed in the methodology (section 5.2.2) 





aligned. The only compounds of interest detected in both molecular networks were a series of 
cyclodepsipeptides. The cyclodepsipeptide molecular network cluster found in fraction #3 is 
shown in Figure 5.4. The full molecular network with all clusters, nodes and edges is displayed 
in Figure 8.1 in the Appendix. There were nine nodes detected by molecular networking, two 
corresponded to valinomycin, and two to montanastatin, both of which are known 
cyclodepsipeptides (Pettit et al., 1999). Valinomycin was detected at m/z 1111.6409 (M+H+) 
and 1128.6616 (M+NH4
+). Montanastatin was detected at m/z 741.4288 (M+H+) and 758.4552 
(M+NH4
+). Six nodes were clustered with valinomycin and montanastatin, indicating they have 
very similar fragmentation patterns and that they are cyclodepsipeptide analogues. All 
analogues were detected as ammonium adducts, and their observed m/z, corresponding masses  
and retention times are displayed in Table 5.4. As seen with previous adducts it is believed that 
the ammonium adducts are formed from the ammonium formate in the aqueous phase. With 
the exception of montanastatin there is a mass difference of 14 Da between each 
cyclodepsipeptide which could correspond to a methylene group (Ma et al., 2014).  The 
retention time increases as the size of the cyclodepsipeptide increases which suggests that the 
larger peptides are more non-polar as they retain to the C18 HPLC column slightly longer. This 
supports the addition of the aliphatic methylene groups to each peptide. These analogues did 
not match any compounds in the GNPS library (Wang et al., 2016). The protonated forms of 
each cyclodepsipeptide can be observed in each of their MS/MS spectra which are displayed 
in the Appendix Figures 8.4-8.8. 
 
The cyclodepsipeptide cluster from fraction #4’s molecular network (Figure 5.5) and was found 
to be very similar to fraction #3’s network (Figure 5.4), which corroborates the 1H NMR results 
(Figures 5.1 and 5.2.) The only differences between the two molecular networks were the 
presence of an analogue with m/z of 1072.6 Da in fraction #3, not seen in fraction #4 and the 
presence of an analogue with m/z of 1156.6 Da in fraction #4, not seen in fraction #3. 
Overlaying the experimental MS/MS spectra of fraction #3 with the GNPS library MS/MS 
spectra of valinomycin and montanastatin revealed they were extremely similar, confirming 
their identities (Figures 5.6 and 5.7). The same overlays were conducted with the MS/MS 
spectra of valinomycin and montanastatin in fraction #4, and the results were the same as the 
















Figure 5.4: Molecular network of RP+NP SPE fractions #3, generated by SPE Methods 
#3 and #6. The nodes for valinomycin and montanastatin are highlighted by red arrows. 
 
Figure 5.5: Molecular network of fraction #4 produced by RP + NP SPE Methods #3 








Table 5.4: Detected ammonium adducts and experimental masses of cyclodepsipeptide 
analogues detected by HRMS. 
Experimental Mass (Da) m/z (M+NH4
+) Retention Time 
(minutes) 
740.4218 (Montanastatin) 758.4552 10.21 
1054.5671 1072.5997 10.27 
1068.5820 1086.6151 10.33 
1082.5984 1100.6308 10.46 
1096.6130 1114.6461 10.56 
1110.6339 (Valinomycin) 1128.6616 10.72 
1124.6454 1142.6778 10.82 
1138.6759 1156.6997 10.95 
 
 
Figure 5.6: Valinomycin MS/MS spectral overlay of experimental spectrum (green) vs 
















Figure 5.7: Montanastatin MS/MS spectral overlay of experimental spectrum (green) vs 
GNPS library spectrum (black). 
Valinomycin is a cyclic depsipeptide consisting of the amino and hydroxy acids; L-Valine 
(Val) –D-α-hydroxyisovaleric acid (Hiv) –D-Val–L-Lactic acid (Lac) (L-Val–D-Hiv–D-Val–
L-Lac–) repeated 3 times to produce a cyclic dodecamer (Ovchinnikov, 1979). The structure 
of valinomycin is displayed in Figure 5.8. Depsipeptides are peptides with one or more amino 
acids substituted for hydroxy acids and containing ester and peptide linkages (Kitagaki et al., 
2015). Valinomycin is commonly produced by many Streptomyces species and is a very well-
studied antibiotic (Matter et al., 2009). Valinomycin exhibits potent antibacterial, 
antiretroviral, antifungal, and anticancer activity (Ovchinnikov, 1979; Pettit et al., 1999; Wu 
et al., 2004; Ryoo et al., 2006; Park et al., 2008). More importantly, valinomycin has been 
shown to possess potent antiplasmodial activity, with an IC50 of 5.3 ng/mL against a drug-
sensitive strain of P. falciparum (Gumila et al., 1996). Valinomycin is a neutral ionophore, 
much like the crown ethers discussed in Chapter 4, with a lipophilic backbone and a central 
cavity where it can coordinate cations by ion-dipole interactions between its carboxylic oxygen 
atoms (Fong, 2016). Valinomycin binds and facilitates passive diffusion of cations through cell 
membranes and disrupts essential electrochemical gradients in cells, which is why it exhibits 
such a broad range of antibiotic activities. Valinomycin is highly selective for potassium ions 















valinomycin is 103–104 times more stable when complexed with K+ compared to Na+ 
(Ovchinnikov, 1979). 
 
Figure 5.8: Molecular structure of valinomycin with each amino and hydroxy acid 
labelled (Chemicalize). 
 
Montanastatin is a cyclodepsipeptide, which consists of the same sequence of amino and 
hydroxy acids as valinomycin (L-Val–D-Hiv–D-Val–L-Lac–), repeated twice instead of three 
times to form a cyclic octamer (Pettit et al., 1999). The structure of montanastatin is displayed 
in Figure 5.9. Montanastatin was isolated from Streptomyces anulatus and exhibits moderate 
antibacterial and anticancer activity in vitro (Pettit et al., 1999). Interestingly, in the same 
investigation valinomycin was shown to be substantially more active against the tested 
bacterial and cancer cell lines than montanastatin, despite their similar chemical compositions 
(Pettit et al., 1999). This is thought to be due to montanastatin’s smaller ring size, which is 
likely affecting ion selectivity and binding. Changes in ring size affects ion selectivity and thus 
possibly efficacy, which is also seen with the crown ethers (Pettit et al., 1999; Gokel et al., 
2004). The exact mechanism of action of montanastatin has not been elucidated, but it is 
reasonable to believe it acts by electrochemical gradient disruption, much like valinomycin and 
other neutral ionophores. Other cyclodepsipeptides have been found to possess antiplasmodial 
activity. For example Paecilodepsipeptide A from the pathogenic fungus Paecilomyces 
cinnamomeus BCC 9616 exhibited weak antiplasmodial activity against the multi-drug 
resistant strain of P. falciparum K1 with an IC50 of 4.9 μM (Isaka et al., 2007). Another example 
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is Chaiyaphumine‐A, isolated from Xenorhabdus SP. PB614, which shows good 
antiplasmodial activity against P. falciparum (strain unknown) with an IC50 of 0.61 µM 
(Grundmann et al., 2014). 
 
 
Figure 5.9: Molecular structure of montanastatin with each amino and hydroxy acid 
labelled (Chemicalize). 
 
While the GNPS molecular networking feature and library search are powerful tools it does 
not contain all known natural products and several other methods were employed to support 
the presence of the cyclodepsipeptides in fractions #3 and #4 and link their presence to 
antiplasmodial activity. Comparison of the 1H NMR spectra of montanastatin and valinomycin 
published by Pettit et al. (1999), to the 1H NMR spectra of NP SPE fractions #3 and #4 revealed 
matching signals (Figures 5.1, 5.2 and 5.3). Signals at δH 0.95, 0.96, 0.98 and 0.99 were 
observed and are theorized to represent methyl groups in Hiv and D-Val and L-Val 
respectively. Signals at δH 1.43 were proposed to represent methyl groups from L-Lac. Signals 
at δH 2.23 and 2.25 represent methine groups in branched chain in D-Val and L-Val, and Hiv 
respectively. Pettit et al. (1999) also reported signals at δH 4.25, 4.30, 5.00 and 5.05 which were 
assigned to methine groups attached to the peptide bond that form the backbone of 
valinomycin. Not all signals with these same chemical shifts were not observed in fraction #3 
and #4’s 1H NMR spectra however similar signals at δH 4.3, 4.4, 4.6 and 5.3 were seen and 
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believed to correlate to methine protons attached to heteroatoms (Silverstein et al., 2005). The 
major matching signals missing in fraction #3 and #4’s 1H NMR spectra that are present in 
valinomycin’s were at δH  6.96 and 6.94 which correspond to protons attached to nitrogens 
involved in amide bonds (Silverstein et al., 2005). Figure 5.10 is fraction #3’s 1H NMR 
spectrum and is annotated with the matching signals reported by Pettit et al. (1999). These 
results add further evidence to suggest that the cyclodepsipeptides are present. However, as the 
samples were not completely pure and only 1H NMR analysis was done, it cannot be confirmed 
that these signals are from montanastatin and valinomycin.  
 
Figure 5.10: 1H NMR spectrum of fraction #3 produced through SPE Methods #4 and 
#6 annotated with the matching signals from valinomycin (Pettit et al., 1999). 
The HRMS data of all past active fractions produced from previous extractions and different 
purification methods were screened for the presence of cyclodepsipeptides. The m/z signals 
presented by the molecular networking results were used (Table 5.4). Valinomycin, 
montanastatin, and the cyclodepsipeptide analogues were detected in all of the past active 
fractions and in none of the inactive blank samples, suggesting that they are linked to the 
antiplasmodial activity displayed by strain PR3. The LC-MS data of each cyclodepsipeptide 
including observed m/z, retention time, peak height and peak intensity, in each active fraction 



























fraction and were not found in any inactive fractions. The only missing peptide is m/z  
1156.6997 from fraction #5, which displayed weak antiplasmodial activity (Table 5.3). It’s not 
possible to determine if this lower activity is linked to the absence of m/z 1156.6997 with the 
data available. In Chapter 3, it was hypothesised that, when grown in ISP-2 or JCM #61, strain, 
PR3 produced different antiplasmodial compounds. This was found to be incorrect as analysis 
of crude extracts and fractions from cultures grown in both media, ISP-2 and JCM #61, 
contained the cyclodepsipeptides. The amount of each cyclodepsipeptide present could be 
altered by the different growth conditions, which could explain the differences in activity of 
the fractions generated from cultures grown in the two media.  
Further evidence of the presence of the cyclodepsipeptides was achieved by sequencing the 
genome of strain PR3 followed by antiSMASH analysis (sections 5.2.3 and 5.2.4, respectively). 
antiSMASH analysis revealed that strain PR3 contained the BGC required to synthesise 
valinomycin (Figure 5.11).  
Valinomycin and montanastatin are synthesised by non-ribosomal peptide synthetases (NRPS). 
Briefly, NRPSs consist of enzymatic domains each of which is responsible for a different 
action, such as activation, covalent binding, or modification of a substrate molecule, and finally 
condensation of the domain’s product to that of the neighbouring domain in the enzyme (Mootz 
et al., 2002). Domains are organised into modules and each module is responsible for the 
binding of a single substrate. Amino acids and other substrates are covalently bound as 
thioesters to the enzyme attached 4՜-phosphopantetheine (Ppant) prosthetic group. Following 
modifications, these bound substrates are then linked to the downstream domain’s product by 
condensation. Possible modifications that can occur to each peptide include cyclization (to 
form a macrocycle), dehydration, methylation, acylation, and glycosylation. The NRPS 
product grows by step-wise chain extension from the N terminus to C terminus direction. The 
final product is cleaved from the last Ppant group and released. The type of NRPS described 
here is known as linear. Two other types exist, iterative and nonlinear. Iterative NRPSs use 
their modules or domains more than once to produce a single product. In nonlinear NRPSs, the 
domain order within a module can be different from the conserved order seen in the other two 
systems. This allows unique modifications, such as internal cyclization. NRPSs are able to 
incorporate unique amino acids and α-hydroxy carboxylic acids, as seen in valinomycin 
biosynthesis (Cheng, 2006). NRPS products can be linear, cyclic or branched cyclic, such as 
the macrocyclic lactones (Mootz et al., 2002). 
166 
 
Valinomycin biosynthesis is performed by an NRPS consisting of two core enzymatic units, 
VLM1 and VLM2, each of which is composed of two modules (Cheng, 2006; Paulo et al., 
2019). In valinomycin biosynthesis, D-α-hydroxyisovaleric acid (D-Hiv) is the starting 
component followed by the epimerization of L-valine (L-Val) to D-Val and its incorporation. 
Next L-lactic acid (Lac) is incorporated and finally L-Val is bound to form a tetradepsipeptide 
chain (Paulo et al., 2019). Valinomycin biosynthesis is an example of iterative NRPS synthesis, 
as the process is repeated twice more by the same modules, to produce a linear twelve 
membered depsipeptide chain (Mootz et al., 2002). This is cyclized by the VLM2 thioesterase, 
to produce the final cyclic dodecadepsipeptide (Paulo et al., 2019). Montanastatin biosynthesis 
was recently shown to follow the same process with two iterations instead of three. 
After the detection of the valinomycin BGC by antiSMASH analysis, BLASTP analysis was 
conducted on the genome sequence of strain PR3 (section 5.2.4) (Table 5.5). The BLASTP 
results revealed that strain PR3 contained genes which encode amino acid sequences with 
extremely high similarity to the consensus sequences of VLM1 and VLM2, originally 
sequenced from Streptomyces tsusimaensis strain ATCC 15141, in the NCBI database (Cheng, 
2006). The genes that encode the VLM1 and VLM2 enzymes are referred to as vlm1 and vlm2. 
The detection of the valinomycin BGC and amino acid sequence similarity to VLM1 and 
VLM2 proves that strain PR3 has the biosynthetic potential to produce valinomycin and 
montanastatin. 
The antiSMASH results revealed that strain PR3 contained several additional genes flanking 
the core vlm1 and vlm2 gene sequences (Figure 5.11). The association of these genes with vlm1 
and vlm2 suggests they may play a role in cyclodepsipeptide biosynthesis. If these additional 
genes code for enzymes with the ability to tailor the core valinomycin molecule, it could 
explain the presence of the cyclodepsipeptide analogues detected by molecular networking.  
 
Figure 5.11: Biosynthetic gene cluster of strain PR3 (top) compared to the valinomycin 
biosynthetic gene cluster of S. tsusimaensis ATCC 15141 (bottom; accession number 
DQ174261) (Blin et al., 2019). The core module sequences, vlm1 and vlm2, are shown in 





Table 5.5: BLASTP results of the VLM-like proteins of strain PR3 (Benson et al., 2012). 





































In summary, molecular networking analysis of the active NP SPE fractions #3 and #4 of strain 
PR3 revealed the presence of the cyclodepsipeptides, valinomycin, montanastatin and related 
analogues. 1H NMR analysis of the NP SPE active fractions and comparison to published 
spectra for valinomycin and montanastatin supported the proposal that cyclodepsipeptides were 
present. The detection of multiple cyclodepsipeptides with similar sequences and amino acids 
could explain the overlapping base signals seen in the 1H NMR spectra (Figures 5.1 and 5.2). 
Finally, genome mining and BLASTP analysis revealed the presence of the biosynthetic genes 
required for valinomycin biosynthesis in strain PR3’s genome. The core genes vlm1 and vlm2 
were flanked by additional genes not seen in the consensus BGC of S. tsusimaensis ATCC 
15141. These additional genes were suspected to be linked to the presence of the 
cyclodepsipeptide analogues detected by molecular networking. Overall, this provides strong 
evidence that the cyclodepsipeptides are present in strain PR3’s fractions. Valinomycin is a 
known antibiotic and possesses potent antiplasmodial activity against P. falciparum (Gumila 
et al., 1996). This activity is similar to the activity displayed by strain PR3’s most active 
fractions. Analysis of the HRMS data of past active fractions showed that these 
cyclodepsipeptides were consistently present in the active fractions and extracts throughout the 
entire investigation and were not present in the blank or inactive samples (See Appendix, 
Figures 8.9-8.15. Confirmation of the presence of the cyclodepsipeptides by multiple methods, 
association with past active fractions, and review of the literature strongly suggests that the 
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cyclodepsipeptides are responsible for the antiplasmodial activity displayed by Streptomyces 
strain PR3.  
 
5.3.4 Elucidation of Novel Cyclodepsipeptides 
 
While the GNPS library search failed to identify the cyclodepsipeptide analogues, structures 
have been proposed in the literature. In a similar fashion to this investigation, Paulo et al. 
(2019) identified valinomycin, montanastatin, and five additional cyclodepsipeptides present 
in the EtAc extract of Streptomyces strain CBMAI 2042 using molecular networking and 
genome mining (Paulo et al., 2019). They detected additional genes flanking the vlm1 and vlm2 
core sequences and hypothesized that these could be responsible for the production of 
additional cyclodepsipeptides. This was also observed with strain PR3’s valinomycin BGC and 
supports the theory that the additional genes detected by antiSMASH are responsible for the 
production of the cyclodepsipeptide analogues (Figure 5.11).  
By studying the MS/MS spectra of the novel cyclodepsipeptides and the biosynthesis of 
valinomycin, Paulo et al. (2019) proposed structures for the detected cyclodepsipeptide 
analogues. Analysis of the MS/MS spectrum of a cyclic peptide can be used to elucidate its 
structure, as mass fragments represent alternating units that comprise the peptide backbone (Jia 
et al., 2006). Knowledge of the biosynthesis of the compound of interest allows an 
understanding of the components available to produce analogues, simplifying the identification 
of these mass fragments (Paulo et al., 2019). Any difference in a cyclodepsipeptide’s MS/MS 
spectrum represents a deviation from the core structure of valinomycin and a change in the 
biosynthesis of the novel cyclodepsipeptide. Paulo et al. (2019) proposed that these 
cyclodepsipeptide analogues may be synthesised by a combination of two different 
mechanisms, the incorporation of Lac instead of Hiv and the incorporation of  leucine or 
isoleucine (Leu/Ile) instead of Val (Challis et al., 2000; Paulo et al., 2019). Substitution of 
Leu/Ile for Val has been seen in other biosynthetic pathways with adenylation domains that 
bind Val, such as in lichenysin biosynthesis (Galli et al., 1994). The cyclodepsipeptides 





Table 5.6: The predicted structures of the cyclodepsipeptide analogues identified by 
Paulo et al. (2019) and found in the molecular network of NP SPE fractions #3, and #4 
of Streptomyces strain PR3.  
m/z (Da) (M+NH4














Each image displayed here was obtained and edited with permission from Bruno Sacchetto 
Paulo, author of Paulo et al., (2019). Each colour represents an amino or hydroxy acid to 
highlight the differences in biosynthesis. D-Hiv (blue), D-Val (pink), L-Lac (yellow), L-Val 








Table 5.7: The predicted structures of the cyclodepsipeptide analogues identified by 
Paulo et al. (2019) and found in the molecular network of NP SPE fractions #3 and #4 of 
Streptomyces strain PR3.. 
m/z (Da) (M+NH4














Each image displayed here was obtained and edited with permission from Bruno Sacchetto 
Paulo, author of Paulo et al., (2019).  Each colour represents an amino or hydroxy acid to 
highlight the differences in biosynthesis. D-Hiv (blue), D-Val (pink), L-Lac (yellow),  L-Val 
(green) and Leucine// Isoleucine (red) (Paulo et al., 2019). 
 
Two nodes, corresponding to compounds with m/z 1072.5697 and m/z 1086.6110 that were 
detected in the molecular network of fractions #3 of Streptomyces strain PR3 were not 
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elucidated by Paulo et al. (2019). These nodes were linked to the ammonium adducts of these 
compounds and their theoretical masses were calculated as 1054.5671 Da and 1068.5820 Da, 
respectively (Table 5.4). These will be referred to as compounds 1054 and 1068, respectively. 
Using the workflow and analysis done by Paulo et al. (2019) as a guide, the structures of 
compounds 1054 and 1068 were elucidated.  
The molecular network matched compound 1054 and 1068 to valinomycin which suggests they 
have similar structures, therefore valinomycin’s MS/MS was used as a starting point. 
Valinomycin’s MS/MS spectrum displays a number of unique mass fragments that were used 
to compare and understand the structural differences between it and the cyclodepsipeptide 
analogues. When peptides fragment they produce fragments with either N-terminal charged 
ions (a,b) or fragments with C-terminal charged ions (yz) (Liu et al., 2009). Cyclic peptides do 
not typically produce C-terminal charged fragments therefore only a and b fragments are 
detected. Fragments known as b ions are the amino acid residues + (H+), bo are b ions which 
have lost a H2O group (-18.01056 Da) and a ions are b ions which have lost the C terminus CO 
group (-27.9950 Da) (Liu et al., 2009). In the MS/MS spectra of valinomycin, compound 1054 
and 1068 (Figures 5.12, 5.13, 5.15) there are a conserved set of mass fragments and mass shifts. 
These are the mass fragment of m/z 144.1012, 172.0959, 244.167, 343.2197 and 371.2158. The 
masses of the three core components of valinomycin, D/L Val, D-Hiv and L-Lac are 99.0684 
Da, 100.0524 Da and  72.0211 Da respectively. The signals from m/z 144.1012 and 172.0959 
represent the a and b type fragment ions of the Lac-Val dimer respectively. The mass shift of 
Da from m/z 144.1012 to 244.167 represents the addition of a Hiv group  making m/z 244.167 
a a fragment of the Lac-Val-Hiv trimer. The final shift of Da from m/z 244.167 to 343.2197 
represent the addition of another Val. This makes m/z 343.2197 and 371.2158 the a and b ions 
of the Lac-Val-Hiv-Val tetramer. These peaks represent one pass of valinomycin synthesis. In 
valinomycin’s MS/MS spectrum these masss shift patterns repeat twice more to produce the 
docdecadepsipeptide. For example the mass fragment m/z 713.4820 is the b fragment of two 
sets of Lac-Val-Hiv-Val fragments and represents two passes of valinomycin synthesis.The 
presence of these peaks in the MS/MS spectra of 1054 and 1068 reveals that these compounds 
contain at least one Lac-Val-Hiv-Val tetramer as valinomycin does. However, the MS/MS 




Figure 5.12: Valinomycin's MS/MS spectrum. 
Compound 1054’s MS/MS spectrum reveals that many more lactic acid groups are present in 
its structure compared to valinomycin’s. A mass shift of 171.0895 Da from m/z 144.1012 to 
315.1897 represents the addition of a Lac-Val group to form a Lac-Val-Lac-Val tetramer. This 
mass shift of 171.08 Da is repeated twice more to form a type fragments with m/z 486.2771 
and 657.3654, these represent 3 and 4 sets of Val-Lac dimers respectively. The mass shifts 
from m/z 657.3654 to 757.4181 then to m/z 856.4829 and finally to m/z 1027.5727 represent 
the addition of a Hiv, Val and Lac-Val dimer respectively. These fragments represent one pass 
of valinomycin biosynthesis and support the previous hypothesis that there is one conserved 
pass of valinomycin biosynthesis involved in synthesising compound 1054. The fragment m/z 
1027.5727 is a a type fragment and the addition of 27.995  (+CO) brings the final mass to m/z 
1055.541, the protonated form of compound 1054. This suggests that compound 1054 
contained 4 sets of Lac-Val dimers and one Val-Hiv-Lac-Val tetramer. This suggests that two 










cyclodepsipeptides as discussed previously (Paulo et al., 2019). This correlates to the mass 
difference of 56.0668 Da between compound 1054 and valinomycin. The complete structural 
elucidation of compound 1054 is tabulated and displayed in Table 5.8 with each fragment, its 
observed and theoretical m/z, mass error and intensity. It must be noted that a few mass 
fragments display a high mass error which puts their accuracy into question. However, the 
proposed structure is consistent with all mass fragments and patterns which suggests it is 
accurate. The proposed structure of compound 1054 is displayed in Figure 5.13.The MS/MS 
spectrum of compound 1054, annotated with some of the major mass shifts and neutral losses 
is displayed in Figure 5.14. Compound 1054 has a predicted formula of C50H82N6O18 with a 
theoretical mass of 1054.5685 Da and a calculated mass of 1054.5671 with a low mass error 
of -1.3 ppm. A compound with the same mass and formula was located on the PubChem 
database (National Center for Biotechnology Information, 2019). However, the structure was 
defined as a cyclic peptide comprised of repeating valine-alanine units. The source was not 
given and no other reports of this structure were found, so further comparison was not possible. 
Searching other sources, such as the KEGG and MassBank databases yielded no matches.  
 
Figure 5.13: Proposed molecular structure of compound 1054 with each amino and 




Table 5.8: Identity of the mass fragments in compound 1054's MS/MS spectrum with 









Lac 72.0806 72.0211 825.7438 b 
Lac-Val 144.1012 144.1023 -7.93186 a 
Lac-Val 172.0959 172.0973 -8.38479 b 
Val-Lac-Hiv 244.1167 244.1548 -155.942 a 
2(Lac-Val) 315.1897 315.1919 -6.93546 a 
Lac-Val-Hiv-Val 343.2197 343.2232 -10.1625 a 
Lac-Val-Hiv-Val 371.2158 371.2182 -6.43287 b 
Val-Lac-Hiv-Val-Lac 415.2043 415.2443 -96.3698 a 
3(Lac-Val) 486.2771 486.2814 -8.90225 a 
Val-Lac-Hiv-Val-Lac-Val 514.3079 514.3127 -9.39312 a 
Lac-Val-Hiv-Val-Lac-Val 542.3024 542.3077 -9.83021 b 
3(Lac-Val)-Lac 558.2994 558.3026 -5.65643 a 
Lac-Val-Hiv-Val-Lac-Val-Lac 614.3225 614.3289 -10.3528 b 
4(Lac-Val) 657.3654 657.3710 -8.47619 a 
4(Lac-Val) 685.395 685.3660 42.35401 b 
4(Lac-Val)-Hiv 757.4181 757.4234 -7.00137 a 
4(Lac-Val)-Hiv-Lac 828.4538 828.4605 -8.1054 a 
4(Lac-Val)-Hiv-Lac 856.4829 856.4555 31.97481 b 
4(Lac-Val)-Hiv-Lac-Val-Lac 1027.572 1027.5451 26.21977 a 
4(Lac-Val)-Hiv-Lac-Val-Lac 1055.541 1055.5401 0.702958 b 





Figure 5.14: MS/MS spectrum of compound 1054 annotated with mass fragments and 
corresponding components. 
 
The same workflow applied to compound 1054’s MS/MS spectrum was used to elucidate 
compound 1068’s structure. Starting from the matching peaks in valinomycin’s MS/MS 
spectrum aided the elucidation. The mass shift of 171.9849 Da from m/z 343.2197 to 415.2046 








from m/z 415.2046 to 528.2884 suggests that a Leu/Ile groups is added. Paulo. et al (2019)’s 
proposes that Val groups can be substituted for a Leu/Ile and reported it in several 
cyclodepsipeptides (Paulo et al., 2019). The mass shift of 171.08 Da from  m/z 528.2884 to 
699.4119 then to m/z 870.4919 and final to m/z 1041.5887  suggests the addition of  Lac-Val 
dimers. These mass shifts are supported by additional shifts seen in 1068’s spectrum. The 
171.0885 Da mass shift from m/z 144.1012 to 315.1897 represents the addition of a Lac-Val 
dimer to form a a type Lac-Val-Lac-Val tetramer. Another 177.0879 Da mass shift is observed 
from m/z 315.1897 to 486.2776 which represents a a type 3 (Lac-Val) hexamer. These same 
mass shifts are seen in 1054’s MS/MS spectrum (Figure) and suggests that the same 2 Lac 
substitutions for Hiv are seen in 1054 are also present in 1068’s structure. The addition of a 
CO group seen by the mass shift of 27.995 Da from the a type fragment m/z 1041.5887 forms 
the b type m/z 1069.585 and completes the final proposed structure. In summary it is proposed 
that compound 1068 differs from valinomycin’s structure by 2 Lac substitutions for 2 Hiv 
groups and 1 Ile/Leu substitution for 1 Val group. This correlates with the 42.0519  Da mass 
difference between valinomycin and compound 1068’s masses. The complete strucutrual 
elucidation of compound 1068 is tabulated and displayed in Table 5.9 with each fragment, its 
observed and theoretical m/z, mass error and intensity. Again, it must be noted that a few mass 
fragments displayed a high mass error which puts their accuracy into question. However, the 
proposed structure is consistent with all mass fragments and patterns which suggests it is 
accurate. The proposed structure of compound 1068 is displayed in Figure 5.15. The MS/MS 
spectrum of compound 1068, annotated with some of the major mass shifts and neutral losses 
is displayed in Figure 5.16. Compound 1068 has a chemical formula of C51H84N6O18 with a 
theoretical mass of 1068.5842 Da and an experimental mass of 1068.5820 Da, with a low mass 
error of -2.0 ppm. No compounds with matching structures or chemical formulae were found 
in the GNPS library, PubChem, Massbank and KEGG. Therefore, both compounds 1054 and 





Table 5.9: Identity of the mass fragments in compound 1068's MS/MS spectrum with 
observed and theoretical m/z's, mass error and fragment ion type. 
 
 







Lac-Val 144.1012 144.1023 -7.93186 a 
Lac-Val 172.0959 172.0973 -8.38479 b 
Val-Lac-Hiv 244.1167 244.1548 -155.942 a 
2(Lac-Val) 315.1897 315.1919 -6.93546 a 
Lac-Val-Hiv-Val 343.2197 343.2232 -10.1625 a 
Lac-Val-Hiv-Val 371.2158 371.2182 -6.43287 b 
Val-Lac-Hiv-Val-Lac 415.2046 415.2443 -95.6473 a 
3(Lac-Val) 486.2776 486.2814 -7.87404 a 
Val-Lac-Hiv-Val-Lac-Leu/Ile 528.2884 528.3284 -75.6745 a 
Val-Lac-Hiv-Val-Lac-Leu/Ile 556.318 556.3234 -9.67243 b 
Val-Lac-Hiv-Val-Lac-Leu/Ile-Lac-Val 699.4119 699.4179 -8.61288 a 
Val-Lac-Hiv-Val-Lac-Leu/Ile-Lac-Val-Lac 771.4315 771.4391 -9.79079 a 
Val-Lac-Hiv-Val-Lac-Leu/Ile-Lac-Val-Lac-
Val 
852.4919 852.4731 22.05982 bo 
Val-Lac-Hiv-Val-Lac-Leu/Ile-Lac-Val-Lac-
Val 
870.4919 870.5075 -17.8827 a 
Val-Lac-Hiv-Val-Lac-Leu/Ile-Lac-Val-Lac-
Val-Lac 
942.5219 942.5286 -7.10429 a 
Val-Lac-Hiv-Val-Lac-Leu/Ile-Lac-Val-Lac-
Val-Lac-Val 
1023.576 1023.5626 12.7617 bo 
Val-Lac-Hiv-Val-Lac-Leu/Ile-Lac-Val-Lac-
Val-Lac-Val-Lac 
1041.589 1041.5731 14.94125 a 
Val-Lac-Hiv-Val-Lac-Leu/Ile-Lac-Val-Lac-
Val-Lac-Val-Lac 
1051.563 1051.5576 5.289677 bo 
Val-Lac-Hiv-Val-Lac-Leu/Ile-Lac-Val-Lac-
Val-Lac-Val-Lac 








Figure 5.15: Proposed molecular structure of compound 1068 with each amino or 





The Metabolomics Standards Initiative (MSI) characterises the level of confidence that can be 
attached to a proposed structure based on the data used to elucidate it (Blaženović et al., 2018). 
In the MSI ranking, level 0 refers to pure isolated compounds with fully elucidated 
stereochemistry and 3D structures. Level 1 refers to compounds with full 2D structural 
elucidation by techniques such as HRMS and 2D NMR. The methylated crown ethers discussed 












were elucidated based on biosynthetic logic and MS/MS spectrum analysis with comparison to 
literature and library searches. This attaches a level 2 confidence level to these structures, as 
they were determined by at least two orthogonal pieces of information including evidence that 
excludes all other candidates. To fully characterise the cyclodepsipeptide analogues proposed 
in this investigation and by Paulo et al. (2019), they either need to be purified and characterised 
or synthesised and characterised.  
 
To purify each cyclodepsipeptide, more advanced chromatographic techniques would be 
required. After RP+NP SPE, active fractions could be separated by HPLC or Ultra Performance 
Liquid Chromatography (UPLC). UPLC is a chromatographic system that provides improved 
separation, with much shorter run times (Craige Trenerry and Rochfort, 2010). This is achieved 
by a combination of 1.7 µm reverse phase packing material and a system that can operate at 
6000–15000 pressure per square inch (psi). Typically, HPLC systems use 3-5 µm packing 
material and operate at 2000–4000 psi. Reducing the particle size of the packing material of 
the solid phase and increasing the flow rate increases separation efficiency. This leads to greater 
resolution and sensitivity. Extensive HPLC separation steps have been shown to be able to 
separate montanastatin from valinomycin (Pettit et al., 1999; Singh et al., 2019). In both 
investigations, the recovery of montanastatin was poor and, to overcome this, the Streptomyces 
strains were grown in bioreactors to obtain large amounts of crude material. Theoretically, the 
same processes should be able to purify the cyclodepsipeptide analogues from the crude 
extracts of strain PR3. Singh et al. (2019) investigated the cultivation conditions and discovered 
that Streptomyces lavendulae strain ACR DA1 produced large quantities of cyclodepsipeptides 
at low temperatures (Singh et al., 2019). While it is unknown if strain PR3 would respond in 
the same manner, more in-depth study of strain PR3’s secondary metabolism under different 
cultivation conditions could improve cyclodepsipeptide production. Once purified, the 
cyclodepsipeptide structures could be fully elucidated by HRMS and 2D NMR and compared 
to the predicted structures. Alternatively, the predicted structures of the cyclodepsipeptide 
analogues could be synthesised for further study. A modified version of the method used to 
synthesise montanastatin may be suitable for the other analogues (Doi and Asano, 2002). The 
synthesis of the cyclodepsipeptides and the development of purification methods after culture 
optimisation and bioreactor cultivation of strain PR3 were beyond the scope of this 
investigation. To investigate if the cyclodepsipeptides could be developed further, fraction #3 
(SPE Method #6) was selected for antiplasmodial efficacy and host selectivity evaluation. 
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Fraction #3 was selected as it was the most active fraction and was deemed to be moderately 
pure, as 1H NMR analysis suggested it contained the cyclodepsipeptides and minor impurities. 
 
5.3.5 Antiplasmodial Efficacy and Host Selectivity of the 
Cyclodepsipeptides 
 
To better evaluate the antiplasmodial efficacy and host selectivity of the cyclodepsipeptide 
fraction, valinomycin (≥ 98% purity, Merck®, Germany) was subjected to the same series of 
tests to allow a comparison of the data. Fraction #3 and valinomycin were tested for 
antiplasmodial activity against the drug-sensitive strain of P. falciparum, NF54 (section 2.2.4). 
Antiplasmodial efficacy was also determined against the multidrug resistant strain of P. 
falciparum, K1 (section 5.2.5).  
Fraction #3 displayed excellent antiplasmodial activity against NF54, with a mean IC50 of 25 ± 
3.5 ng/mL (Table 5.10). Valinomycin displayed very potent activity against NF54, with a mean 
IC50 of 1.4 ± 0.4 ng/mL, which matched the efficacy displayed by the positive controls used 
(Table 5.10). This activity is comparable to the published antiplasmodial data for valinomycin 
(Gumila et al., 1996). Fraction #3 exhibited good activity against the multidrug-resistant K1 
strain, with a mean IC50 of 101 ± 1 ng/mL. This is within the acceptable range for in vitro 
activity of a candidate compound against resistant strains, discussed in Chapter 2 (Pink et al., 
2005). Valinomycin continued to display extremely potent activity and exhibited an IC50 of 8.4 
± 0.3 ng/mL against the K1 strain. The controls were within the acceptable ranges. 
The resistance index (RI) is used to compare the antiplasmodial activity of a compound against 
drug-sensitive and resistant strains to estimate if its action is impacted by resistance. The RI is 
the ratio of the drug-resistant IC50 versus the drug-sensitive IC50 (K1 IC50/NF54 IC50). The RIs 
are compared to the positive controls that are affected by resistance, in this case, chloroquine. 
The RI of chloroquine was 32, while fraction #3, valinomycin and the second control, 
artesunate, had RIs of 4, 6 and 2, respectively (Table 5.10). The low RIs and IC50s displayed, 
suggest that valinomycin and fraction #3 are not affected by the Plasmodium resistance 




Table 5.10: Mean antiplasmodial activity of fraction #3 (SPE Method #6) and 
valinomycin against P. falciparum strain NF54 (drug-sensitive) and strain K1 (multidrug-











activity against P. 










25 ± 3.5 
 







1.4 ± 0.4 
 






6.4 ± 0.5 
 
 







1.8 ± 0.1 
 




While valinomycin is an effective antibiotic, it displays very poor host selectivity and is barred 
from clinical use (Wu et al., 2004; Paananen et al., 2005). To determine if the isolated 
cyclodepsipeptide fraction displayed similar toxicity, both fraction #3 and valinomycin were 
tested for cytotoxicity and haemotoxicity (sections 2.2.6 and 2.2.7, respectively). Valinomycin 
displayed no haemotoxicity, but did display cytotoxicity against the CHO and HepG2 cell lines, 
with mean IC50s of 12.4 ± 1.1 and 1.8 ± 0.8 µg/mL respectively (Tables 5.11 and 5.12). While 
data could not be found for the same cell lines, these results are comparable to studies of 
valinomycin in similar mammalian cell lines (Bugelski et al., 2000). For example, valinomycin 
was shown to have an IC50 of 9.57 ng/mL against the Vero cell line (Wu et al., 2004). Fraction 
#3 showed no cytotoxicity up to 100 µg/mL against the CHO cell line nor any haemotoxicity 
against human erythrocytes (Tables 5.11 and 5.12). However, it did show moderate 
cytotoxicity against the HepG2 cell line, with a mean IC50 of 10.3 ± 2.2 µg/mL. Despite this, 
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fraction #3 exhibited a SI above 100 against all the tested cell lines, which suggests it is 
selectively targeting P. falciparum.  
 
Table 5.11: Mean antiplasmodial activity against P. falciparum, NF54 and mean 
cytotoxicity against the Chinese Hamster Ovary and HepG2 cell lines of fraction #3 (SPE 






































(Fractions #3 ) 
 
 


















1.41 ± 0.4 
 
12.4 ± 1.1 
 










0.01 ± 0.001 
 
 










Table 5.12: Haemotoxicity of fraction #3 (SPE Method #6) and valinomycin, N=2 







against P. falciparum 
































The discovery of these new cyclodepsipeptides could have an important impact in antimalarial 
drug development. Neutral ionophores are receiving increased interest as novel antimalarials. 
Ionophores have been found to present potent antiplasmodial efficacy and a recent study found 
that the neutral ionophore, maduramicin, was able to inhibit Plasmodium gametocytes (Gumila 
et al., 1996; Sun et al., 2015; Maron et al., 2016). The inhibition of the development of the 
gametocyte stage prevents the transmission of the malaria parasite. This is one of the Single 
Exposure Radical Cure and Prophylaxis (SERCaP) parameters desired in future antimalarials 
(Burrows et al., 2013). The study also found that P. falciparum infected erythrocytes are more 
sensitive to the actions of these neutral ionophores than uninfected erythrocytes (Maron et al., 
2016). The results obtained in this investigation support this observation. As discussed 
previously, the Plasmodium parasites remodel the erythrocyte upon infection and are heavily 
reliant on ion transport making them vulnerable to ionophore activity. These published studies 
and the results obtained in this investigation show the potential of neutral ionophores as novel 
antimalarials. Therefore, further study needs to focus on purifying the cyclodepsipeptides from 
Streptomyces strain PR3 and evaluating their antiplasmodial efficacy and host selectivity. 
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It must be noted that it is possible that valinomycin is the only antiplasmodial 
cyclodepsipeptide present and the efficacy and toxicity values determined for fraction #3 are 
from valinomycin being diluted by the other components in the mixture. This cannot be 
determined at this stage of the investigation, but the structural similarity predicted for the 
cyclodepsipeptide analogues suggests they could have a similar mechanism of action to 
valinomycin, which may equate to similar efficacy. The changes in structure could, however, 
lead to alterations in ion selectivity and binding, which could affect efficacy and selectivity. 
This is documented in the efficacy of MCEs (this study) compared to other crown ethers (Gokel 
et al., 2004). This is also observed with the cyclodepsipeptides. For example, while it displayed 
weaker antibacterial and anticancer activity, montanastatin was found to display better host 
selectivity than valinomycin (Pettit et al., 1999). The cyclodepsipeptide analogues could be as 
toxic as valinomycin or less efficacious, but it is also possible that one or more of the analogues 
displays matching efficacy and improved selectivity. Not only is it possible that one or more 
display suitable parameters for clinical development, but they could also be used as scaffolds 
to synthesise improved derivatives. In summary, the efficacy and selectivity results for the 
fraction #3 cyclodepsipeptides, while inconclusive are still promising and the individual 
cyclodepsipeptides need to be purified before sound conclusions can be drawn. 
 
5.3.6 Relationship Between Cyclodepsipeptides and Methylated 
Crown Ethers 
 
During bioassay guided fractionation an interesting relationship between the 
cyclodepsipeptides and the MCEs was suspected. During the investigation, potent 
antiplasmodial activity was detected from an impure sample. This active sample was studied 
in Chapter 3 and referred to as fraction 540, as the m/z 540 was tracked and collected by HPLC-
MS. Fraction 540 was found to have antiplasmodial efficacy of 27 ± 7 ng/mL against P. 
falciparum NF54 (section 3.3.3, Table 3.10). 1H NMR analysis of fraction 540 revealed it to 
be too impure to elucidate the structure. Comparatively, the cyclodepsipeptide fraction #3 
presented strong antiplasmodial activity of 25 ± 3.5 ng/mL, and its 1H NMR spectrum 
suggested that there had been a significant improvement in purity. 
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 Generally, removing impurities improves the antiplasmodial activity of the fraction; however, 
the efficacy displayed by fraction 540 and fraction #3 are comparable. Analysis of the past 
HRMS data of fraction 540 revealed the presence of both the MCEs and the cyclodepsipeptides 
(Appendix, Figure 8.11). Due to this it was hypothesised that the MCEs and cyclodepsipeptides 
interacted in a synergistic manner and further study was conducted to determine if this was 
true. 
A mixture of compounds can interact in three broad ways: additive, synergistic, or antagonistic 
(van Vuuren and Viljoen, 2011). In terms of antibiotics, an additive effect represents no 
interaction between the compounds present and any antibiotic activity displayed is merely a 
summation effect. An antagonistic effect is when the compounds interact to display less than 
the additive effect. Comparatively, a synergistic effect is when a mixture displays greater than  
the additive effect. Synergistic effects can occur for several reasons: pharmacodynamic 
synergism, pharmacokinetic synergism, by overcoming resistance against partner compounds 
or by reducing the adverse side effects of partner compounds (Caesar and Cech, 2019).  
Pharmacodynamic synergism results from the compounds in combination inhibiting multiple 
targets, which has an overall stronger effect than would be expected from adding the effects of 
the individual compounds (Hu and Zhang, 2012). Pharmacokinetic synergism occurs when the 
compounds in combination improve each other’s absorption, stability, distribution, or 
elimination, which increases efficacy (Wagner and Ulrich-Merzenich, 2009). 
There is no standardised methodology to determine the relationship between compounds 
(Matthews et al., 2017). Many models and methods are employed, with the majority based on 
two definitions of additivity; the Loewe additivity model and the Bliss independence model. 
The general isobole equation, based on the Loewe additivity model, is the most popular for 
studying combination effects in many fields, including antimalarial drug research (Fivelman et 
al., 2004; Wagner and Ulrich-Merzenich, 2009; Matthews et al., 2017). In this model, the 
nature of the interaction between two compounds is determined by the sum of the fraction IC50 
(ƩFIC), determined using equation 1  and the shape of a plotted isobologram (Fivelman et al., 
2004; Matthews et al., 2017). 
 
Equation 1: ƩFIC = FICA + FICB 
FIC50A = IC50x/ IC50A 
187 
 
Where IC50A is the IC50 of the compound alone, and IC50Ax is the IC50 of the compound in a 
specific fixed-ratio. If the ƩFIC  is equal to 1, then the interaction is deemed as additive, if the 
interaction is less than 1, it is synergistic and if it is greater than 1, it is antagonistic (van Vuuren 
and Viljoen, 2011). An isobologram is a graphical representation of combination effects 
between two samples, where its axes represent the doses of the individual agents and the plotted 
points represent the combined effect of each combination, i.e. the ƩFIC (van Vuuren and 
Viljoen, 2011; Caesar and Cech, 2019). When two compounds do not interact, their 
isobologram plot forms a straight line, which represents additivity. If they are synergistic, the 
plot will form a concave curve below the additivity line. If they are antagonistic, the plot will 
result in a convex curve above the line. A generic isobologram showing the three types of 
interactions is shown in Figure 5.17. 
To determine the relationship between the cyclodepsipeptide and MCEs, the fixed-ratio 
isobologram method (section 5.2.6) was used. Fraction #3, generated by SPE Method #6, 
(section 5.2.1) and used in previous antiplasmodial efficacy determination, was used to 
represent the cyclodepsipeptides. Fraction #4, produced by SPE Method #5 (section 3.2.3.5), 
which was used in the antiplasmodial efficacy determination of the MCEs in Chapter 4, was 
used to represent the MCEs. The concentrations and ratios used for testing are displayed in 
Table 5.1. 
 
Figure 5.17: Generic isobologram showing the three possible relationships between two 





The results of the fixed-ratio method suggested that there is a synergistic relationship between 
the MCEs and the cyclodepsipeptides. When plotted as an isobologram the FIC50’s of the 
cyclodepsipeptide fraction and the MCE fraction fall below the additivity line and have a 
general concave curve suggesting synergy (Figure 5.18).  
The ƩFIC of each fixed ratio, was less than 1, which suggested that there is a synergistic 
relationship between the cyclodepsipeptides and the MCEs (Table 5.13)(Fivelman et al., 2004). 
However, the lack of a standard methodology to determine synergy makes analysis of these 
results difficult. For example, the ƩFIC cut-off value for each interaction is widely debated, as 
results can be misinterpreted or biased. Some reviewers believe that the cut-off values for the 
ƩFIC should be ≤ 0.5 to be classed as synergistic, 0.5–1 for additive, 1.0 to 4.0 for non-
interacting and > 4 for antagonistic (van Vuuren and Viljoen, 2011; Caesar and Cech, 2019). 
Therefore, characterisation of the relationship between the cyclodepsipeptides and MCEs 
depends on the cut-off values used when interpreting the data presented. Taking this into 
consideration, when the cyclodepsipeptides and the MCEs are combined in the fixed ratios of 
4:1, 3:2 and 1:4, the results suggest that there is an additive, or weak synergistic, effect. The 
ƩFIC of these fixed-ratios are greater than 0.5, but less than 1. However, when dosed in the 
fixed ratio of 2:3, both the isobologram and the ƩFIC suggest that there is a definite synergistic 
relationship between the two neutral ionophores, as the ƩFIC is less than 0.5 and the 
corresponding point on the isobologram falls much lower than the others. This is highlighted 
in red in Table 5.13. 
Due to the lack of consensus in the scientific community on which method is the best to 
determine synergy, an additional model based on the work of Chou and Talalay was used to 
check the results obtained from the fixed-ratio method (Chou and Talalay, 1984). Chou and 
Talalay argue that synergy is a physiochemical interaction, not a theoretical statistical problem 
and developed a model which employs the mass-action law principle (Chou and Talalay, 1984; 
Chou, 2010). The mass-action law principle derives a median-effect equation, which was 
derived from four existing, well-studied physiochemical equations. These were the Henderson-
Hasselbach, Hill, Michaelis-Menten and Scatchard. Additional factors, such as the shape of the 
inhibition curve are considered, with efficacy, the ƩFIC and shape of the isobologram (Chou 
and Martin, 2005). The result of the analysis is the combination index (CI) which defines the 
interaction. Broadly, if a combination generates a CI of 1, this represents additivity and  CI 
values of < 1 and > 1 represent synergy and antagonism, respectively. A detailed description 
of what each CI represents is displayed in Table 5.14 (Chou and Martin, 2005). Using these 
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methods, a series of software programmes, such as CompuSyn and CalcuSyn, were developed 
to allow easy, automated data analysis (Chou and Talalay, 1984; Chou and Martin, 2005) 
 
 





































Methylated Crown Ethers FIC50 




Table 5.13: Mean antiplasmodial activity and fractional IC50s of the cyclodepsipeptides 
and methylated crown ethers at each fixed-ratio dose and their corresponding sum of 












































































































Table 5.14: Description of each combination index range (Chou and Martin, 2005). 
Combination Index Range (CI)  Description 
< 0.1 Very strong synergism 
0.1–0.3 Strong synergism 
0.3–0.7 Synergism 
0.7–0.85 Moderate synergism 
0.85–0.90 Slight synergism 
0.90–1.10 Nearly additive 
1.10–1.20 Slight antagonism 
1.20–1.45 Moderate antagonism 
1.45–3.3 Antagonism 
3.3–10 Strong antagonism 
> 10 Very strong antagonism 
 
The raw data produced by the fixed-ratio method was inputted into CompuSyn (section 5.2.7). 
This allowed a direct comparison to the results generated from the fixed-ratio method and, as 
CompuSyn analyses the raw data, bias and misinterpretation were removed. The results from 
CompuSyn corroborate the results obtained from the fixed-ratio method (Table 5.15). The CIs 
of the fixed-ratios 4:1 and 1:4 suggested a synergistic relationship, while the 3:2 ratio displayed 
a CI suggesting moderate synergism. The fixed-ratio 2:3 generated a very low CI, suggesting 
very strong synergism between the cyclodepsipeptides and the MCEs. This is highlighted in 
red in Table 5.15. 
The results obtained from both models suggest that combining the cyclodepsipeptides and 
MCEs elicits a synergistic response. Both models suggested that the best fixed ratio was 2:3 or 
a µg/mL combination of 1:40 of cyclodepsipeptides to MCEs. Exactly why this combination 
is more effective than the others or how the MCEs potentiate the action of the 
cyclodepsipeptides is unknown. Although the synergistic activity is likely due to their shared 
ionophore structures, the exact mechanism of action still needs to be elucidated. 
These results may also explain why fraction 540 displayed such strong antiplasmodial activity 
despite being impure, and why other fractions, such as the HPLC-MS purified fraction 870 
showed weaker activity. Both fractions contained the MCEs and cyclodepsipeptides, but if the 
ratios were slightly different it would have had a large impact on the nature of the synergistic 
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relationship between the two ionophores, which would have impacted antiplasmodial efficacy. 
The cultivation conditions of Streptomyces strain PR3 may also have affected the number of 
cyclodepsipeptides present in the active fractions, which could explain the activity differences 
between the ISP-2 and JCM #61derived fractions. It was, unfortunately, not possible to directly 
compare the HRMS results of fraction 540 and 870 with fraction #3, or with each other because, 
at this stage of the investigation, no material of fractions 540 and 870 remained. As the 
conditions were not controlled, comparing past HRMS data from different runs at different 
times was considered to be too inaccurate. 
Table 5.15: Combination index values for each fixed-ratio compound combination 
























Further study is required to reproduce these results with different synergy models such as the 
Bliss independence or checkerboard models (Caesar and Cech, 2019). However, these results 
are intriguing , and future work could focus on determining the viability of using the MCEs in 
combination therapy with the cyclodepsipeptides and other neutral ionophores. As discussed 
in Chapter 4, the MCEs showed no toxicity against the CHO and HepG2 cell lines and, no 
haemotoxicity, suggesting host selectivity. The MCEs’ selectivity implies that using them in 
combination with the more-toxic ionophores, like valinomycin, could reduce the toxic side 




6 Conclusion  
6.1 Research Summary 
 
In conclusion, the research objectives set at the beginning of the investigation were met, but 
more work is required to confirm these observations. Initial screening of the filamentous 
actinobacteria revealed a high number of hit candidates from a small sample size indicating 
that that these microorganisms do have the ability to produce potent antiplasmodial agents. 
This is supported by literature (Gumila et al., 1996; Prudhomme et al., 2008; Bennur et al., 
2015; Zin et al., 2017). To determine if these antiplasmodial compounds were novel and 
suitable for lead drug development, they needed to be identified and elucidated. Therefore, the 
hit candidates were evaluated for further study and Streptomyces strain PR3 was selected as its 
crude extracts displayed good antiplasmodial efficacy and no cytotoxicity against three 
mammalian cell lines, CHO, HEPG2, and erythrocytes. 
The crude extracts of strain PR3 were studied by bioassay-guided fractionation supported by 
HRMS and NMR analysis. During the investigation a molecule with mass of 870 Da was 
associated with antiplasmodial activity. Subsequent purification by reverse and normal phase 
solid phase extraction (RP+NP SPE) and structural elucidation by HRMS and 2D-NMR 
revealed the compound to one of several novel methylated crown ethers (MCE). These MCEs 
were shown to be plastic derivatives specifically, oligomers of polypropylene glycol in the 
XAD 16-N extraction resin. These oligomers were predicted to cyclize in water to form the 
MCEs. While these MCEs were found to possess weak antiplasmodial activity, they were non-
toxic against the CHO and, HepG2 cell lines, and human erythrocytes, suggesting they could 
have biomedical applications. 
The employment of the Global Natural Products Social (GNPS) molecular networking 
workflow led to the identification of a series of cyclodepsipeptides in the most active NP SPE 
fractions, fraction #3 and #4 (SPE Method #6, section 5.2.1). These included valinomycin, 
montanastatin, and several cyclodepsipeptide analogues. This discovery was supported by 
HRMS analysis of past samples, 1H NMR analysis, comparison to literature, and genome 
mining. Further study of these analogues led to the elucidation of two new cyclodepsipeptides, 
compounds 1054 and 1068 by mass spectrometry and biosynthetic logic. The most active SPE 
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fraction, fraction #3, was almost wholly comprised of cyclodepsipeptides and displayed good 
antiplasmodial activity against the drug-sensitive NF54, and multidrug-resistant K1, strains of 
P. falciparum. No cytotoxicity was displayed against the CHO cell line nor haemotoxicity 
against human erythrocytes. Moderate cytotoxicity was measured against the HepG2 cell line, 
but the SI suggested that the fraction was selective.  
Valinomycin was detected in fraction #3 and the chromatographic methodology developed was 
unable to separate the cyclodepsipeptide analogues due to their close structural similarities. 
Therefore, it is a possibility that valinomycin is the cause of the antiplasmodial activity and 
cytotoxicity detected in fraction #3. Due to the structural similarities of the analogues to 
valinomycin, it is also possible that the cyclodepsipeptide analogues are contributing to fraction 
#3’s antiplasmodial activity and cytotoxicity. The cyclodepsipeptide analogues may or may 
not, exhibit greater selectivity than valinomycin as small changes in structure can alter the 
efficacy and selectivity of neutral ionophores (Pettit et al., 1999; Gokel et al., 2004). Other 
neutral ionophores such as maduramicin, have been found to exhibit potent and selective 
activity against multiple stages of the P. falciparum lifecycle (Gumila et al., 1996; Maron et 
al., 2016). Therefore, neutral ionophores such as the cyclodepsipeptides, may make suitable 
candidates for novel antimalarial compounds and require further study. Finally, through the use 
of two separate models, it was estimated that combining the cyclodepsipeptides and MCEs 
elicits a synergistic increase in antiplasmodial activity. This requires further study to determine 




Several limitations need to be noted to inform future studies. 
During screening, the antiplasmodial efficacy of certain active crude extracts was not 
replicated. Only the strains selected for further study in this investigation and related ones, 
were cultured, extracted, and tested multiple times. Before studying the remaining selected hit 
strains, their antiplasmodial efficacy must be reproduced.  
The failure to purify the cyclodepsipeptide analogues from one another impeded the evaluation 
of their antiplasmodial efficacy, host selectivity, and further description. Subsequent studies 
must focus of the purification of the cyclodepsipeptides to obtain more information about their 
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antiplasmodial activity and selectivity. The same issue is faced with the MCEs as a series of 
MCEs were present in the tested fraction and MCEs of certain ring sizes may be contributing 
to antiplasmodial activity to a greater or lesser extent. 
The combination studies conducted only provide an estimate of synergy between the 
cyclodepsipeptides and the MCEs. Impure fractions were employed to obtain these results, 
therefore the ratios of the mixtures are likely inaccurate. The impurity of the fractions makes it 
impossible to specify exactly which components are interacting. While this limited data 
analysis, it was still clear that the cyclodepsipeptides and MCEs interact in a synergistic 
fashion. Once pure samples have been obtained, combination studies should be repeated to 
obtain a more accurate understanding of the synergistic relationship between the 
cyclodepsipeptides and MCEs. Additional models such as the Bliss independence and 
checkerboard models could also be employed to corroborate the synergy predicted by this 
investigation. 
 
6.3 Future Prospects  
 
The results presented in this investigation and in literature suggest the neutral ionophores could 
be developed into novel antimalarial compounds. Therefore, in the investigator’s opinion, 
future research should focus on the purification or synthesis of the cyclodepsipeptide analogues 
for evaluation. 
The selected hit candidates that were not investigated warrant further study. Strains such as 
Streptomyces strain PR10 displayed highly active crude extracts which could be due to novel 
compounds. More intensive screening of the filamentous actinobacteria is also required to fully 
evaluate their antiplasmodial potential and to isolate novel compounds. This will generate new 
hit candidates that could be studied. All future studies should utilize the GNPS library and 
molecular networking functions to aid dereplication and compound identification. 
The MCEs also require closer study. As discussed, they may have biomedical applications or 
present new chemistry. The exact mechanism of cyclization of polypropylene glycol oligomers 
should be elucidated to improve the purification or allow synthesis of the MCEs. The MCEs 






This investigation is one of the few to study the antiplasmodial potential of the filamentous 
actinobacteria. While only a small sample size was screened many positive hits were observed 
suggesting they are suitable source for novel antimalarials. 
This study failed to isolate and evaluate a suitable novel antiplasmodial agent, however it did 
discover a novel class of crown ethers that to the author’s knowledge have not been reported 
in literature.  
The work published by Paulo et al. (2019) was supported by the results discussed in this 
investigation and through the same workflow two new cyclodepsipeptides were elucidated. 
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8. Appendix  
 
Table 8.1: Raw efficacy data for each positive control, chloroquine and artesunate, for all 
filamentous actinobacteria screening  results displayed in Tables 2.1 and 2.2. 
Assay Number 
 
Antiplasmodial activity against P. falciparum, NF54 
IC50 (ng/mL) 
Chloroquine Artesunate 
#1 3,5 3,6 
#2 4,6 2,1 
#3 6,2 2,9 
#4 2,2 4,0 
#5 6,8 4,9 
#6 3,4 4,2 
#7 4,4 5,9 
#8 7,1 3,5 
#9 5,8 1,9 
#10 4,0 5,9 
#11 7,8 5,6 
#12 7,2 2,1 
#13 5,3 3,8 
#14 6,1 5,9 
#15 5,3 4,4 
#16 5,3 5,6 
#17 5,5 4,5 
#18 7,2 3,8 
 
 
Table 8.2: Mean antiplasmodial activity of ethyl acetate and methanol blanks, N=2 
biological repeats with 4 technical repeats. 
Sample Antiplasmodial activity against P. 
falciparum, NF54 IC50  
Ethyl Acetate Blank > 0.25 % (v/v) 
Methanol Blank > 0.25 % (v/v) 
Chloroquine 6.2 ± 1.4 ng/mL 




Figure 8.1: Molecular network of fraction #3  produced though RP + NP SPE Methods 
#3 and #6, and visualised through Cytoscape (Shannon et al., 2003). Each red node is a 
MS/MS spectrum and each black edge connects similar spectra. The cluster representing the 




Figure 8.2: Valinomycin MS/MS spectral overlay of experimental spectrum (green) vs 


















Figure 8.3: Montanastatin MS/MS spectral overlay of experimental spectrum (green) vs 

































Figure 8.8: Table displaying the LC-MS data of the cyclodepsipeptides and [150]crown-




Figure 8.9: Table displaying the LC-MS data of the cyclodepsipeptides and [150]crown-
15 in a RP SPE MeOH fraction (section 3.2.3.3). 
 
 
Figure 8.10: Table displaying the LC-MS data of the cyclodepsipeptides and 
[150]crown-15 in a PHREE SPE fraction (section 3.2.3.4) 
 
Figure 8.11: Table displaying the LC-MS data of the cyclodepsipeptides and 






Figure 8.12: Table displaying the the LC-MS data of the cyclodepsipeptides and 
[150]crown-15 in fraction 870 (section 3.3.5.4). 
 
Figure 8.13: Table displaying the LC-MS data of the cyclodepsipeptides in NP SPE 
fraction #3 (section 3.2.3.5). 
 
Figure 8.14: Table displaying the LC-MS data of the cyclodepsipeptides in NP SPE 






Figure 8.15: Table displaying the LC-MS data of the cyclodepsipeptides in NP SPE 
fraction #5 (section 3.2.3.5). 
